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Abstract 
 
Apart from its primary function in the synaptic hydrolysis of acetylcholine, 
acetylcholinesterase (AChE) has been shown through in vitro demonstrations to be able 
to promote various non-cholinergic functions, including cell adhesion and neurite 
outgrowth, differentiation, and amyloidosis. AChE was also shown to bind to mouse 
laminin-111 in vitro by an electrostatic mechanism. Previous results suggest that the site 
on AChE recognised by certain monoclonal antibodies (MAbs) might be critical for 
differentiation. These MAbs were found to inhibit both laminin binding and cell adhesion 
in neuroblastoma cells. In this study, the structure and characteristics of this site were 
investigated, using the AChE-laminin interaction as a template as well as a detailed 
epitope analysis of the MAbs. The interaction sites of AChE and laminin were 
investigated using phage display, modelling and docking, synthetic peptides, enzyme 
linked immunosorbent assays (ELISAs) and conformational interaction site mapping. 
Docking of AChE with the single-chain variable fragments (scFvs) produced from the 
phage display showed the major recognition motifs to be the 90Arg-Glu-Leu-Ser-Glu-Asp 
motif, the 40Pro-Pro-Met-Gly sequence, and the 59Val-Val-Asp-Ala-Thr-Thr (human) 
motif. Mouse AChE was found to interact with the basic structures Val2718-Arg-Lys-Arg-
Leu2722; Tyr2738-Tyr2739, Tyr2789-Ile-Lys-Arg-Lys2793; and Val2817-Glu-Arg-Lys2820, on the 
α1 G4 domain of laminin. ELISAs using synthetic peptides confirmed the involvement of 
the AG-73 site (2719-2729). This site overlaps with laminin’s heparin-binding site. 
Docking showed the major component of the interaction site on AChE to be the acidic 
Arg90-Glu-Leu-Ser-Glu-Asp95 (omega loop), and also involving the Pro40-Pro-Val42, 
Arg46 (linked to Glu94 by a salt bridge) and the hexapeptide Asp61 Ala-Thr-Thr-Phe-Gln66. 
Epitope analysis showed the MAb’s major recognition site to be the sequence Pro40-Pro-
Met-Gly-Pro-Arg-Arg-Phe48 (human AChE). The MAbs also reacted with the proline-
rich sequences Pro78-Gly-Phe-Glu-Gly-Thr-Glu84 and Pro88-Asn-Arg-Glu-Leu-Ser-Glu-
Asp95. These results define the interaction sites involved in the AChE-laminin interaction 
and suggest that the interaction plays a role in cell adhesion. 
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Despite the in vitro demonstrations of the importance of AChE’s non-classical functions, 
the AChE knockout survives. Results from this study suggest the possibility of functional 
redundancy between AChE and other molecules in early development. Using these in 
vitro findings that AChE is able to bind laminin-111, information on the interaction sites, 
as well as results from the monoclonal antibody (MAb) epitope analysis, the idea of 
redundancy was investigated. Docking and bioinformatics techniques were used to 
investigate structurally similar molecules that have comparable spatiotemporal expression 
patterns in the embryonic nervous system. AChE has been shown to be involved in the 
pathogenesis of Alzheimer’s disease, thus molecules associated with brain function and 
neurodegeneration were also investigated. Molecules with which AChE could be possibly 
redundant are syndecans, glypicans, perlecan, neuroligins and the low-density lipoprotein 
receptors and their variants. AChE was observed to dock with growth arrest-specific 
protein 6 (Gas6) as well as apolipoprotein E3 (ApoE-3) at the same site as the laminin 
interaction. The AChE interaction site was shown to resemble the apolipoprotein-binding 
site on the low density lipoprotein receptor, and related molecules, including the low 
density lipoprotein receptor-related molecule (LRP) and the sortilin-related receptor 
(SORL1). These molecules, along with apoE, are associated with Alzheimer’s disease. 
Resemblances to the triggering receptor on myeloid cells (TREM1) were also suggested; 
this is interesting as AChE has been implicated in both haematopoiesis and 
haematopoietic cancers. Coimmunoprecipitation results, applied to investigate alternative 
ligands for AChE, confirmed the AChE-laminin interaction in neuroblastoma cells, and 
also suggested the existence of other binding partners.  
 
In conclusion, characterisation of the AChE-laminin interaction sites and investigation of 
structurally similar sites in other molecules suggests a role for AChE in the stabilization 
of the basement membrane of developing neural cells and provides a feasible explanation 
for the survival of the knockout mouse. Furthermore, the demonstrated similarity of the 
AChE interaction site to sites on molecules, notably the low density lipoprotein receptor 
family and SORL1 and their apolipoprotein ligands that are implicated in the pathology 
of Alzheimer’s disease, as well as the possible link to haematopoietic differentiation and 
cancers, warrants further investigation.   
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Opsomming 
 
Talle in vitro studies wys dat die ensiem asetielcholienesterase (AChE), behalwe vir sy 
klassieke rol in die hidrolise van asetielcholien (ACh), ‘n aantal nie-cholinerge rolle 
vertolk insluitend in sel adhesie, in die uitgroei van neurieten, in differensiering, asook in 
amyloidosis. Dit is vooraf gewys dat AChE, met behulp van elektrostatiese meganismes, 
in vitro met muis laminin-111 kan bind. Dit word verneem dat die area op AChE wat 
herken word deur monoklonale teenliggaampies (MAbs), moontlik ‘n kritiese area is met 
betrekking tot differensiasie. Dieselfde MAbs is gevind om beide die laminin-interaksie, 
sowel as sel adhesie van neuroblastoma selle, te inhibeer. In hierdie projek word die 
struktuur en eienskappe van die betrokke kritiese areas ondersoek deur die AChE-laminin 
interaksie te gebruik as sjabloon. ‘n Gedetailleerde analise van die teenliggaam epitoop 
het ook geskied. Met behulp van faag vertoon, modellering en hegting, sintetiese 
peptiede, ensiem-gekoppelde immunosorbent toetse (ELISAs) en  konformasie interaksie 
area kartering, is die betrokke interaksie areas bestudeer. Hegting van enkel-ketting 
varierende fragment (scFv) volgordes, verkry vanaf die vaag vertoon, aan AChE dui dat 
die hoof herkennings motiewe die 90Arg-Glu-Leu-Ser-Glu-Asp motief, die 40Pro-Pro-
Met-Gly volgorde, en die 59Val-Val-Asp-Ala-Thr-Thr (mens) motief is. ‘n Interaksie 
tussen muis AChE en die α1 G4 domein van laminin is gevind. Die interaksie betrek die 
basiese structure: Val2718-Arg-Lys-Arg-Leu2722; Tyr2738-Tyr2739, Tyr2789-Ile-Lys-Arg-
Lys2793; en Val2817-Glu-Arg-Lys2820. Die betrokkenheid van die AG-73 (2719-2729) area 
by hierdie interaksie is bevestig met ELISA eksperimente wat sintetiese peptiede 
inkorporeer. Die AG-73 area oorvleuel die heparin interaksie area op laminin. Hegtings 
eksperimente wys dat die hoof komponent van die interaksie area op AChE die suur 
volgorde Arg90-Glu-Leu-Ser-Glu-Asp95 op die omega-lus is. Die interaksie betrek ook die 
Pro40-Pro-Val42, Arg46 (gekoppel aan Glu94 deur ‘n sout-brug) en die heksapeptied Asp61 
Ala-Thr-Thr-Phe-Gln66 motiewe. Analise van die MAb epitoop wys die hoof erkennings 
area as volgorde Pro40-Pro-Met-Gly-Pro-Arg-Arg-Phe48 (mens AChE). Die MAbs blyk 
ook gunstig te wees teenoor prolien-ryke volgordes soos Pro78-Gly-Phe-Glu-Gly-Thr-
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Glu84 en Pro88-Asn-Arg-Glu-Leu-Ser-Glu-Asp95. Die areas betrokke by die AChE-
laminin interaksie is dus gedefinieer en ‘n moontlike rol vir hierdie interaksie in sel 
adhesie word voorgestel.  
 
Die noodsaaklikheid van AChE se nie-klassieke funksies word bevraagteken na die 
oorlewing van die AChE uitklop-muis. Resultate hier dui op die moontlikheid van 
funksionele oortolligheid as verduideliking hiervan, spesifiek met betrekking tot 
molekules betrokke in vroëe ontwikkeling asook in die proses van neurale agteruitgang. 
Deur gebruik te maak van die in vitro demonstrasies van die AChE-laminin interaksie, 
informasie verkry ten opsigte van die betrokke interaksie areas, asook resultate verkry 
vanaf die monoklonale teenliggaam (MAb) epitoop analise, word die idee van 
funksionele oortolligheid ondersoek. Hegtings en bioinformatika tegnieke is gebruik om 
molekules met soortgelyke strukture en uitdrukkings patrone in die embrioniese 
senuweestelses te ondersoek. Ko-immuno presipitasie tegnieke is gebruik om so 
moontlike alternatiewe ligande vir AChE te ondersoek. Moontlike funksionele 
oortolligheid van AChE met die volgende molekules is gevind: syndecan; glypican; 
perlecan; neuroligin; asook die lae-digtheid lipoproteien (LDL) reseptore en hul variante. 
Hegting van AChE met ’growth arrest-specific’ proteien 6 (Gas6) en die apolipoproteien 
E3 (apoE3) is gedemonstreer en gevind om dieselfde area as die laminin interaksie te 
betrek. Die betrokke interaksie area op AChE het ooreenstemminge met die 
apolipoproteien interaksie area op die LDL reseptor asook met verwante molekules soos 
die lae-digtheids lipoproteien reseptor-geassosieerde molekuul (LRP) en die sortilin-
geassosieerde reseptor (SORL1). Hierdie molekules, insluitend apoE, speel beduidende 
rolle in die patologie van Alzheimer se siekte. Ooreenkomste tussen AChE en die 
verwekkings reseptor op myeloïde selle (TREM1) is ook voorgestel, die interaksie is van 
belang siende dat AChE voorheen geassosieer is met beide haematopoiesis en 
haematopoietiese kankers. Ko-immuno presipitasie resultate bevestig die AChE-laminin 
interaksie en dui op die moontlike teenwoordigheid van alternatiewe ligande vir AChE in 
vivo. 
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In konklusie, karakterisering van die AChE-laminin interaksie areas, gepaard met 
identifisering van struktureel ooreenstemmende areas in ander molekules, dui op ‘n rol 
vir AChE in die stabilisering van die basale membraan en verskaf dus ‘n geldige 
verduideliking vir die oorlewing van die AChE uitklop-muis. Die ooreenstemming van 
die AChE interaksie area met areas op ander molekules (spesifiek geassosieer met 
Alzheimer se siekte), asook die moontlike assosiasie van AChE met haematopoietiese 
differensiering en kanker, lê die grondslag vir verdere ondersoeke. 
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1. Introduction and Literature Review 
 
1.1 Historical Aspects  
 
As early as the 1900s scientists already had a clear idea of the human nervous system and 
how it works. They identified that individual cells called neurons form the basis of this 
system and that these cells communicate with one another via electrical messengers. The 
mechanisms underlying the travelling of these messengers between two adjacent cells, 
however, were still unknown (Dellon & Dellon, 1993; Moreno & Tharp, 2007; Changeux 
& Edelstein, 2005). In 1904 a young Cambridge undergraduate, Thomas R. Elliott, 
proposed that a chemical compound, today called a neurotransmitter, was responsible for 
carrying the message from one cell to another. Even though Elliott originally postulated 
that adrenaline might be the substance liberated when the nervous stimulus reaches the 
periphery, his work intrigued another scientist and friend of his, Henry Dale (Elliott, 
1904). Nearly two decades after Elliott’s hypothesis, a German scientist, Otto Loewi in 
collaboration with Dale, went on to identify the compound responsible as acetylcholine 
(ACh) (Loewi & Navratil, 1926). In 1936, Loewi and Dale were awarded the Nobel Prize 
in Physiology or Medicine “for their discoveries relating to the chemical transmission of 
nerve impulses” ("The Nobel Prize in Physiology or Medicine 1936". Nobelprize.org. 28 
Mar 2011 http://nobelprize.org/nobel_prizes/medicine/laureates/1936/). 
 
Dale had already postulated the existence of cholinesterases (ChEs) back in 1914 (Dale 
1914). In 1932, Stedman and colleagues observed that horse serum had a “splitting” 
effect on ACh. Their experiments demonstrated that there is an enzyme present in the 
blood-serum of horses which hydrolyses both acetyl- and butyryl-choline. The name 
“choline-esterase” was suggested for this enzyme (Stedman et al., 1932). Later studies by 
Mendel and Rudney, however, showed that the serum contained two enzymes capable of 
hydrolyzing ACh (Mendel & Rudney, 1943). Today the term ‘cholinesterase’ is used to 
define a family of enzymes that specifically catalyze the hydrolysis of choline esters. 
Even though both of the enzymes documented by Mendel and colleagues belong to the 
class serine hydrolases, they are distinguished by their specificities towards substrates 
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and inhibitors. The term Acetylcholinesterase (AChE) was assigned to the enzyme 
capable of hydrolyzing ACh, the smallest member of the choline ester series, faster than 
any other choline ester. AChE was found primarily in neural synapses and blood; the 
latter is therefore also known as red blood cell (RBC) or erythrocyte cholinesterase. 
Similarly, Butyrylcholinesterase (BChE) was defined by its capacity to hydrolyze other 
choline esters, including the larger BCh, as well. The enzyme commission recommended 
in 1964 the term AChE (Acetylcholine Acetylhydrolase; EC 3.1.1.7) for a ‘true’ and 
‘specific’ cholinesterase. The less specific BChE (Acylcholine Acylhydrolase; EC 
3.1.1.8), was termed simply “cholinesterase” or “pseudocholinesterase”. A 53% identity 
between AChE and BChE was revealed through sequence analysis indicating a very 
strong homology between the two enzymes (Schumacher et al., 1986; Lockridge et al., 
1987). Mutagenesis of only a few amino acids can convert AChE into a BChE-like 
enzyme (Harel et al., 1992; Vellom et al., 1993; reviewed in Legay, 2000). In practical 
terms, such as assays, the two enzymes are distinguished by their reaction with different 
inhibitors: AChE is specifically inhibited by BW284c51 (1,5-bis [4-
allyldimethylammoniumphenyl] pentan-3-one dibromide), and BChE by the 
organophosphate iso-OMPA (tetra [monoisopropyl] pyrophosphortetramide) (Luo et al., 
2006).  
 
1.2 The Cholinergic System  
 
1.2.1 Components and Neurotransmission 
 
The main physiological function of AChE, i.e. the hydrolysis of the neurotransmitter 
ACh at cholinergic synapses and neuromuscular junctions, is a rapid process occurring 
within one millisecond after ACh’s release. This reaction allows for precise temporal 
control of muscle contraction (Rosenberry et al., 1975). In the central nervous system, 
synapses of the basal forebrain and brain stem complexes are all cholinergic, while in the 
peripheral nervous system, the entire parasympathetic nervous system, all neuromuscular 
junctions, and the preganglionic neurons of the sympathetic nervous system are also 
cholinergic. In the peripheral nervous system, ACh has effects that include contraction of 
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smooth muscles (Hurwitz et al., 1967), dilation of blood vessels (Furgott & Zawadzki, 
1990), increased glandular secretions (e.g. Jin et al., 1992), and slowing of heart rate  
(Loewi & Navratil, 1926). 
 
The molecular components of the cholinergic system include: ACh, the neurotransmitter; 
choline acetyltransferase (ChAT), the enzyme responsible for ACh synthesis; the 
acetylcholine receptors (AChR, both muscarinic and nicotinic; see section 1.2.2) which 
bind ACh and generate the signal, and AChE, the enzyme responsible for the breakdown 
of ACh, thus controlling the duration of the signal (Figure 1 show the components 
involved in cholinergic neurotransmission). This system also contains another component 
called the vesicular acetylcholine transporter (VAChT) which is a neurotransmitter 
transporter responsible for loading ACh into secretory organelles in neurons making it 
available for secretion (Erickson & Varoqui, 2000). The action of AChE in hydrolyzing 
the neurotransmitter is necessary to limit the duration of post-synaptic AChR activation. 
 
Like all neurotransmitters, ACh can elicit either an excitory or inhibitory response, 
depending on the receptor to which it binds. Even though there is still many unanswered 
questions on how exactly ACh elicits a nerve impulse, the basic mechanism has been 
determined. By binding to its target receptor, ACh transfers its chemical signal. It is 
important that this binding is reversible in order for the nerve impulse to be terminated. It 
was found that immediately after binding, the ACh molecule is hydrolyzed i.e. breaking 
the ester bond by addition of H2O, ending the nerve impulse and hence enabling the two 
separate compounds, choline and acetate, to form new ACh and the nerve impulse-
cascade to continue (Figure 2) (Changeux & Edelstein, 2005).  
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Figure 1. Components of synaptic neurotransmission. (Katzung, 2001; Hardman et 
al., 2001).  
 
 
 
Figure 2. Hydrolysis cascade. AChE catalyses the hydrolysis of ACh (Wilson & 
Henderson, 2007) 
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1.2.2 Acetylcholine Receptors 
 
As mentioned above, there are two types of ACh receptors (AChR) that bind ACh and 
transmit its signal: muscarinic AChRs (mAChRs) and nicotinic AChRs (nAChRs). 
Muscarinic receptors, primarily abundant in the central nervous system (CNS), are 
characterised through their interaction with an H2O soluble toxin derived from a 
mushroom (Amanita muscaria) called muscarin (reviewed in Brann et al., 1993). 
mAChRs form part of the G-protein coupled receptors (GPCRs), also known as seven 
transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine 
receptors, and G protein-linked receptors. GPCRs comprise a large and diverse protein 
family of transmembrane receptors whose primary function is to transduce extracellular 
stimuli into intracellular signals by using a second messenger cascade system. This 
system involves the increase of intracellular calcium to transmit signals inside the cells, 
thus mediating a slow metabolic response (King et al., 2003; Kroeze et al., 2003). 
Estimates of the exact size of the GPCR superfamily vary. Fredriksson et al. (2003) listed 
over 800 during an analysis of the GPCRs in the human genome. This large-scale 
systematic phylogenetic analysis included the majority of GPCRs in the human genome 
and resulted in the classification of GPCRs into five families (Glutamate, Rhodopsin, 
Adhesion, Frizzled/Taste 2, and Secretin) (Fredriksson et al., 2003). ACh-receptor 
binding induces a conformational change within the receptor leading it to associate with 
the activation of an intracellular G protein. G proteins are composed of three subunits: α, 
β, and γ. Receptor activation of these protein requires a dual mechanism that involves 
guanine nucleotide exchange and changes in subunit conformation, and result in G 
proteins acting as enzymes catalyzing downstream intracellular events (Lee et al., 1992). 
An inhibitory postsynaptic potential is created where activation of the G protein 
decreases the probability of postsynaptic neuronal firing (Destexhe & Sejnowski, 1995). 
mAChRs are involved in a large number of physiological functions in the human body, 
including contraction of smooth muscles, heart rate and force and the release of 
neurotransmitters (reviewed in Brann et al., 1993). 
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Nicotinic receptors (reviewed in Takacs et al., 2001), characterised through their 
interaction with nicotine in tobacco, function as ligand-gated ion channels mediating fast 
synaptic transmission of the neurotransmitter by forming pores in the cells plasma 
membranes. nAChRs can be either neuronal or muscle type. The muscle–type nAChRs 
are localised at neuromuscular junctions (NMJs) where an electrical impulse from a 
neuron to a muscle cell signals contraction of the muscle. These muscle tone regulatory 
functions of these receptors make them targets for muscle relaxants. There are many 
types of neuronal nAChRs located at synapses between neurons as in the CNS where they 
are involved in learning and memory, arousal, reward, motor control, analgesia and 
cognitive function. Once two ACh molecules bound to and activated the receptor, a 
conformational change occurs resulting in the formation of an ion pore producing a rapid 
increase in the cellular membrane permeability of sodium and calcium ions. This results 
in the excitation and depolarisation of the muscle cell producing muscular contraction. 
The influx of calcium ions affects the release of neurotransmitters. The ACh binding site 
on the nicotinic receptor is a target for a variety of neurotoxins. These neurotoxins 
include a family of polypeptides found in certain snake venoms called α-neurotoxins (e.g. 
erabutoxin) which serve as antagonists for the ACh binding site (reviewed in: Endo & 
Tamiya, 1987; Menez, 1991). Upon binding to the nAChR, the neurotoxin prevents the 
binding of ACh which reversibly blocks the opening of the ion channel and formation of 
a pore preventing cations from passing through. This could result in neuromuscular 
inhibition of the envenomated species (Karlin, 1993).  
 
1.3 Acetylcholinesterase 
 
1.3.1 Evolution, Phylogeny and Distribution  
 
AChE is a type B carboxylesterase belonging to the α/β hydrolase fold protein 
superfamily. This group is defined by a common structural homology and the subfamily 
includes the cholinesterases (EC 3.1.1.7; EC 3.1.1.8), cholinesterase-domain proteins 
(CLAMS), carboxylesterases (EC 3.1.1.1), non-specific esterase and lipases (EC 3.1.1.3) 
(Holmquist, 2000). Although many of these proteins show little sequence homology, 
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conservation of the topology suggests that they diverged from a common ancestor (Ollis 
et al., 1992). The carboxylesterases and the cholinesterases on the other hand, are 
sequentially related. The cholinesterases are specialised carboxylesterases and have 
evolved from carboxylesterases (Shibata et al., 1993). Carboxylesterases are found in 
eubacteria, protozoans, fungi and metazoans. They are not seen in either plants or 
archeabacteria (Pezzementi et al., 2010).  
 
AChE is found in vertebrate nervous, muscular and haematopoietic systems and AChE-
like enzymes are also found in many invertebrate groups (Grisaru et al., 1999). AChE-
like proteins have been reported in algae (Raineri & Modenesi, 1986), Paramecium 
(Corrado et al., 1999), and the slime mould, Dictyostelium, where it was found to 
promote aggregation (Rubino et al., 1989). Examination of these sequences, however, 
indicates that these enzymes are not true cholinesterases (Johnson et al, unpublished). 
True cholinesterases, as defined by the presence of the choline-binding site (mammalian 
numbering: Trp 86, Tyr 133, Glu 202 and Phe 337) (Sussman et al., 1991), are first seen 
in the nervous tissue of the Platyhelminthes. Cnidarians, which do have primitive nervous 
systems, do not have cholinesterases. Presumably, the ACh hydrolysis function is 
accomplished by carboxylesterases in these animals. Observations of AChEs non-
neuronal distribution gave rise to the idea that AChE may have other functions apart from 
its traditional cholinergic role and will be discussed in more depth in sections to follow 
(see section 1.6). 
 
1.3.2 AChE Structure 
 
1.3.2.1 Gene and Transcription 
 
Through the techniques of fluorescent in situ hybridization coupled with selective 
polymerase chain reaction (PCR), the human AChE gene was found to reside on 
chromosome 7q22 (Ehrlich et al., 1992). The AChE gene is activated by cholinergic 
neurotransmission, suggesting a feedback mechanism where neurotransmission possibly 
leads to increased AChE protein formation as well as accelerated degradation of ACh at 
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cholinergic synapses (Nitsch et al., 1998). Increased synthesis of ACh leads to increased 
stimulation of AChR, which leads to increased expression of AChE (Choi et al., 2003). 
Cholinesterases are synthesized into the endoplasmic reticulum, processed, transported 
through the secretory pathway, and then targeted to their final destination. The primary 
translation product contains an N-terminal secretion signal. This is cleaved in the mature 
protein. The N-terminal signal is followed by a small C-terminal region and the catalytic 
domain (Massoulié et al., 1999). Early genetic linkage studies suggested that, for the 
human AChE gene, allelic variants at a single locus exists (Coates & Simpson, 1971). 
The core of human AChE, common to all variants, consists of 543 amino acids. These 
amino acids are encoded by exons E2, E3 and E4 of the AChE gene. Exon E1 is a non-
coding exon (Soreq et al., 1990). At post-transcriptional level, alternative splicing of the 
remaining two exons (E5 and E6) give rise to different C-terminal regions generating 
alternative AChE mRNA species (Li et al., 1993). The different splice variants, together 
with the association of AChE catalytic subunits with additional domains and proteins, 
result in an array of oligomeric forms. These oligomeric forms are broadly grouped into 
globular and asymmetric forms (Massoulie, 2002). The different molecular forms are 
discussed in more detail in section 1.3.2.3. 
 
1.3.2.2 Gene Expression and Activation 
 
Neurons, hematopoietic cells and muscle cells have been the main focus in unfolding the 
molecular mechanisms underlying the regulation of AChE gene expression (Angus et al., 
2001; Luo et al., 1994; Tung et al., 2004; Soreq & Seidman, 2001). Post-transcriptional 
regulatory mechanisms seem to play an important role in the induction of AChE 
expression by stabilizing existing transcripts in all the molecular forms (Chan et al., 
1998; Coleman & Taylor, 1996; Deschenes-Furry et al., 2003; Luo et al., 1994). 
Transcriptional activation of the AChE gene in Torpedo, mouse, rat and human have, on 
the other hand, been reported to be regulated by several regulatory elements within the 
AChE promoter (Angus et al., 2001; Ben Aziz-Aloya et al., 1993; Chan et al., 1999; 
Ekstrom et al., 1993; Mutero et al., 1995; Siow et al., 2002). During the differentiation of 
myoblasts into myotubes, the elevation of intracellular Ca2+ seemed to increase AChE 
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transcript levels. This suggested that transient increases of intracellular Ca2+ may be 
critical for the commitment of AChE expression during myogenesis (Luo et al., 1994). 
With the use of chick or mouse myotubes expressing promoter-reporter constructs from 
genes of AChE, the pathway to activation of the AChE gene was shown to involve 
protein kinase C and once again, intracellular Ca2+. At the neuromuscular junctions of 
vertebrates, adenosine triphosphate (ATP) is known to stabilize ACh in the synaptic 
vesicles and is co-released with it. It seems that ATP acts via the ATP receptor to 
stimulate AChE expression, which is mediated by protein kinase C and intracellular Ca2+ 
release (Choi et al., 2003).  
 
Amyloid precursor protein (APP) was reported to increase AChE activity in p19 
embryonic carcinoma and retina cells via a calcium influx mechanism (Melo et al., 2003; 
Sberna et al., 1997). Apoptosis in various cell types, including non-nervous, non-muscle 
and non-hematopoietic systems, was found to induce AChE expression, suggesting a 
novel role for AChE in apoptosis (Zhang et al., 2002). Calcium is an important second 
messenger and plays significant roles in the modulation of intracellular processes such as 
apoptosis (Demaurex & Distelhorst, 2003; Groenendyk et al., 2003). Ca2+ overload has 
been suggested as the final pathway of all types of cell death (Rizzuto et al., 2003). 
Studies show that cytosolic Ca2+ plays a key role in AChE regulation during apoptosis 
(Zhu et al., 2007). It is thus safe to conclude that calcium is an important mediator in the 
regulation of AChE expression and its role in other processes involving AChE will be 
discussed in later sections. 
 
1.3.2.3 Primary, Secondary and Tertiary Structure 
 
The primary structure of several cholinesterases is shown in Figure 3. As mentioned 
above, AChE belongs to the α/β hydrolase fold protein superfamily. These proteins 
contain a β-sheet internal scaffold of several β-strands supporting an array of helices and 
loops (Figure 4) (Sussman & Silman, 1992). In addition to the sequence homology, other 
common features of carboxylesterases and cholinesterases are a Ser-His-Glu catalytic 
triad (Figure 5), characteristically located at the bottom of a deep gorge, and the so-called 
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carboxylesterase type B signature 2, the EDCLYLN motif, which surrounds a Cys 
residue involved in disulphide bonding. The sequence immediately surrounding the 
active site Ser is conserved in the family, and is described by ProSite pattern PS00122 
(carboxylesterase type B serine active site; consensus pattern F-[GR]-G-x(4)-[LIVH]-x-
[LIV]-x-G-x-S-[STAG]-G, where the single “S” is the active Ser). The carboxylesterase 
type B signature 2 is described by ProSite pattern PS00941, [EDA]-[DG]-C-L-[YTF]-
[HVT]-[DNS]-[LIV]-[LIVFYW]-x-[PQR] (Sigrist et al., 2010). 
 
 
                                                                 * 
 T. californica AChE     .(64).PNNCQQY...(91).SEDCLYL..(197).FGESAGG 
 Bovine AChE             .(66).QSVCYQY...(93).SEDCLYL..(200).FGESAGA 
 Human AChE              .(66).QSVCYQY...(93).SEDCLYL..(200).FGESAGA 
 Human BChE              .(62).ANSCCQN...(89).SEDCLYL..(195).FGESAGA 
 C. rugosa lipase        .(57).GPSCMQQ...(94).SEDCLTI..(206).FGESAGS 
 G. candidum lipase      .(58).SPACMQL..(102).NEDCLYL..(214).FGESAGA 
 
                                                                * 
 T. californica AChE     (251).NLNC....NLNSDEELIHCLRE..(324).NKDEGSF 
 Bovine AChE             (254).LVGCPPGGAGGNDTELVACLRA..(331).VKDEGSY 
 Human AChE              (254).LVGCPPGGTGGNDTELVACLRT..(331).VKDEGSY 
 Human BChE              (249).LTGC....SRENETEIIKCLRN..(322).NKDEGTA 
 C. rugosa lipase        (265).NAGC......GSASDKLACLRG..(338).QNDEGTF 
 G. candidum lipase      (273).YAGC...DTSASANDTLECLRS..(351).QEDEGTA 
 
                                                 * 
 T. californica AChE     (399).NVICPLM..(437).GVIHGYE..(518).VQMCVFW 
 Bovine AChE             (406).NVVCPVA..(444).GVPHGYE..(526).AQACAFW 
 Human AChE              (406).NVVCPVA..(444).GVPHGYE..(526).AQACAFW 
 Human BChE              (397).NFICPAL..(435).GVMHGYE..(517).AQQCRFW 
 C. rugosa lipase        (414).GFTLARR..(446).GTFHSND..(520).AGYDALF 
 G. candidum lipase      (427).LFQSPRR..(460).GTFHGNE..(531).EGISNFE 
 
 
 
Figure 3. Primary structure of cholinesterases. The partial α/β hydrolase fold 
sequences are numbered from the amino terminus of the mature protein. Commonly 
conserved residues are highlighted in bold and include those of the catalytic triad 
(marked by asterisks) and the cysteines involved in intra-subunit disulphide bonds 
(http://www.weizmann.ac.il/sb/faculty_pages/Sussman/kurt/fig6.html).  
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Figure 4. The secondary structure of AChE. The β-sheets are shown in green and the 
α-helices in red (Ripoll et al., 1992). 
 
AChE itself is a large (~68-kDa) single domain protein containing the characteristic 
hydrolase fold (Abram et al., 1989; Wasserman et al., 1993). When the crystal structure 
for Torpedo californica (Tc) AChE was revealed (Sussman et al., 1991) the active centre 
was shown to be buried at the bottom of a narrow gorge, about 20Å deep, lined with 
conserved aromatic residues (Figure 6). This gorge was termed the active site gorge 
(ASG) and the entire gorge lining as well as its periphery seems to be involved in the 
catalytic reaction. The ASG is only ~5Å wide at a bottleneck formed by van der Waals 
surfaces of Tyr 121 and Phe 330 (residue numbers refer to TcAChE sequence). The 
diameter of the quaternary choline moiety was found to be 6.4Å. It seems that substantial 
breathing motion of the gorge is required for sufficient substrate and product trafficking 
(Colletier et al., 2006). Seeing as AChE is one of the most efficient enzymes known, with 
an impressive turnover number, it might seem counter-intuitive to have the active site 
located deep within the enzyme. But these structures have been strongly conserved 
throughout all life forms and thus clearly have a selective advantage. It is likely that the 
confinement of the substrate in a relatively small space and surrounded almost entirely by 
the enzyme allows for exact positioning and stabilization (Harel et al., 1996). See section 
1.3.3 for details on catalysis. 
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Several specific subsites have been identified within the gorge; the numbering used 
corresponds to TcAChE numbering followed by mammalian (human and mouse) AChE 
numbering in brackets (Figures 5 & 7). These sites include the actual active or acylation 
site (Ser 200 (203), His 440 (447) and Glu 327 (334)), a hydrophobic or choline-binding 
subsite (also called the anionic site; Trp 84, Phe 330, Tyr 130 and Glu 199 (mammalian: 
Trp 86, Tyr 337, Tyr 133 and Glu 202)) which binds and stabilizes the choline moiety of 
the substrate, the acyl pocket (Phe 288 (295) and Phe 290 (297)) and the oxyanion hole 
(Gly 118 (121), Gly 119 (122), Ala 201 (204)) involved in the stabilization of the 
substrate transition state (Sussman et al., 1991; Sussman & Silman, 1996; Shafferman et 
al., 2005). An additional anionic site (the peripheral site or peripheral anionic site (PAS; 
Tyr 70 (72), Asp 72 (74), Tyr 121 (124), Trp 279 (286) and Tyr 334 (341)) surrounds the 
rim of the gorge, on the molecule’s surface. The PAS is a secondary substrate binding 
site lying approximately 20Ǻ distant from the active site itself, and binds ACh as the first 
step in the catalytic pathway (Hosea et al., 1996; Mallender et al., 2000). This site 
allosterically modulates catalysis and is also the main binding site for specific inhibitory 
compounds (see section 1.3.4 for details on AChE inhibitors) (Radic et al. 1991).  
 
 
Figure 5. The 3D 
structure of 
TcAChE. The 
catalytic triad is 
highlighted in red, 
Trp 84 in the 
catalytic anionic 
subsite (CAS; 
choline binding 
subsite), Trp 279 at 
the PAS, and the 
bottleneck residue 
Phe 330 in blue 
(residue numbers 
refer to TcAChE) 
(Colletier et al., 
2006). 
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Figure 6. The active site gorge of 
AChE. A cross-section through the 
ASG of TcAChE, showing the 
residues involved in the CAS, PAS 
and the catalytic triad (Silman & 
Sussman, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Structure of 
TcAChE. The different 
subsites are shown: the 
active site (in red), the 
choline-binding site (in 
blue) and the PAS (in 
yellow) (Johnson & 
Moore, 2006). 
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There are a number of surface loops associated with the PAS (Figure 8) which 
incorporate several of its residues. The Cys residue (Cys 96), which is part of the 
carboxylesterase type B signature 2 motif (described above), forms a disulphide bond 
with Cys 69 (Barak et al., 1995). The residues between them form a large omega loop. 
Omega loops are non-regular secondary structures found in globular proteins. They are 
characterized by a polypeptide chain that follows a loop-shaped course in three-
dimensional space and are so-called because it forms the shape of the Greek upper-case 
Ω, with the two Cys residues forming the link at the base (Fetrow, 1995). Structural 
homology is found between AChE Cys 69-Cys 96 loop and the lid loop that seizes 
substrate in neutral lipases. This structural element is conserved throughout the 
esterase/lipase family (Cygler et al., 1993). Two of the PAS residues (Tyr 70 (72) and 
Asp 72 (74)) lie on the Cys 69-Cys 96 omega loop. Trp 84 (86), the major component of 
the anionic choline-binding subsite near the base of the gorge, lies on the latter section of 
this loop. A section of the loop thus runs between the PAS at the rim of the gorge, and the 
bottom of the gorge, and these residues form part of the gorge lining (Sussman et al., 
1991). The high aromatic content of the active site gorge and the PAS specifically is a 
remarkable feature of AChE and it is the aromatic residues contained within the gorge 
lining that contributes to its flexibility. It was found that even in the absence of ligand, 
AChE can assume different conformations (Xu et al., 2008). 
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Figure 8. Mouse AChE (PDB code 1J06) showing the PAS and associated omega 
loops. One of the two catalytic subunits is shown. The arrow indicates the opening of the 
ASG. PAS residues (Tyr 72, Asp 74, Tyr 124, Trp 286 and Tyr 341) are shown in green 
with the omega loop (Cys 69-Cys 96) in yellow apart from the two PAS residues, Tyr 72 
and Asp 74 which are in green. The sequences 40-54 are shown in red and 55-66 in blue 
(Johnson et al., 2008). 
 
 
When the 3D structure of TcAChE was examined, the enzyme showed a marked 
asymmetric spatial distribution of charged residues. These residues are segregated into a 
‘northern’ negative hemisphere (where the mouth of the gorge is taken as the northern 
pole) and a ‘southern’ positive one. This electrostatic pattern gives rise to the strong 
negative dipole moment found in AChE, running more or less parallel to the direction of 
the active site gorge (Ripoll et al. 1993; Porschke et al. 1996). The asymmetric 
distribution of surface potentials contributes directly to the steering of the positively 
charged ACh towards the active site (Antosiewicz et al., 1996). There are seven acidic 
residues near the opening of the gorge. These residues directly contribute to this dipole 
moment. See section 1.3.3 for details on the role of the dipole moment in catalysis. 
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1.3.2.3 Quaternary Structure 
 
As mentioned above, alternative splicing of the AChE gene generate alternative 
molecular forms. Even though these molecular forms, sometimes called size-isomers, are 
identical in catalytic properties, their subunit assembly, hydrodynamic behavior, ionic or 
hydrophobic interactions, and modes of cell surface associations differ substantially 
(Massoulié et al., 1993; Massoulié & Toutant, 1988; Taylor, 1991). These molecular 
forms are (Figure 9): 
 
(a) AChE-T/ AChE-S: Splicing of exons E1-E2-E3-E4-E6 results in a 40 amino acid 
peptide at the C-terminal end of the catalytic domain. This form is an amphipathic protein 
and contains cysteine, which allows for dimerisation and the formation of higher order 
AChE oligomers. It also contains seven aromatic residues, including three tryptophans, 
organized in an amphiphilic α-helix, with these residues forming a hydrophobic cluster, 
and which allow for interaction with the membrane-anchoring proteins ColQ and 
hydrophobic Proline Rich Membrane Anchor (PRiMA) (Massoulié, 2002). This 
transcript, called AChE-T (for tailed) by Massoulié (Massoulié, 2002) and AChE-S (for 
synaptic) by Soreq (Soreq et al., 2010), is the major AChE splice variant, and the form 
predominating in synapses and neuromuscular junctions. It is also the principal form in 
brain and muscle tissue (Grisaru et al., 1999; Seidman et al., 1995). 
 
(b) AChE-H/ AChE-E:  The second molecular variant is produced by splicing exons E1-
E2-E3-E4-E5-E6 producing a 43 amino acid peptide at the C-terminus. This peptide is 
cleaved after residue 14 of E5 (residue 557 from the N-terminus) and is linked to 
glycophosphotidylinositol (GPI), which allows for membrane association. These AChE 
isoforms, called AChE-H (for hydrophobic) and AChE-E (for erythrocyte) are found in 
Torpedo muscle and the erythrocyte membrane of mammals (Massoulié et al., 1999; 
Massoulié, 2002). 
 
(c) AChE-R:  This third major AChE specie is formed by continuous transcription 
through intron 14 to yield E1-E2-E3-E4-I4-E5-E6 and produces a hydrophilic 26 amino 
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acid C-terminal peptide that lacks cysteine, and thus remains monomeric. This 
“readthrough” form, expressed in embryonic and tumour cells, is also induced in 
response to AChE inhibition and stress (Grisaru et al., 1999; Karpel et al., 1994, Karpel 
et al., 1996). AChE-R RNA is also significantly less sTable than the AChE-S isoform 
(Chan et al., 1998). A shift in the splicing pattern of AChE is often seen as a result of its 
transcriptional activation. This can lead to the accumulation of this rare AChE variant. 
AChE-R mRNA levels measured after 30 minutes of confined swim stress, for example, 
was shown to be considerably increased compared to normal levels. The same result 
presented after exposure to anti-AChEs or acetylcholine analogues (Soreq & Seidman, 
2001). 
 
 
 
Figure 9. AChE isoforms (Grisaru et al., 1999) 
 
Apart from these three major AChE molecular forms, a fourth form exists. This form is 
also called AChE-S, but here the S stands for ‘snake’ or ‘soluble’ as it is found in Elapid 
snakes (Bungaris, Naja, etc.) only. These snakes possess a high level of secreted and 
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soluble monomeric AChE in their venoms. Through partial peptide sequencing, Cousins 
et al. showed that this AChE form is very closely homologues to other AChEs, but it has 
not been found in significant levels in other tissues. Gene analysis of the AChE-S form 
revealed the absence of an H exon and the presence of a T exon, which is expressed in 
the snake muscle. It also contains a novel S exon which encodes the C-terminal of the 
venom enzyme. AChE’s role in the snake venom is unclear as AChE does not reinforce 
toxicity and is also a non-toxic entity by itself (Cousin et al., 1996; Cousin et al., 1998; 
Massoulié et al., 1999). 
 
1.3.2.4 Post Translational Modifications 
 
During biosynthesis, cholinesterases are transferred into the endoplasmic reticulum 
because of their N-terminal secretory signal peptide. Here, in addition to alternative 
splicing, they are subjected to various post translational modifications in the secretory 
pathway. These modifications include oligomerization, association with membrane-
anchoring proteins and glycosylation, further producing even more variations of the 
molecule (Massoulié et al., 2005). Different post-transcriptional modifications and 
quaternary associations are determined by the H and T C-terminal peptides. Cysteine 
residues of the C-terminal peptide of AChE-H transcripts may form intercatenary 
disulfide bonds and contain signals for cleavage and the addition of GPI. These residues 
allow for the formation of mature GPI-anchored amphiphilic dimers. Likewise, the 
AChE-T peptide contains a free cysteine located near its C terminus and this peptide 
allows for a variety of quaternary associations (Massoulié et al., 1993; Sussman et al., 
1991). Dimers of both AChE-H and –T peptides may further associate to produce 
tetramers (dimers of dimers).  
 
As mentioned, AChE-T is mostly expressed in mammalian cholinergic tissues where the 
C-terminal 40-residue peptide allows the formation of AChE-T tetramers (Massoulé et 
al., 2005; Massoulé & Bon, 2006). Heteromeric complexes assemble around structural 
proteins where complexes containing collagen ColQ are attached to the basal lamina at 
NMJs and complexes containing proline-rich membrane anchor (PRiMA) are anchored in 
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cell membranes (Gennari et al., 1987; Inestrosa et al., 1987; Krejci et al., 1997; Feng et 
al., 1999; Perrier et al., 2002). It was shown that the T-peptide forms an amphiphilic α-
helix with a sector containing the seven aromatic residues conserved in all vertebrate 
ChEs (Bon et al., 2004). These aromatic residues play an important role in the association 
of four T-peptides with proline-rich motifs found in the N-terminal regions of ColQ and 
PRiMA called proline-rich attachment domains (PRADs) (Perrier et al., 2002; Bon et al., 
1997; Belbeoc’h et al., 2004). Interactions with ColQ seem to be mostly dependant on the 
T-peptide as addition of this peptide at the C-terminus of foreign proteins was found to 
enable these proteins to form tetramers associated with ColQ (Bon et al., 1997). The 
PRAD motif of ColQ is preceded by a pair of adjacent cysteines which can form 
disulfide-like bonds with the C-terminal cysteines of the two T-peptides, where the 
remaining two T-peptides are disulfide-linked to each other. It was shown that the 
disulfide bonds between the PRAD and the T-peptides could only form when the 
cysteines were located at opposite extremities (Bon et al., 2004). ColQ and PRiMA differ 
in the lengths of their proline-rich motifs. ColQ contains 10 and PRiMA 15 residues. 
They also differ markedly in the number of prolines in their PRADs (8 in ColQ, 14 in 
PRiMA) (Noureddine et al., 2007). The numbers and dispositions of cysteines in ColQ 
and PRiMA are also very different which may lead to different organization of 
complexes. It was reported that the two PRADs of ColQ and PRiMA differ in their 
interaction with AChE-T subunits. Very few heavy dimers in the complexes formed with 
the PRiMA PRADs were found. In certain complexes it was shown that all four AChE-T 
subunits appeared to be disulfide-linked to PRiMA, whereas in others, they were 
associated only in pairs (light dimers). Mutation of the last aromatic residue in the T-
peptide was shown to differently affect the formation of complexes with the PRADs of 
ColQ and PRiMA. The quaternary organization of AChE-T tetramers with ColQ and 
PRiMA thus appear to be somewhat different (Noureddine et al., 2008). Figure 10 shows 
the N-terminal sequences of human ColQ and PRiMA containing the PRADs, as well as 
the organization of the disulfide bonds between the T-peptides and ColQ, along with a 
schematic model of the AChE collagen-tailed molecule. 
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Fig 10. (A) The sequences of the N-terminal regions of human ColQ and PRiMA, 
containing the PRADs, are shown. The PRAD segment is underlined and cysteines 
contained within the sequence are doubly underlined. A potential N-glycosylation site is 
also indicated. (B) The organization of disulfide bonds between the four T-peptides and 
ColQ. (C) A schematic model of an AChE collagen-tailed molecule: the Figure shows 
only one AChE tetramer attached to one of the three collagen ColQ subunits (Massoulé & 
Bon, 2006; modified from Dvir et al., 2004).  
 
The presence or absence of the collagen ColQ tail is used to characterize the different 
molecular forms of AChE. Isoforms lacking the ColQ tail are termed globular (G) forms. 
Globular forms constitute a heterogeneous group, which can be subdivided into 
monomers (G1), dimers (G2) and tetramers (G4) (Figure 11) (Massoulié et al., 1992; 
Massoulié et al., 1993). G1 is largely intracellular and appears to be a precursor form of 
G4 (Lazar & Vigny, 1980). These G forms can be amphiphilic or nonamphiphilic and 
they represent the major fraction of AChE in most vertebrate tissues (Toutant & 
Massoulié, 1987; Massoulié & Toutant, 1988). If there is no association with GPI or 
PRiMA, these forms are hydrophilic. Hydrophilic G isoforms are frequently found in 
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embryonic development, and they may be precursors of the more complex forms. 
Amphiphilic isoforms include amphiphilic dimers, usually GPI-linked, as found in the 
erythrocyte membrane, and amphiphilic tetramers, linked to PRiMA, which appear 
during differentiation in the embryo and are the predominant form in the synapses of the 
CNS of the adult (Bon et al., 1991; Bon et al., 1988a; Bon et al., 1988b).  
 
ColQ-linked isoforms are also known as asymmetric or A forms, because of the 
appearance conferred by the addition of the tail (Figure 11). Asymmetric forms 
predominate in neuromuscular junctions, and include tetramers (A4), octamers (A8), 
consisting of two tetramers linked to ColQ, and, most commonly, dodecamers (A12), 
consisting of three tetramers linked to ColQ (Massoulié et al., 1992b;  Massoulié et al., 
1993). It has been suggested that, although the functional significance of these AChE 
polymorphisms are still elusive, it allows the placement of catalytically active subunits in 
distinct cell types and sub cellular locations to perform site-specific functions. In 
mammals, for example, glycophospholipid-linked dimers are found preferentially in 
hematopoietic tissue whereas asymmetric forms are exclusively expressed in 
differentiated muscle and neuronal cells (Chan et al., 1998).  
 
 
 
Figure 11. Alternative splicing of molecular forms of AChE (Krejci, 1998) 
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Yet more variation is conferred by differences in glycosylation. Post translational 
glycosylation can have multiple effects on the transport of proteins towards the cell 
surface, their biological activity, their stabilization and also functional conformation (Chu 
et al., 1978; Gibson et al., 1979; Dubé et al., 1988; Matzuk et al., 1989; Semenkovich et 
al., 1990). ChEs are multimeric glycosylated ectoenzymes displaying several potential 
glycosylation signals, although, the number and location are not conserved throughout 
the ChE family (Velan et al., 1993). For example, human BChE has nine potential sites 
where human AChE has only three N-linked glycosylation sites: Asn 265, Asn 350, Asn 
464 (Lockridge et al., 1987; Prody et al., 1987; Soreq et al., 1990; Velan et al., 1993). 
Mouse and rat AChE also contain three where foetal bovine AChE has five (Rachinsky et 
al., 1990; Legay et al., 1993; Kronman et al., 1995). The three glycosylation sites in 
human AChE are conserved in all mammalian ChEs sequenced to date (Gentry & Doctor, 
1991). Site-directed mutagenesis analysis of these three sites showed that all three 
glycosylation signals are utilized but not all the secreted molecules are fully glycosylated. 
It was also found that glycosylation at all three sites is important for effective 
biosynthesis and secretion and glycosylation mutants presented impaired stability 
reflected in their increased susceptibility to heat inactivation (Velan et al., 1993).  
 
In pathology, several neurodegenerative disorders, such as Alzheimer’s disease (AD) and 
Creutzfeldt-Jakob disease (CJD), have been found to cause characteristic alterations in 
the glycosylation patterns of certain brain proteins (Saez-Valero et al., 1999). Mutations 
of the AChE gene have also been linked to certain cancers. A more in depth discussion 
on these topics follows.  
 
1.3.2.4.1  Anchorage of AChE in the basal lamina and cell membrane 
 
In the neuromuscular junction, AChE is anchored in the basal lamina by ColQ. ColQ 
binds to the heparan sulfate proteoglycan perlecan, which in turn binds to the 
dystroglycan complex through α-dystroglycan (Peng et al., 1999). ColQ also binds to 
MuSK, forming a ternary complex of AChE/ColQ, perlecan and MuSK (Cartaud et al., 
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2004). These interactions result in clustering of AChE, and the formation of scaffolds 
through which AChR can be clustered by activation of the MuSK.  
 
During development of the nervous system, and in the adult central nervous system, the 
predominant isoform is the amphiphilic G4, which is anchored in the cell membrane by 
PRiMA. PRiMA contains a number of domains: an extracellular domain, which contains 
the PRAD, a transmembrane domain, and a cytoplasmic domain (Perrier et al., 2002). 
PRiMA is targeted to membrane rafts, possibly by its CRAC (cholesterol 
recognition/interaction amino acid consensus) motif located at the C-terminus (Xie et al., 
2010). PRiMA-linked AChE in fibroblasts and astrocytes is also reported to co-localise 
with perlecan (Anderson et al., 2008). 
 
1.3.3 Catalysis in AChE  
 
High speed action is a prerequisite of any enzyme functioning in the nervous system. 
AChE is thought to be one of the fastest enzymes and its turnover number is of special 
interest. The entire course of signal transmission at the neuromuscular junction i.e. the 
release of ACh, its diffusion across the synaptic cleft, its reversible interaction with the 
AChR and, finally, hydrolysis by AChE, occurs within milliseconds. This rapid process 
must, therefore, be tightly integrated both spatially and temporally (Scholl & Scheiffele, 
2003; Bourne et al., 2003). AChE has an unusually high turnover number especially for a 
serine hydrolase, operating at a rate close to that of diffusion (Quinn, 1987; Scholl & 
Scheiffele, 2003). According to Wilson and Harrison (1961) the turnover number for 
AChE at 25oC, a pH of 7.0 and ACh level of 2.5 x 10-3M, was found to be 7.4 x 105min-1. 
The importance of rapid cholinergic transmission is also underlined by the magnitude of 
AChE’s kcat/KM, ≈ 109 M-1·s-1 (Nolte et al., 1980; Radic et al., 1992), which ranks as one 
of the highest catalytic efficiencies known (Fersht, 1985). In vertebrates, because of their 
intelligence and quick movements, selective pressure has driven AChE to become an 
almost ‘perfect enzyme’ (Quinn, 1987).  
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It was originally suggested, through kinetic studies, that the substrate might be attracted 
to the active site by a large number of negative charges in the vicinity (Nolte et al., 1980). 
This notion was later disproved by the crystal structure characterization of AChE 
(Sussman et al., 1991). Theoretical calculations indicated the presence of a large, 
permanent dipole moment which may guide the substrate to the gorge (Ripoll et al., 
1993; Tan et al., 1993). Mutagenesis of the seven acidic residues near the opening of the 
gorge was found to adversely affect AChE’s catalytic efficiency (Shafferman et al., 1994; 
Zhou et. al., 1998). Because of the position of the active site at the bottom of a gorge, the 
substrate has to be guided down the gorge as rapidly and efficiently as possible. Choline 
esters such as ACh, are positively charged and thus electrostatically attracted towards the 
opening of the gorge and the negative charge surrounding the PAS (Felder et al., 1997; 
Silman & Sussman, 2008). Even though the importance of the electrostatic guidance 
mechanism in accelerating the binding of cationic ligands is unquestioned, a lot of 
controversy over the contribution of the dipole moment to the high turnover rate exist 
(Shafferman et al., 1994; Antosiewicz et al., 1995). Antosiewicz et al. (1996) showed 
that in AChE, there is an electrostatic steering of substrate present where the effects of 
electrostatics were observed mainly in the area above the entrance to the gorge. The 
charge distribution seems to become more important as the ligand moves down the gorge. 
It was stated that neither the enzyme’s total charge, nor its dipole moment, can fully 
account for this electrostatic steering of ligand to the active site. It appears that there is no 
simple correlation between the rate constants and electrostatic aspects such as net charge 
and dipole moment. It is evident that higher moments of the enzyme’s charge distribution 
are also important. That being said, electrostatic steering does exist, as indicated by the 
fact that the hydrolysis and encounter rate constants for cationic substrate are 
substantially larger than those for neutral substrate (Antosiewicz et al., 1996). 
 
Apart from the dipole moment, other factors also contribute towards enzyme function. 
Choline esters also contain a quaternary ammonium group. Quaternary ammonium 
groups interact with aromatic rings and seeing as the gorge is lined with a number of 
aromatic residues, the substrate thus interact with their side chains as it heads down the 
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gorge (Xu et al., 2008). As mentioned these aromatic residues also contributes to the 
flexibility of the gorge in order to accommodate substrates larger than the gorge itself. 
 
The first step in the catalytic pathway is the binding of the substrate to the PAS of the 
AChE molecule. The PAS enhances catalytic efficiency by ‘trapping’ the substrate on its 
way to the catalytic site or active centre (Mallender et al., 2000; Hosea et al., 1996). Trp 
286 (numbering from here on refers to mammalian unless otherwise stated) in the PAS is 
especially important in the binding of cationic ligands (Ordentlich et al., 1993; Bourne et 
al., 2003). It has been shown that substrate binding at the PAS triggers a conformational 
change that is transmitted allosterically to the acylation site (De Ferrari et al., 2001a). A 
relay of cation-pi interactions with Trp 86, Phe 295 and Tyr 341 assist in movement down 
the gorge (Branduardi et al., 2005). The fourteen aromatic residues within the gorge are 
involved in this relay system (Sussman et al., 1991). When ACh reaches the base of the 
gorge, it binds to the choline-binding site. Trp 86 is the major component of this site, 
interacting with the quaternary ammonium of the choline moiety by cation-pi interactions 
(Sussman et al., 1991). This binding positions the ACh molecule optimally for 
nucleophilic attack on the vulnerable ester bond by the Ser (Ser 203) of the acylation site 
(Eastman et al., 1995). In the reaction, His 447 acts as a general acid-base catalyst, 
accepting or donating a proton. It is possible that the acidic residue of the triad, Glu 334, 
functions by forming a temporary salt bridge with the His (Dodson & Wlodawer, 1998). 
The oxyanion hole and the acyl pocket are involved in stabilization of the transient and 
fragile transition state. The acyl pocket is responsible for substrate selectivity by 
preventing access of larger members of the choline ester series and the oxyanion hole 
provides hydrogen bond donors that stabilize the tetrahedral transition state of the 
substrate (Ordentlich et al., 1998). Finally, the molecule is stabilised by cation-pi 
interactions with Trp 86 in the active centre. 
 
An intriguing feature of AChE reactivity is the modulation of catalytic activity following 
ligand binding to the PAS (Changeux, 1966; Hucho et al., 1991). The concentration of 
neurotransmitter and other charged species, such as Ca2+, Mg2+ and Na+, fluctuate in the 
synaptic cleft. Such catalytic activity modulation can play a significant role in adjusting 
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to these fluctuations (Berman & Nowak, 1992). Opposite to Michaelis-Menten kinetics, 
when substrate concentration is at a high, a reduction in turnover i.e. substrate inhibition 
is seen. This is a consequence of substrate binding to the PAS (Radic, 1991; Aldridge & 
Reiner, 1969). A number of reasons could account for this, including physical blocking of 
the gorge entrance preventing access of additional substrate molecules; charge repulsion 
between molecules or even an allosteric interaction between the active and peripheral 
sites could occur involving conformational changes in the enzyme molecule (Taylor et 
al., 1994).  
 
1.3.4 Inhibitors 
 
Cholinergic nerves control cognition and fast skeletal muscles. AChE is an important 
mediator in these functions and thus essential for life. It is for this reason that AChE is 
targeted by a variety of anti-cholinesterases and inhibitors. Some of these inhibitors 
remain of value as medical agents contributing in drug development for the treatment of 
diseases such as Alzheimer’s disease, myasthenia gravis and glaucoma. Other inhibitors 
target AChE as toxins such as insecticides and snake venoms and some anti-
cholinesterases even possess potential for insidious use as chemical warfare agents 
(Soreq & Seidman, 2001; Pope et al., 2005).  
 
The inhibition of AChE by anti-cholinesterases, such as insecticides, results in the 
accumulation of ACh at the synaptic terminals and subsequent overstimulation of 
postsynaptic cells leading to death (e.g. Ecobichon, 1991). Many of these, such as 
carbamates and organophosphates, bind irreversibly and competitively to the active or 
acylation site serine. Other inhibitors, for example edrophonium, bind to the anionic 
(hydrophobic subsite) site. Yet other inhibitors, for example, BW284c51 (1.5-bis(4-
allyldimethylammoniumphenyl)-pentan-3-one dibromide), propidium iodide and 
fasciculin 2 from green mamba snake venom, bind to the PAS (Figure 12 show the 
different structures of PAS binding inhibitors). This inhibition is non-competitive, and is 
a result of allosteric modulation. Inhibitors that bind to the hydrophobic subsite within the 
gorge, as well as others binding non-competitively at the PAS, also exist. Competition of 
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substrate for binding with ligand specific for the PAS as well as site-directed mutagenesis 
studies show that the sites controlling substrate inhibition and inhibitor binding, overlap 
(Radic et al., 1991; Marchot et al., 1993; Shafferman et al., 1992).  
 
 
 
Figure 12. Structures of PAS-binding inhibitors (Johnson & Moore, 2006) 
 
Compounds binding directly to the PAS include quaternary inhibitors, such as gallamine, 
that have structures resembling the quaternary ammonium group of ACh and thus bind in 
the same manner as ACh. Bisquaternary inhibitors are long thin molecules with 
quaternary ammonium groups on each end. These inhibitors include BW284c51, 
decamethonium and E2020 (Aricept), and span both the anionic site and the PAS. Here 
Tyr 72, Tyr 124 and Trp 286 participate in this binding (Vellom et al., 1993; Kryger et 
al., 1998; Felder et al., 2002). A small cationic inhibitor called propidium binds to a 
pocket formed by the aromatic residues of the PAS centered around Trp 286 where as 
various parts of the (-)-huperzine A molecule bind to the anionic site and the PAS (Dvir 
et al., 2002).  
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A 61 amino acid peptide from mamba venom called fasciculin-2, is a member of the 3 
loop toxin family that also include the α-bungaratoxin and the cardiotoxins. Fasciculin-2 
is evolved to have a binding site that is highly specific for the PAS and thus show a high 
affinity and selectivity for AChE (Radić et al., 1994). This inhibitor blocks substrate 
access by inserting one of the loops into the gorge entrance while another loop binds to 
the 69-96 omega loop (Harel et al., 1995; Bourne et al., 1995). The residues of the 275-
305 loop on the opposite end of the gorge is also included and Van der Waals contacts 
are made with the PAS tyrosine residues (Tyr 72, Tyr 124 and Tyr 341) by loop II of the 
fasciculin molecule which is also packed against Trp 286.  
 
PAS-binding inhibitors inhibit partly by steric hindrance of the gorge entrance, for 
example fasciculin-2 that obscures approximately 200A2 of the AChE surface after 
binding (Bourne et al., 1995), and partly by allosteric modulation binding of structures 
within the gorge, in particular Trp 86 (Eastman et al., 1995; Barak et al., 1995). An 
example of this is where the mutation of Trp 86 reduces the ability of propidium to 
inhibit AChE (Ordentlich et al., 1993). This occurrence suggests coupling between this 
residue and the PAS (Johnson & Moore, 2006).  
 
The toxic effects of anti-cholinesterases such as insecticides have been studied in adult as 
well as young animal models and the sensitivity seems to be age-related. Young animals 
seem to be generally more susceptible to the lethal effects of these compounds (Brodeur 
& DuBois, 1963; Lu et al., 1965; Benke & Murphy, 1975; Harbison, 1975). Species-
related differences in susceptibility can be partially explained by a differential sensitivity 
in AChE (e.g. Johnson & Wallace, 1987). Gagne and Brodeur hypothesized that this may 
also explain the increased sensitivity in younger rats vs. adult rats (Gagne & Brodeur, 
1972). This hypothesis makes sense when taking into account the many changes that 
occur during development of the nervous system (Benjamins & McKhann, 1981). The 
age-related differences in sensitivity in rat brain AChE to two carbamates (aldicarb and 
carbaryl), as well as to the activated oxons of two organophosphorus (chlorpyrifos-oxon 
and malaoxon; active metabolites of chlorpyrifos and malathion, respectively) 
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insecticides were investigated. Results showed that AChE in young and adult brain 
differs mostly in its specific activity while kinetics and sensitivity to anti-cholinesterase 
insecticides are not different (Mortenson et al., 1998). 
 
AChE-directed insecticides are facing increased resistance among target species leading 
to a resurgence of disease vectors, insects destructive to agriculture, and residential pets. 
The concern for human toxicity from current compounds is also growing (e.g. Pang et al., 
2009; Polsinelli et al., 2010). Many disease-transmitting insect and agricultural pests 
contain two AChE genes, AP and AO (reviewed in Polsinelli et al., 2010). Reports 
showed the presence of a free cysteine residue at the entrance to the active site of AP-
AChE. This was seen in lower organisms but not at that of AO-AChE and AChEs from 
mammals, fish or birds (Pang, 2006; Pang et al., 2009). A small Cys-targeting molecule 
that irreversibly inhibits all AChE activity was recently extracted from aphids (Pang et 
al., 2009). Identical exposure to human AChE had no effect. These findings provide 
insight into the development of human-safe insecticides. 
 
1.4 Butyrylcholinesterase 
 
As mentioned above, AChE is very closely related to BChE with a sequence identity of 
50% (Harel et al., 1992). These two enzymes have been distinguished by their substrate 
specificity. AChE hydrolyzes acetylcholine much faster, and is much less active towards 
butyrylcholine, whereas BChE displays similar activity towards the two substrates 
(Mendel & Rudney, 1943; Chatonnet & Lockridge, 1989). BChE is also able to act upon 
a more diverse and larger set of substrates, as the narrow groove of the gorge, as well as 
the dimensions of the acyl pocket, limit entry of larger molecules to the AChE active site. 
A number of choline esters are subject to hydrolysis by BChE, a few of which include 
ACh, BCh, propionylcholine as well as benzoylcholine (Layer, 1991).  
 
In muscle fibers, BChE is also concentrated at the neuromuscular junction (Jedrzejczyk et 
al., 1984; Kasprzak & Salpeter, 1985). It was shown that during the development and 
regeneration of myofibres in vivo, the accumulation at synaptic sites of AChRs, AChE, 
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and BChE, are all triggered by the same molecule. This molecule was shown to be 
similar, if not identical, to an aggregating factor previously identified in Torpedo electric 
organ (Wallace, 1986). During the development of chicken skeletal muscle, the amounts 
and forms of AChE change in parallel with those of BChE (Lyles et al., 1979). BChE 
activity was found to be very high during the developmental stage prior to hatching. 
Localization of AChE and BChE during this stage is unclear, but an identical location is 
implied by the fact that subunits of both participate in the same asymmetric forms (Tsim 
et al., 1988).  
 
In the nervous system, most research on the brain cholinergic system has been devoted to 
AChE, where BChE has been viewed as a non-specific, non-essential enzyme almost 
interfering with studies on AChE (Darvesh et al., 2003; Silver, 1974). This view was 
changed by observations that BChE could have more specific functions in this context. 
Expression of BChE in distinct populations of neurons has been reported, as well as its 
role in co-regulating cholinergic neurotransmission (Friede, 1967; Tago et al., 1992; 
Darvesh & Hopkins, 2003; Darvesh et al., 1998; Mesulam et al., 2002). BChE also seems 
to be involved in the development of the nervous system (Robertson & Mostamand, 
1988; Layer, 1991; Dubovy & Haninec, 1990; Kostovic & Goldman-Rakic, 1983). 
Before the onset of synaptogenesis in the chicken neural tube, AChE and BChE are 
expressed in a mutually exclusive manner (Layer, 1983). In early embryonic neural 
development, prior to synaptogenesis, BChE is diffusely distributed along the ventricular 
layer in the developing neural tube (Layer, 1995). Here, BChE seem to precede and 
influence AChE expression. A functional role for BChE in the regulation of cell 
proliferation and the onset of differentiation during early neuronal development, 
independent of its enzymatic activity, has been reported (Layer 1983; 1991; Mack & 
Robitzki, 2000).  
 
Comparing the catalytic machinery of BChE to that of AChE, it is apparent that they 
differ in a number of ways, all of which contribute to its reduced specificity. First of all, 
the PAS is largely absent, and, within the gorge, the acyl pocket is larger due to the 
replacement of both of the Phe residues (Phe 295 and Phe 297 in AChE) with Leu and 
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Val (Masson et al., 1999; Harel et al., 1992; Vellom et al., 1993). The larger acyl pocket 
enables accommodation of the larger substrates in BChEs. The number of aromatic 
residues in the BChE gorge is reduced from AChE’s 14 to 8 in BChE (Jbilo et al., 1994). 
BChE also lacks the negative dipole moment seen in AChE (Botti et al., 1998).  
 
Kaplan et al. (2001) showed human AChE to be eight times faster than BChE (AChE: 
Km=140µM & kcat= 4 x 105/min; BChE: KM= 40µM & kcat= 0.5 x 105/min). Although 
BChE is not as fast as AChE, it still is a fast enzyme in its own right. A number of factors 
contribute towards the differences in catalytic prowess between these two enzymes. Even 
though no direct evidence exists, differences in charge distribution, specifically the lack 
of the dipole moment in BChE, could account for the reduction in the efficiency of BChE 
in comparison with AChE. Another contributing factor could be the reduction in the 
number of aromatic residues in BChE. Both these factors are responsible for the steering 
of substrate down the gorge. It seems that the fundamental part of the catalytic machinery 
is the same in both AChE and BChE (i.e. the active site and the choline-binding site 
which functions in positioning the substrate). This would account for the fact that they 
are both good enzymes. The differences lie in the ‘modulatory’ parts of the catalytic 
apparatus that contribute directly to efficiency and turnover.  
 
The ‘modulatory’ differences in AChE and BChE are most likely due to the differences 
in function between the two enzymes. Although the specific function of BChE have yet 
to be determined, BChE have been shown to play a major role in detoxification where it 
scavenges organophosphates and other inhibitory compounds (Nicolet et al., 2003). It is 
thus useful for BChE to be able to accommodate a variety of substrates, hence the more 
versatile acyl pocket. AChE and BChE also seem to play different roles in the NMJ. 
AChE is very fast but is inhibited at higher substrate concentrations, while BChE is less 
fast but is also activated at higher substrate concentrations. BChE may thus function as 
both protector and backup for AChE. In the AChE knockout mouse, for example, BChE 
was observed to have taken over the synaptic functions of AChE (Xie et al., 2000). 
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There is suggestive evidence that BChE may play a role in regulating the expression of 
AChE (Koelle et al., 1976; Layer et al., 1992). Despite the high level of homology 
between AChE and BChE, they are encoded by different genes, located on different 
chromosomes (Soreq et al., 1987; Arpagaus et al., 1990; Gaughan et al., 1991). BChE is 
thought to have originated by gene duplication and seem to occur in different 
phylogenetic lineages (McClellan et al., 1998). In mammals, these two enzymes are each 
encoded by a single gene: AChE at 7q22, and BChE at 3q26.1-q26.2 (Getman et al., 
1992). The duplication of the ancestral BChE gene most probably occurred before the 
split of cartilaginous fish but after the divergence of jawless fish as BChE is found in 
Torpedo, birds and mammals, but not in hagfish or lamprey (Pezzimenti et al., 1998). 
Table 1 is a summarized comparison between the two ChEs. 
 
Table 1. Comparison of AChE and BChE. 
 
 ACETYLCHOLINESTERSASE 
(AChE): E.C. 3.1.1.7 
BUTYRYLCHOLINESTERASE 
(BChE): E.C. 3.1.1.8 
Gene 
location 
7q22 3q26.1-q26.2 
Substrates 
subject to 
hydrolysis 
ACh ACh, BCh, propionylcholine, 
benzoylcholine 
 
Specific 
inhibitor 
BW284C51 (1,5 bis [4-
allyldimethyl ammonium 
phenyl] pentane-3-one 
dibromide)  
Iso-OMPA (tetra 
[monoisopropyl] 
pyrophosphortetramide)  
Catalytic 
machinery 
PAS present;  14 aromatic 
residues in the gorge; narrow 
acyl pocket; high turnover 
number; dipole moment 
PAS largely absent; 8 aromatic 
residues in the gorge; larger 
acyl pocket; lower turnover 
number; no dipole moment 
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1.5 Cholinesterase-Domain Proteins (CLAMS)  
 
AChE is sequentially homologous to a number of other proteins, collectively known as 
the cholinesterase-domain proteins (Krejci et al., 1991). These proteins appear to have 
lost their enzyme function secondarily, and the majority functions as cell adhesion 
molecules particularly during neural developments. For this reason, they have been 
termed the “CLAMS” (Cholinesterase-Like Adhesion Molecules) (Gilbert & Auld, 
2005). The CLAMS include the invertebrate proteins neurotactin, gliotactin and glutactin, 
and the neuroligins. Gliotactin is found in nematodes and arthropods; neurotactin and 
glutactin is found only in insects, and neuroligin is found in many invertebrate and 
vertebrate species (noted through sequence/genome analysis – unpublished observations). 
The vertebrate protein thyroglobulin is the only cholinesterase-domain protein that is not 
a cell adhesion molecule. Botti et al. (1998) described a consistent ring-shaped pattern of 
negative charge surrounding the gorge entrance that was apparent in CLAMs as wel as 
ChEs that mediated cell adhesion (see below), namely, neuroligin, neurotactin, glutactin 
and AChE. The motif was not apparent in BChE, which does not mediate cell adhesion. 
These molecules were therefore termed the “electrotactins” (Botti et al., 1998). 
 
Thyroglobulin was the first AChE-homolog to be identified. This protein is the precursor 
of the thyroid hormones and contains an AChE-like sequence at its carboxyl end 
(MacPhee-Quigley et al., 1986). A 28% amino acid identity extending over 544 residues 
and involving over 90% of the AChE sequence, but only the C-terminal portion of the 
much larger thyroglobulin, was found (Swillens et al., 1986). When the hydropathy 
profiles of the homologous regions were determined, a striking resemblance suggested 
that these regions in both proteins adopt a similar three-dimensional structure. AChE and 
thyroglobulin are both known to interact with the cell membrane and it is because of this 
that it was suggested that the AChE-like domain of thyroglobulin is involved in the 
binding (Swillens et al., 1986). These predictions speculate that thyroglobulin may have 
evolved from a copy of the AChE gene and are consistent with the hypothesized common 
evolutionary origin of the nervous and endocrine systems in vertebrate stating that both 
evolved to support intracellular communication (Chatonnet & Lockridge, 1989). 
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Thyroglobulin is the only homologous molecule that is not neural, but thyroid is derived 
from the neural crest in the embryo indicating a possible link. 
 
Glutactin, a strongly anionic sulfated glycoprotein, is an important component of 
Drosophila embryonic basement membranes. Even though glutactin contains a signal 
peptide and an N-terminal domain strongly resembling thyroglobulin, AChE as well as 
other serines esterases, it lacks the essential serine residue of the catalytic triad found in 
the AChEs. The presence of glutactin at several basement membrane sites suggests that it 
might be a component of the extracellular matrix. In Drosophila, glutactin also functions 
as a cell adhesion molecule (Olson et al., 1990). 
 
Gliotactin, another transmembrane protein, is expressed by peripheral glia of Drosophila 
where it is involved in the formation of the blood-brain barrier. The extracellular domain 
of gliotactin contains sequence similarities with members of the serine esterase family. 
The catalytic triad is missing indicating a structural function for the serine esterase 
domain (Auld et al., 1995). 
 
The neuroligins (isoforms 1-4) are found in vertebrates and invertebrates and constitutes 
a multigenic family of mammalian brain-specific AChE-homologous proteins. Through 
alternative splicing, these proteins are subject to considerable heterogeneity and they 
have been suggested to exert overlapping functions in mediating recognition processes 
between neurons (Ichtchenko et al., 1996). Neuroligins, sharing 34% residue identity 
with AChE, are involved in synaptogenesis and they can trigger de novo formation of 
pre-synaptic structures through their interaction with β-neurexins in the post-synaptic 
membrane (Scheiffele et al., 2000; Rao et al., 2000; Biederer & Stagi, 2009). Their 
expression in non-neuronal cells has been found to induce synaptic vesicle clustering as 
well as pre-synaptic differentiation in adjacent axons. These actions were prevented by 
addition of the extracellular domain of β-neurexin (Scheiffele et al., 2000). Neuroligins 
bind to β-neurexin through their extracellular AChE-like domains (Ichtchenko et al., 
1996); it is thus presumed that AChE may also be able to bind β-neurexin (Soreq & 
Seidman, 2001). However, AChE cannot substitute for the extracellular domain of 
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neuroligin (Comoletti et al., 2010). Neuroligin-neurexin connections may also play an 
important role in interneuronal recognition pathways where they could possibly regulate 
axonal pathfinding and plasticity. In development, cross-talk between AChE and 
neurexins have been suggested in experiments where overexpression of mice bearing the 
human AChE transgene was found to suppress neurexin Iβ production in embryonic 
transgenic mouse motor neurons (Andres et al., 1997). Neuroligin 1 (NL-1) and 
neuroligin 2 (NL-2) are involved in excitatory and inhibitory synapses, respectively 
(Chubykin et al., 2005). Mutations in neuroligin-3 and neuroligin-4 have been associated 
with autism (Jamain et al., 2003).  
 
Neurotactin is a transmembrane cell adhesion molecule and it has been observed that a 
substitution of its extracellular domain with Torpedo AChE also promotes cell adhesion 
(Darboux et al., 1996). In Drosophila, it has been described as a glycoprotein expressed 
in neuronal and epithelial tissues during embryonic and larval stages. The heterophilic 
adhesive properties of neurotactin indicate a role in interneuronal interactions. Structural 
analysis of neurotactin show that the extracellular domain is comprised of an N –terminal 
region, a catalytically inactive AChE-like domain consisting of a gorge with a three-
dimensional structure almost identical to that of AChE, a short hydrophobic 
transmembrane region as well as less conserved intracellular C-terminal region (Hortsch 
et al., 1990; Darboux et al., 1996). CAMs homologous to AChE are shown in Figure 13. 
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Figure 13. Cell adhesion molecules homologous to AChE. On the basis of amino acid 
sequences, AChE-like proteins have been identified. These include rat (r) neurologin, 
Drosophila (d) gliotactin, neurotactin and glutactin as well as the bovine (b) 
thyroglobulin. Represented are the percentage sequence identities of the AChE-like 
regions, signal peptide domains, transmembrane sequences (TM, patterned) and the 
position of the active site serine (Ser, circle) (http://www.ensam.inra.fr/cholinesterase; 
Grisaru et al., 1999). 
 
 
1.6 Non-Classical Role for AChE 
1.6.1 Indications of Alternative Functions 
 
From early on in the study of AChE, certain facts surrounding this enzyme raised 
speculations of it functioning in ways separate to its classical, cholinergic function. The 
wide distribution of AChE throughout the human body, for instance, as well as its 
apparent abundance in most living organisms, hint that although hydrolysis of ACh is its 
main function, it very likely is not its only function. The term “non-classical” may be 
defined as any function outside that of ACh hydrolysis in the synapse and neuromuscular 
junction. Such a non-classical function may be either enzymatic or non-enzymatic. The 
former could involve hydrolysis of ACh or another substrate in a non-synaptic context, or 
enzymatic functions of a different type; the latter, functions that may be mediated by a 
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structural site, such as signaling functions resulting from interaction with other proteins 
or molecules, or even phosphorylation.  
 
Distribution, solubility, as well as functional effects, form the basis of these non-classical 
speculations. The idea that AChE may have functions outside of ACh hydrolysis was 
originally suggested by histochemical observations showing the presence of AChE in 
early embryonic development prior to synaptogenesis (Drews, 1975). Both AChE and 
BChE have also been described in various tissues during development as the evident 
presence of BChE in some embryonic cells. In this context it has been shown that BChE 
can be replaced by AChE, suggesting a role as an embryonic cholinesterase (Chatonnet & 
Lockridge, 1989). It is also apparent that not all AChE activity is localized with its 
presumed substrate, ACh (Silver, 1974; Massoulié & Bon, 1982; Eckenstein & 
Sofroniew, 1983). High concentrations of AChE activity have been found in erythrocytes 
(Ott et al., 1982), platelets, megakaryocytes (Paulus et al., 1981) and plasma (Small et 
al., 1987). AChE presence has also been observed in developing avian cartilage (Layer, 
1990) and developing oocytes and sperm (Malinger et al., 1989; Soreq et al., 1990; 
Sastry et al., 1981).  
 
1.6.1.1 The non-neuronal cholinergic system and non-classical distribution of ACh 
and AChE 
 
From the beginning of life, cholinergic communication and regulation has been 
established in primitive uni- and multicellular organisms (Wessler et al., 1999, 2001, 
2003; Horiuchi et al., 2003). The cholinergic components are even found in a variety of 
living systems that lack nervous systems. ACh is a phylogenetically ancient molecule, 
and its presence, together with its receptors, has been detected in plants, fungi, bacteria, 
protozoa as well as in all living animals (Horiuchi et al., 2003). The specific function of 
ACh in fungi and lower invertebrates are still unknown. In plants ACh has been 
implicated in the regulation of differentiation, phyotochrome-mediated processes, as well 
as ion water transport (Hartmann & Kilbinger, 1974a, 1974b; Jaffe, 1970; Raineri & 
Modenesi, 1986; Smallman & Maneckjee. 1981; Wessler et al., 2001). The expression of 
Stellenbosch University http://scholar.sun.ac.za
 38 
AChRs (both muscarinic and nicotinic) in mammalian cells, along with the ubiquitous 
synthesis of ACh, gives an indication of the complexity of biological systems. Single 
non-neuronal cells use the same receptor subtypes and signal-transduction pathways as 
cholinergic neurons to communicate among each other and to maintain organ 
homeostasis (reviewed in Wessler & Kirkpatrick, 2008). Although the functions of these 
non-neuronal systems are very poorly understood, the widespread synthesis of ACh in 
non-neuronal cells have been the focus of many reviews over the last decade (Sastry and 
Sadavongvivad, 1978; Grando, 1997; Wessler et al., 1998, 1999, 2001, 2003, 2008; 
Kawashima and Fujii, 2000, 2004; Eglen, 2006; Grando et al., 2006, 2007; Kurzen et al., 
2007).  
 
Evidence for ACh synthesis is provided by positive anti-ChAT immunoreactivity, ChAT 
enzyme activity and ACh content. Originally the most widely used method for 
identifying cell bodies of cholinergic neurons relied on AChE histochemistry. However, 
it was later questioned whether AChE has a legitimate role as a specific marker for 
cholinergic neurons alone as it is also found in different populations of monoaminergic 
neurons and non-neuronal structures (Rossier, 1977; Butcher, 1978; Fibiger, 1982). It 
seems that even in the nervous system, AChE activity is not always associated with 
cholinergic neurons or their terminals. Even though most cholinergic neurons contain 
AChE activity, many non-cholinergic neurons show AChE activity (Small, 1990). Today, 
antibodies directed against ChAT offers a more specific immunohistochemical method 
for identifying cholinergic cell bodies (e.g. Mesulam et al., 1983; Kimura et al., 1981).  
 
The vast majority of human non-neuronal cells seem to demonstrate ACh. Examples 
include: cells of the kidney, urogenital tract, plasenta, glandular tissue, and eye; as well as 
epithelial, endothelial, and mesenchymal cells (reviewed in Wessler & Kirkpatrick, 2008; 
Grando, 1997). Schlereth and colleagues documented the release of non-neuronal ACh in 
human skin in 2006 as the first evidence of in vivo release of non-neuronal ACh from 
human tissue (Schlereth et al., 2006). Embryonic stem cells in mice also synthesize 
considerable amounts of ACh (Paraoanu et al., 2007) and the release of non-neuronal 
ACh was shown in isolated tissue such as human placenta and tumor cells (Sastry & 
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Krishnamurty, 1978; Wessler et al., 2001; Song et al., 2003). More examples can be seen 
in lymphocytes (Kawashima & Fujii, 2004), as well as in transformed cells and 
haematopoietic precursors (Wessler et al., 1998; Grando, 2003). ACh is also expressed in 
non-neuronal brain cells and tissues where it is synthesized in a wide variety of non-
neuronal cells such as mesothelial, meninges, blood vessels, immune cells, as well as 
glia, muscle fibres and parenchymal cells. These groups are presumably cholinoceptive 
(Eckenstein & Sofroniew, 1983; Mesulam, 1988a; Mesulam et al., 1984).  
 
Outside the nervous system, AChE expression has been reported in several cell types, 
including haematopoietic cells (Soreq & Seidman, 2001), osteoblasts (Genever et al., 
1999), endothelial cells (Carvalho et al., 2005) and apoptotic cells (Zang et al., 2002). 
Within the adult human brain, AChE have been found in areas that lack cholinergic 
innervations and its distribution in tissue with no corresponding ACh or ChAT has been 
puzzling biochemists for years (Karczmar, 1969; Silver 1974; Layer & Willbold, 1995). 
An example is the high concentrations of AChE found in the cerebellum, a brain area 
containing very few cholinergic synapses. In several brain regions there is a disparity 
between levels of AChE and ChAT (Silver, 1974) which can be visualized in neurons and 
compared directly to AChE (Levey et al., 1983; Cuello & Sofroniew, 1985). First 
evidence of a soluble, secreted form of AChE was identified many years ago during 
experimental work performed in the adrenal medulla (Chubb & Smith, 1975). Soon after, 
it was shown that a similar phenomena occurs in the central nervous system (CNS) where 
AChE can be detected in the cerebrospinal fluid (Chubb et al., 1976). It seemed that, 
because the levels of AChE in the cerebrospinal fluid were dramatically reduced after an 
electrolytic lesion of the substantia nigra, that this region must be one of the main origins 
of the secreted form (Greenfield & Smith, 1979). It was later reported that in the 
substantia nigra, AChE is secreted from dendrites of non-cholinergic, dopaminergic 
neurons where AChE appears to extend local neurotrophic effects, thus activating 
neurons known to respond to dopamine and not AChE (Llinas & Greenfield, 1987; Webb 
& Greenfield, 1992).  
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AChE expression has been reported within the cortical pyramidal neurons of the rat brain 
where it contributes to their maturation and establishment of synaptic connection (Geula 
et al., 1993). During post-natal development, as shown in the rat brain, non-cholinergic 
expression of AChE occurs. Here it is expressed in the form of transient activity within 
certain fibers and terminals in the somatosensory visual and auditory cortices as well as 
in a large population of cortical pyramidal neurons (Kristt, 1979; Kristt & Waldman, 
1982; Robertson et al., 1991; Robertson et al., 1985). The origins of these AChE-rich 
fiber systems are thalamic neurons which themselves seem to express AChE transiently 
during postnatal development (Kristt, 1983; Kristt & Waldman, 1981; Robertson, 1987; 
Robertson, 1988; Robertson et al., 1991). See section 1.6.2.2 for details on the 
developmental expression of AChE. 
 
Non-neuronal ACh is released from cells, such as epithelial and endothelial cells, and 
binds to n- and mAChRs and neighbouring cells. Here ACh acts via paracrine, autocrine 
and juxtacrine mechanisms as a local cell signalling molecule or cytotransmitter 
controlling multiple cell functions such as proliferation, differentiation, apoptosis, 
secretion, cytoskeleton organization, lateral migration, ciliary activity, cell-cell contact 
and immune functions (Grando, 1997; Wessler et al., 1998, 1999, 2003; Kawashima & 
Fujii, 2000; Grando et al., 2003). Most cell types lacking cholinergic innervation express 
n- and mAChRs that are part of this autocrine and paracrine regulatory loop. ACh seems 
to play an intermediary role in the interactions of non-neuronal cells with the external 
environment, hormones, growth factors, cytokines and also the neural system. These 
factors can, on the other hand, affect the expression and function of the non-neuronal 
cholinergic system (reviewed in Wessler & Kirkpatrick, 2008). During signal 
transduction, additional endogenous compounds are able to stimulate cholinergic 
receptors too (e.g. Raufman et al., 2003; Alexander et al., 2006), enabling cells to receive 
input from hormone-like pathways as well as local pathways. These endogenous 
allosteric modulators play an essential role as sophisticated tools to fine-tune the 
cholinergic input to a cell. An example is the allosteric modulation of the neuronal α4 
subtype receptor through progesterone (Valera et al., 1992).  
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A wide variety of modulatory functions have been associated with ACh. ACh have been 
shown to be involved in central respiratory control (Burton et al., 1994; Gillis et al., 
1988; Metz, 1958; Murakoshi et al., 1985; Nattie & Li, 1990; Weinstock et al., 1981). 
Central cholinergic mechanisms contribute to respiratory failure caused by 
organophosphate poisoning (Lotti, 1991). Both in vivo and in vitro demonstrations 
showed that perturbations of ACh synthesis, release, degradation, or activation of AChRs 
in the brain stem result in perturbations of respiratory pattern (Foutz et al., 1987; Gillis et 
al., 1988; Nattie & Li, 1990; Burton et al., 1994; Monteau et al., 1990; Murakoshi et al., 
1985). ACh release has also been implicated in the modulation of sleep and wakefulness. 
The pontine reticular formation (PnO) contains an oral component that contributes to the 
generation of cortical electroencephalogram (EEG) activation and rapid eye movement 
(REM) sleep (Lydic & Baghdoyan, 2005; Steriade & McCarley, 2005). ACh present in 
the PnO was found to promote REM sleep (Lydic & Baghdoyan, 2008). Blocking 
degradation of ACh thus activates the EEG and enhances REM sleep. A role for ACh in 
the modulation of ion channels has been postulated (e.g. Hevron et al., 1986; Renaudon 
et al., 1997). An example is the activation of the inward-rectifing potassium channel 
(IKACh) via the release of ACh from the vagus nerve onto pacemaker cells in the heart 
(Wickman & Clapham, 1995). ACh, through binding to mAChRs, acts via G-proteins to 
activate the IKACh channel (Corey et al., 1998). This activation results in an increase of 
K+ ions flowing out of the cell and causes the cell to hyperpolarize (Morris & Malbon, 
1999). Neurons in hyperpolarized states cannot fire action potentials and this leads to 
slowing of heartbeat. More examples of modulatory roles for ACh has been demonstrated 
in the synaptic mechanisms in the cerebral cortex (Krnjevic, 2004), as well as in 
impulsive action via nAChRs in rats (Tsutsui-Kimura et al., 2010).  
 
A large body of evidence indicates that all elements of the cholinergic system (ChAT and 
ACh synthesis, AChE, release mechanisms, receptors), functionally expressed 
independent of cholinergic innervations, can modify and even control phenotypic cell 
functions (reviewed in Wessler & Kirkpatrick, 2008). Detailed analysis of the regulatory 
role for non-neuronal ACh have been established for the epidermis by the investigation of 
intact skin, wound healing and cultured keratinocytes using different techniques such as 
Stellenbosch University http://scholar.sun.ac.za
 42 
knockout mice, antisense RNA and selective agonists and antagonists (Grando et al., 
1995, 2006; Chernyavsky et al., 2003, 2004, 2005; Kurzen et al., 2004, 2007). AChE 
expression was previously shown in fibroblasts and astrocytes (Thullbery et al., 2005), 
two cell types that play critical roles in wound healing. Anderson et al. (2008) 
investigated the distribution and function of AChE in these cells and reported that 
fibroblasts and astrocytes express high levels of AChE that co-migrates with recombinant 
AChE, but contains very little catalytic activity. Elevation of AChE expression was found 
to increase fibroblast wound healing where addition of anti-AChE antibodies were shown 
to slow it down. It was reported that AChE surface patches co-localise with amyloid 
precursor protein (APP) and the extracellular matrix protein, perlecan (independent of α-
dystroglycan). It was concluded that cell surface AChE may contribute to a generalized 
mechanism for polarized membrane protrusion and migration in all adherent cells 
(Anderson et al., 2008). Studies also show that one of the major nAChR subunits, 
nAChRα7, exhibits an essential role in the cholinergic anti-inflammatory pathway (Metz 
& Tracey, 2005). Although the human skin is not innervated by parasympathetic systems, 
it prominently expresses distinct nAChR subunits such as nAChRα7. These subunits are 
involved in physiological and physiopathological processes such as keratinocyte 
adhesion, migration, differentiation and apoptosis (Arredondo et al., 2002; Zia et al., 
2000; Grando et al., 1995, Chernyavsky et al., 2004). A recent study demonstrated that 
nAChRα7 is time-dependantly expressed in distinct cell types, which may be closely 
involved in inflammatory response and the repair process in wound healing (Fan et al., 
2011).  
 
Morphogenetic properties for ACh have also been well documented. In particular, a role 
for ACh in the promotion of proliferation and suppression of neurite outgrowth, the 
morphological indicator of differentiation in primitive neural cells, has been proposed 
(e.g. Biagioni et al., 2000). AChE, by hydrolysing and thus removing ACh, may thus 
indirectly act as a promoter of neurite outgrowth. Evidence suggests that AChE does, in 
fact, function in this way (Behra et al., 2002). This AChE function could be classified as 
non-classical, but enzymatic. A large body of evidence also show non-enzymatic 
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morphoregulatory effects for AChE on neurons and will be discussed in depth in section 
1.6.2. 
 
In the late 1980s, both trypsin-like and carboxypeptidase-like activity was observed in 
association with AChE. These activities supported the hypothesis that AChE may have a 
role as a neuropeptide processing enzyme postulated to function in regulating growth and 
development (Small, 1988; Small, 1990). However, these activities were found to be due 
to contaminating enzymes (Checler & Vincent, 1989).  
 
Aryl acylamidase activity has also been linked with AChE (Jayanthi et al., 1992). This 
activity is high during early brain development in the chick, and has also been observed 
in association with BChE activity (Boopathy & Layer, 2004; Montenegro et al., 2008). 
The strong association of the activity with both cholinesterases suggests that it may play a 
role, as yet undetermined, in early development. 
 
1.6.2 Non-classical Functions Related to Development and Differentiation 
1.6.2.1 Neurogenesis  
 
During early development, neuronal navigation is essential for establishing the cellular 
organization and specific nerve connections in the nervous system (Kandel et al., 2000; 
Sane et al., 2000). The complexity of the decision necessary to specify multiple cell types 
and to determine their axonal connections is a striking feature of neural development. 
Morphogenesis requires the directed migration of neural cell precursors to designated 
locations in the nervous system as well as the guidance of axon growth cones to their 
synaptic targets (Song & Poo, 2001). Evidence indicates that both forms of navigation 
depend on common guidance molecules, surface receptors and signal transduction 
pathways; thus linking receptor activation to cytoskeletal reorganization (Song & Poo, 
2001; Hatten, 1999; Mueller, 1999;  Tessier-Lavigne & Goodman, 1996). The dorsal 
margin of the neural tube produces neural crest cells that migrate over long distances and 
along specific routes to form sensory, autonomic and enteric ganglia in the peripheral 
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nervous system (Le Douarin et al., 1994). Once their destination is reached, each neuron 
develops dendrites and a single long axon extending along specific routes to reach 
prospective synaptic partners (Goodman & Tessier-Lavigne, 1997). Synapse formation 
requires interaction between pre- and postsynaptic cells to establish connections and so, 
the formation of a network. Cells that fail to make connections undergo apoptosis or cell 
death. Apoptosis is a highly complex process involving cell adhesion molecules (CAMs) 
(e.g. Dransfield et al., 1995), signaling molecules (e.g. Graham et al., 2002), cytokines 
(e.g. Lotem & Sachs, 1999) as well as growth factors (e.g. Wolff et al., 2007). Thus, 
there are two phases during development of the nervous system: the migratory phase and 
the synaptogenic phase, involving the formation of the synaptic network.  
 
Early histochemical studies confirmed the presence of ChE activity during early 
development in the sea urchin, the amphibian, and the chick and rat brain. It was found 
that ChE appears in every embryonic blastema at a very early stage of development, 
independent of innervations. It was interesting to note that this ChE presence disappears 
from the cells after they have assembled into definite organ structures. ChE thus play a 
role in embryonic development and its presence in differentiating cells during a limited 
phase of development is termed “embryonic cholinesterase”. Further observations that 
ChE is found in cells engaged in morphogenetic movements, led to the belief that the 
enzyme is involved in the regulation of cellular movements during development (Drews, 
1975).  
 
The distribution of ChE activity in neuroepithelial, neural crest, somite, and ectodermal 
cells was investigated in a comparative, cytochemical study using chick and mouse 
embryos. Nonspecific staining in these tissues during neurulation showed similar 
distribution in the two species. AChE staining, however, was found to be absent in the 
mouse where the only cells showing the presence of this enzyme at these stages of 
development are blood cells. According to these reports, AChE staining appear later in 
the brain in neural tissues as well as in some migratory neural crest cells. Although AChE 
distribution differences in these two species indicate that the timing of the first 
appearance of AChE is unrelated to neuroepithelial morphogenesis or to neural crest 
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motility, the correlation between nonspecific cholinesterases and morphogenetic 
movements is also supported by these findings (Martins-Green & Erickson, 1988). 
 
1.6.2.2 Developmental Expression of Acetylcholinesterase 
 
Analysis of the developmental expression of AChE during neuronal differentiation from 
a pluripotent stem cell showed that retinoic acid is able to induce differentiation of 
embryoid bodies into neurons and glia. Undifferentiated stem cells showed no AChE 
activity, but commitment to a neuronal pathway resulted in increased levels of AChE 
mRNA, production of a tetrameric form of the enzyme as well as secretion of AChE into 
the culture medium (Coleman & Taylor, 1996). AChE thus seems to be expressed on the 
surface of migrating developing neural crest cells. At this point, expression is limited to a 
hydrophilic tetramer that is secreted into the extracellular matrix. When these cells reach 
their destinations and adhere and differentiate, AChE expression reaches very high levels 
and shifts to a membrane associated tetramer. This isoform is anchored in the cell 
membrane by a post-translationally attached hydrophobic domain rather than association 
by a glycophospholipid tail. Seeing as no change in the transcription rate of the AChE 
gene was detected during the course of differentiation, it was suggested that transcription 
takes place during very early stages of development. Figure 14 shows the temporal 
relationship of the expression of AChE and BChE to the final stages of cell proliferation, 
the onset of differentiation and neurite outgrowth.  
 
It was concluded that an early event in neuronal differentiation is the stabilization of 
mRNA leading to expression of the secreted form of AChE. The transition from secretion 
of the tetrameric form to its localization on the cell membrane is an important step 
associated with neurite outgrowth (Coleman & Taylor, 1996). AChE expression in the 
developing vertebrate brain interestingly corresponds temporally with the major period of 
axon elongation and pathfinding (Hanneman & Westerfield, 1989; Layer, 1991; Ross et 
al., 1992; Schlaggar et al., 1993). 
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Figure 14. The temporal relationship of the developmental expression of AChE and 
BChE. BChE is especially expressed during the final stages of mitosis and the onset of 
differentiation. 13-15 hours after AChE expression is initialized in the cells, G4 positive 
fibers begin to emanate from the cell bodies and grow toward targets (Layer & Willbold, 
1995). 
 
1.6.2.3 Cell Adhesion 
 
It used to be thought that CAMs were simply involved in the anchoring of cells to the 
extracellular matrix. Recently, however, it has been found that cell adhesion is key to the 
developmental process and that certain cell surface adhesion molecules play an important 
part in neuronal navigation (Walsh & Doherty, 1997). During neural development, neural 
cell adhesion molecules nucleate and maintain groups of cells at key sites (reviewed in 
Crossin & Krushel, 2000). Cell adhesion impacts on dynamic processes such as 
intracellular signaling (e.g. Povlsen et al., 2003) and gene expression (e.g. Mahoney et 
al., 2001), leading to cell migration (Huveneers & Danen, 2009), proliferation (e.g. 
Fernandez-Vidal et al., 2006), differentiation (e.g. Shin et al., 2002) and survival. 
Prevention of adhesion suppresses cell growth and induces apoptotic cell death 
(Boudreau et al., 1995). It seems that these molecules are all active in neural development 
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(Holmquist, 2000) and their ChE-like domain has been found to be able to act as a 
protein-protein interaction domain. AChE, being sequentially related to a number of non-
enzymatic cell adhesion and signaling molecules (e.g. Drosophila glutactin, neurotactin, 
gliotactin as well as the mammalian neuroligins), may also engage in protein-protein 
interactions (Paraoanu & Layer, 2008). Although the importance of the electrostatic 
potential of AChE is desputed (Shafferman et al., 1994), it is also well known that 
electrostatic interactions can facilitate target recognition via protein-complex formation. 
Seeing as all the ChE-like adhesion molecules display similar electrostatic characteristics, 
it strongly supports the notion that AChE can function as a CAM (Botti et al., 1998; 
Shafferman et al., 1994).  
 
1.6.2.4 Neuritogenesis  
 
Neurotransmitters have long been associated with non-classical functions related to 
neural differentiation. Some examples include studies showing how glutamate, serotonin 
and dopamine influence neurite outgrowth in culture (Mattson, 1988; Lipton & Kater, 
1989). Many studies have demonstrated that the expression of AChE during early 
development can be closely correlated with the major phase of neurite outgrowth (Layer 
et al., 1988;  1992; Layer, 1991; Layer & Kaulich, 1991; Robertson, 1987; Robertson et 
al., 1988; Robertson & Yu, 1993; Small et al., 1992). It was observed that the expression 
of AChE is a very early step in postmitotic neurons (Layer & Sporns, 1987), occurring 
prior to neurotic processes in brain tissues, cultured spheroids (Layer et al., 1988; 
Weikert et al., 1990) and non-cholinergic neurons in the rat thalamus (Kristt, 1989). Cell 
adhesion is also a major mechanism to direct neurite outgrowth. Given that AChE may 
function as a cell adhesion molecule, a role for AChE in neuritogenesis is not unlikely.  
 
In 1993, Layer et al. (1993) provided the first direct evidence for a role of AChE in 
regulating neuritic growth. It was shown that neurite growth can be modified in vitro by 
some anti-ChEs. The catalytic- and peripheral anionic-site blocking inhibitor, 
BW284c51, was found to decrease neurite outgrowth. On the other hand, echothiopate, 
an inhibitor that blocks only the esterase activity, had no effect on neurite outgrowth, 
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indicating that this non-classical role is not the result of enzyme activity. A secondary site 
on cholinesterase molecules may be responsible for these adhesive functions (Layer et 
al., 1993). Addition of fasciculin 2, a potent blocker of the peripheral site alone, induced 
a similar reduction in neurite growth (de La Escalera et al., 1990), indicating the PAS as 
a possible site of interest associated with these functions. 
 
Various other studies (e.g. Small et al., 1995; Keymer et al., 1998; Anderson and Key 
1999) have also noted similar effects of AChE inhibitors on neurite outgrowth in neural 
cells. The same pattern, that is, inhibition of neurite outgrowth by PAS-binding inhibitors 
such as BW284c51 and fasciculin 2, but not with active site inhibitors such as 
ecothiophate or eserine, was observed throughout.  
 
Addition of AChE or pre-coating plates with AChE also induces neurite sprouting. 
Bataillé et al. (1998) showed that addition of purified AChE to the culture medium of 
embryonic spinal rat motorneurons affected neurite growth. It was reported that when 
AChE was added, the surface as well as the total length of the neurites and axons were 
increased. Several other studies, in particular, Jones et al. (1995), using dopaminergic 
neurons, Munoz et al. (1999), using rat spinal cord neurons, Olivera et al. (2003), using 
hippocampal neurons, and Srivatsan and Peretz (1997), in Aplysia (a marine mollusc) 
used similar methods, and obtained similar results. All these studies indicated a role for 
AChE in the promotion of neurite outgrowth, and suggested that this role was non-
enzymatic, although Bataille et al. (1998) observed some slight effects (slight decrease in 
the number of primary neurites as well as a decrease in the spreading index during the 
first three days in culture) after addition of the active site inhibitor ecothiophate. In 
contrast with Layer (1993), this study shows the possible involvement of both catalytic 
and non-catalytic mechanisms, but suggesting significant involvement of the PAS. Given 
that ACh can act as a suppressor of neurite outgrowth (e.g. Biagioni et al., 2000), and that 
AChE has been shown to indirectly enhance neurite outgrowth by hydrolyzing 
(removing) ACh (Behra et al., 2002), these results could be indicative of this catalytic 
non-classical function of AChE. On the other hand, AChE active site inhibitors, in 
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particular the organophosphates, are able to induce neurotoxicity by mechanisms other 
than AChE inhibition (reviewed in Costa, 2006). 
 
Other studies have investigated AChE-mediated neurite outgrowth using different neural 
cell types cultured on a coating of AChE, rather than adding the AChE to the culture 
medium. These include Small et al. (1995) using isolated chick sympathetic neurons, and 
Johnson and Moore (2000) using human neuroblastoma cells. Similar effects on neurite 
outgrowth were seen. Small et al. (1995), however, noted that these effects seemed 
dependant upon the presence of substratum-bound heparan sulfate proteoglycans 
(HSPG).  
 
Although experiments using inhibitors or the external addition of AChE to the culture 
medium or to the substratum demonstrate a possible morphogenetic role for AChE, 
studies in which the levels of AChE are changed within the neuron itself are more 
definitive. The effects of cell transfection with AChE cDNA has been reported by a 
number of authors: Karpel et al. (1996) using rat glioma cells, Koenigsberger et al. 
(1997), Sharma et al. (2001) and De Jaco et al. (2002), all using various neuroblastoma 
cell lines. All observed a correlation between AChE overexpression and increased neurite 
outgrowth. Lev-Lehman et al. (2000) described excessive neurite outgrowth in transgenic 
mice that overexpressed AChE in motoneurons. 
 
Several studies have investigated the possible differential effects of the AChE splice 
variants on neurite outgrowth. Karpel et al. (1996), using transfection of rat glioma cells, 
observed that, while the most prevalent E6 splice variant (synaptic/tailed AChE) 
promoted neurite outgrowth, the less common stress-related readthrough form (AChE-R) 
did not. Promotion of neurite outgrowth was observed to be unrelated to catalysis but not 
the readthrough form (AChE-R). Sternfeld et al. (1998), likewise, showed a dominant 
role for the E6-derived AChE-T in neurite outgrowth, and also confirmed that the process 
was non-enzymatic. As the splice variants differ at their C-termini, it would be logical to 
conclude that the C-terminus is directly involved in the neurite outgrowth process. 
However, it should also be borne in mind that factors such as differences in 
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oligomerisation and possibly in conformation between the different variants may play a 
part as well. De Jaco et al. (2002), however, did not observe differences between the 
splice variants in their ability to promote neurite outgrowth.  
 
The evidence concerning the effects of oligomerisation on cell adhesion and neurite 
outgrowth is relatively scanty and somewhat conflicting. Day and Greenfield (2002) 
suggested that only AChE monomers were involved. On the other hand, the isoforms 
associated with migration and differentiation, and hence with cell adhesion and neurite 
outgrowth, are tetramers (e.g. Layer & Willbold, 1995; Johnson & Moore, 2000), both 
the secreted hydrophilic G4 and, later, the membrane-associated G4. In the crystal 
structure of the mouse tetramer, Bourne et al. (1999) observed that the PAS is obscured 
in two of the four catalytic domains, so that, if the PAS is indeed involved in promoting 
these processes, the overall efficacy of the molecule would be compromised. 
 
Treatment of cells with anti-AChE antibodies was observed to have an inhibitory effect 
on neurite outgrowth. Sharma and Bigbee (1998) and Sharma et al. (2001) used a 
polyclonal anti-AChE antibody, and Johnson and Moore (2000) used a variety of 
monoclonal antibodies, several of which were known to recognise the PAS specifically. 
These PAS-binding antibodies were also found to affect the adhesion of neuroblastoma 
cells to the substratum: antibody treatment resulted in the cells rounding up, floating, and 
subsequently dying, an observation consistent with the concept of anoikis (cell death as 
result of loss of cell adhesion). The deleterious effects of anti-AChE antibodies on neural 
cells suggest that AChE is necessary for cell survival, adhesion and neurite outgrowth. 
 
The consistent effects of PAS-binding inhibitors, such as BW284c51 and fasciculin 2, as 
well as the effects of PAS-reacting monoclonal antibodies, strongly suggest involvement 
of the PAS in AChE-mediated cell adhesion and neurite outgrowth. The involvement of 
the PAS in the adhesion-mediating and neurite outgrowth-promoting processes was 
confirmed (Johnson & Moore, 1999). On the other hand, Greenfield et al. (2008), present 
evidence for the involvement of C-terminal peptides in both neurite outgrowth and 
apoptosis. 
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1.6.2.5 AChE complexation and the identification of potential AChE ligands 
 
There are two sites on the AChE molecule that appear to be particularly responsive to 
ligand binding and complex formation. One of these is obviously the C-terminal T-
peptide which is responsible for oligomerisation and the association of AChE with the 
anchoring proteins ColQ and PRiMA. Interestingly, the T-peptide aligns with the 
amyloid precursor protein (APP), in particular, the region of APP that cleaves to form the 
amyloid beta-peptide (Greenfield & Vaux, 2002), which is primarily responsible for the 
formation of senile plaques in Alzheimer’s disease. Furthermore, Cottingham et al. 
(2002; 2003) have shown that isolated AChE T-peptides are themselves capable of 
forming amyloid-like fibrils. Greenfield’s group (e.g. Day & Greenfield, 2002) has 
shown that a peptide derived from the T-peptide is capable of promoting neurite 
outgrowth at low concentrations, and apoptosis in higher concentrations, with the 
involvement of the nAChR. 
 
In the neuromuscular junction, AChE associates with heparan sulfate proteoglycans 
(particularly perlecan) in the basal lamina. This interaction is mediated, not through a part 
of the AChE protein, but by ColQ. Interestingly, Anderson et al. (2008) observed an 
association of AChE with both APP and perlecan in the cell membranes of fibroblasts 
and astrocytes (where it would not normally be anchored by ColQ), forming an 
apparently novel signalling complex that might contribute to membrane protrusion and 
cell migration.  
 
AChE has been observed to bind a number of ligands at the PAS. These include the 
amyloid beta-peptide, laminin-111, collagen IV, the prion protein and fibronectin. The 
amyloid beta-peptide was observed to bind a hydrophobic loop containing the PAS 
residue W286 (residues 274-308, Torpedo numbering; De Ferrari et al., 2001). 
Interestingly, a very recent article (Dinamarca et al., 2011) has shown that the AChE 
homologue neuroligin-1, is also capable of binding the amyloid-β peptide. Johnson and 
Moore (2003) observed binding of AChE to the extracellular matrix proteins laminin-111 
and collagen IV. The binding to laminin was later localised to the laminin α1 chain 
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(Johnson et al. 2008a and this thesis); Paraoanu and Layer (2005), however, observed 
binding to domain IV of the β1 chain. Interactions of AChE with the prion protein (Clos 
et al. 2006) and fibronectin (Giordano et al. 2006), also apparently mediated by the PAS, 
as shown by the blocking effects of PAS-binding inhibitors, have also been observed. 
Bigbee and Sharma (2004), using a blot overlay technique, identified potential AChE 
ligands of MW 200, 110, 35 and 33 kDa, respectively. These proteins were not identified.  
 
1.6.2.6 The role of electrostatics in AChE-mediated cell adhesion and neurite 
outgrowth 
 
The PAS, as its name indicates, is anionic in nature. Botti et al. (1998) have described a 
characteristic ring-shaped motif of negative charge surrounding the entrance to the active 
site gorge. This motif is apparent in AChE, as well as in the CLAMS neuroligin, 
gliotactin, neurotactin, and glutactin, all of which have been observed to mediate cell 
adhesion, but not in BChE, which does not. On this basis, they, as described above, 
termed these proteins “electrotactins”, as electrostatics appeared likely to play a major 
role in the adhesion process. The role of electrostatics in AChE-mediated cell adhesion 
and neurite outgrowth has been confirmed by Johnson and Moore (2003) and Bigbee and 
Sharma (2004). 
 
1.6.3 Non-Classical Role in Degeneration  
 
Disorders such as Alzheimer’s , Parkinson’s, Creutzefeldt-Jacob disease, and other 
diseases such as Lewy body dementia and Guam syndrome, are all mostly characterized 
by the progressive loss of cognition due to degeneration of cholinergic neurons in the 
basal forebrain. Although these disorders are all distinct, they share an underlying 
common neurodegenerative mechanism (Calne et al., 1986; Greenfield And Vaux, 2002).  
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1.6.3.1 Amyloid & Fibril Formation 
 
Protein misfolding underlies an array of debilitating human diseases called 
conformational diseases (Fersht, 1999). Proteins can often convert from their normally 
soluble forms to insoluble fibrils or plaques called amyloids (as introduced by Virchow 
(1851), meaning “starch-like”), which accumulate in a variety of organs, affecting normal 
functioning thereof (Tan & Pepys, 1994; Kelly, 1998; Lansbury, 1999; Perutz, 1999). 
These fibrils are typically 60-100Å in diameter and exhibit a characteristic apple-green 
birefringence when stained with the dye Congo Red (Sipe, 1994; Kelly, 1996). 
Aggregation of amyloid is an important process in a wide variety of abnormal diseases 
including Alzheimer’s and Parkinson’s disease (AD & PD), type II diabetes, the 
transmissible spongiform encephalopathies, amyloidotic polyneuropathies and a range of 
less familiar conditions such as fatal familial insomnia (Tan & Pepys, 1994; Fink, 1998).  
 
In Alzheimer’s disease, the key component of extracellular plaques is the 40-42 residue 
Aβ peptide that is produced by endoproteolytic cleavage of the amyloid protein precursor 
(APP) (Evin et al, 1994). Aggregation (fibril formation) of the peptide has been shown to 
be mediated by a multi-step nucleation-dependant polymerization process that is critically 
dependant on pH and ionic strength (Snyder et al., 1994). Amyloid fibrils have been 
found to associate with plasma and extracellular matrix molecules to form amyloid 
deposits that invade the extracellular space (Tan & Pepys, 1994; Merlini & Bellotti, 
2003).  
 
The structure of Aβ enables it to bind to a variety of biomolecules such as lipids, proteins 
and proteoglycans as well as to interact with the cellular membrane. It has been observed 
to bind to apoE, amongst other lipoproteins. ApoE is found in an array of amyloid 
deposits such as Aβ in AD, prion in Creutzfeldt-Jakob disease as well as in light chain 
amyloidosis. It seems to co-localize in all amyloid deposits and is found to specifically 
interact with fibrils in vitro (Namda et al., 1991). The apoE4 allele is a risk factor for 
late-onset AD. 
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Several constituents normally present in the ECM are also found in neuritic plaques 
including proteoglycans, perlecan, collagen IV, entactin, fibronectin, nidogen, AChE and 
BChE (Inestrosa, 1988; Brandan & Inestrosa, 1993). During amyloidosis, the major 
basement membrane components (collagen, entactin, laminin, perlecan) codeposit both 
spatially and temporally with Aβ (Ancsin, 1999). Even though laminin was found to bind 
Aβ, it seems to be a potent inhibitor of Aβ fibril formation (Castillo et al., 2000).  
 
1.6.3.2 Acetylcholinesterase and Neurodegenerative Disorders: Alzheimer’s Disease 
 
The cholinergic aspects of this disease involve synaptic and neuronal loss particularly of 
targeted cholinergic neurons in the basal forebrain, an area concerned with memory and 
cognition (Whitehouse et al., 1982). Dystrophic neurons contain AChE and they are 
incorporated in the peripheral area of senile plaques and stain positive for phosphorylated 
tau (Kasa et al., 2003).  
 
AChE seems to be the common feature shared by the different neuronal groups in which 
lesions occur (Smith & Cuello, 1984). AD brains show neurochemical changes that 
include loss of AChE and ChAT activity associated with cortical cholinergic axons and 
cholinoceptive neurons. Therapeutic interventions to treat the characteristic loss of 
memory and cognitive deficits associated with AD are AChE inhibitors, which, in fact, 
are the only drugs approved for the treatment of Alzheimer’s symptoms. BChE activity, 
on the other hand, is found to increase in AD (Perry, 1980). This increase in activity 
could possibly be a method of compensation for the loss of AChE activity.  
 
It seems that most areas of the brain susceptible to plaque and tangle formation are highly 
AChE and BChE positive (Hirano & Zimmerman, 1962; Ishii, 1966; Ishino & Otsuko, 
1975; Kemper, 1984; Mesulam et al., 1984; Smith & Couello, 1984; McDuff & Sumi, 
1985), and both proteins are associated with the plaques. Reports show that the 
cytotoxicity of amyloid complexes increase as the concentration of AChE increase 
(Munoz & Inestrosa, 1999). The association of BChE with amyloid plaques seems to 
correspond with when Aβ deposits assume the compact β-sheet conformation, suggesting 
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that BChE may participate in the transformation of Aβ from a benign to the malignant 
form found in neurodegeneration (Guillozet et al., 1997). 
 
Although the impact of disturbed cholinergic innervation on plaque formation has been 
documented (Price et al., 1982), the deposition of AChE seems to be unrelated to 
cholinergic neuron degeneration. Plaque-associated AChE differs from uncomplexed 
AChE in its reaction with inhibitors (Mesulam et al., 1987; Geula & Mesulam, 1989). 
The enzymatic properties of tangle and plaque-associated AChE diverge from the AChE 
of normal axons or cell bodies. Another possible explanation is that binding to amyloid 
blocks or affects the sites to which the PAS-binding inhibitors bind.  
 
The in vivo colocalization of AChE and Aβ was recreated in vitro to investigate whether 
these actions occur and if so, how they influence the process leading to amyloid 
deposition (Inestrosa et al., 1996). It was reported that bovine brain AChE, as well as the 
human and mouse recombinant enzyme, accelerated amyloid formation independent of 
the subunit array of the enzyme. This action was not affected by the active site inhibitor 
edrophonium, but addition of the PAS ligand, propidium, did show an effect. On the 
other hand, BChE, lacking the peripheral site, did not affect amyloid formation. From this 
study it seems that AChE may play a role in accelerating Aβ formation and function in 
amyloid deposition (Inestrosa et al., 1996).  
 
Through the process of complex formation with growing fibrils, AChE has been shown to 
promote the aggregation of Aβ-peptide. This process was found to be resistant to high 
ionic strength treatment suggesting that hydrophobic interactions play a role in stabilizing 
the complex (Alvarez et al., 1997). Reyes and colleagues (1997) observed that a PAS-
reacting monoclonal antibody inhibited AChE induction of amyloid formation. De Ferrari 
et al. 2001b, using protein docking and synthetic peptides, identified the amyloid-binding 
site on AChE. This was found to be the hydrophobic peptide 274-308, which incorporates 
the PAS residue W286.  
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Much of the current research on AChE and AD is concerned with the discovery and 
development of new AChE inhibitors, in particular, inhibitors that are capable of 
addressing both the cholinergic deficit and amyloid formation. Such inhibitors would 
bind simultaneously to the active site, to inactivate and address the cholinergic deficit, 
and to the PAS, to block the AChE-Aβ-peptide interaction and thus control amyloidosis 
(for reviews on this topic see Castro & Martinez, 2006; Munoz-Torrero et al., 2008; 
Galdeano et al., 2010). On the basic research side, Garcia-Ayllon et al. (2011) have 
suggested the possibility that the amyloid beta-peptide and P-tau interact through AChE, 
and Dinamarca et al. (2011) have shown that neuroligin (the CLAM AChE homologue) 
is also capable of interacting with the amyloid beta-peptide and promoting amyloidosis.  
 
1.6.4 Acetylcholinesterase and Cancer 
 
A role for ChEs in tumorgenesis has been proposed. It seems that both the AChE and 
BChE genes are amplified, mutated or expressed in a variety of human tumor types 
(Montenegro et al., 2005; 2006; Perry et al., 2002; Vidal, 2005; Zakut et al., 1990; 
Lapidot-Lifson et al., 1989). As a very broad generalization, the patterns of amplification 
and expression follow those observed during neural development, with an association of 
BChE with proliferation and AChE with differentiation. However, there are numerous 
variations on this pattern. It may be that the amplification and expression of the ChEs in 
neoplasia is dependent upon the specific tissue from which the tumour was derived. 
These genes are located within regions subject to non-random chromosomal 
abnormalities associated with myelodysplastic syndromes (MDS) and acute myeloid 
leukemia (AML) (Kere et al., 1989a, 1989b; Kere, 1989). Deletions of the AChE locus is 
associated with MDS and AML, reinforcing the possibility that AChE may play a role as 
a myeloid suppressor gene (Stephenson et al., 1996). A study investigating amplifications 
and deletions in the AChE and BChE genes in sporadic breast tumor cells found tumor 
malignancy grade to be positively correlated to the number of alterations of the BChE 
gene, and tumor size to be significantly higher when the AChE gene was amplified 
(Bernardi et al., 2010). Furthermore, translocations in 7q22 were shown to define a 
critical region associated with uterine leiomyomas (Sargent et al., 1994).  
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The consensus peptide motif S/T-P-X-Z, which is found in many substrates of cell 
division control protein 2 or cdc2-related protein kinases, is also present in both AChE 
and BChE. Cdc2 kinases are master regulators of G2/M transition during the eukaryotic 
cell cycle and its phosphorylation activity has been linked to a variety of cell cycle 
abnormalities that could be involved in cancer formation (e.g. Hosoya et al., 1994; 
Furukawa et al., 2000). Soreq and colleagues proposed the possibility that 
phosphorylation by cdc2-related kinases may be the molecular mechanism linking 
cholinesterases with tumor cell proliferation (Grifman et al., 1997). Organophosphorus 
compounds have been known to induce tumorgenetic risks (Soreq & Zakut, 1993; Brown 
et al., 1991).  
 
The haematopoietic effects of AChE have also been postulated (Kawashima & Fujii, 
2003a, 2003b). These effects include reduction in proliferation of multipotent stem cells 
committed to erythropoiesis, megakaryocytopoiesis and macrophage production, and 
promotion of apoptosis in their progeny (Soreq et al., 1994). Constitutional 
rearrangements of 7q22 have also been found to lead to haematopoietic malignancies 
(Forrest & Lee, 2002), affects that are reportedly attributed to the non-catalytic properties 
of AChE-R (Grisaru et al., 2001; Deutsch et al., 2002). AChE-R has been shown to 
interact with protein kinase C in glioblastoma cells where it elicits a cellular signal 
transduction response that promotes tumorgenesis (Perry et al., 2004).  
 
Alterations in CAM expression have been shown to be significant in the development of 
tumors, specifically in the regulation of proliferation and apoptosis, cellular motility and 
invasion, as well as the cell surface localization of metalloproteinase angiogenesis 
(reviewed Varner & Cheresh, 1996). Our own as well as other evidence show that AChE 
is able to promote cell adhesion and differentiation in immature and malignant neural 
cells (Layer & Wilbold, 1995).  
1.7 The Basement Membrane: Importance of Laminin 
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Basement membranes (BM) consist of thin sheets of highly specialized ECM molecules. 
They are present at the epithelial/mesenchymal interface of most tissue surrounding 
muscle, peripheral nerve fibers as well as fat cells. Components of the BM are able to 
regulate biological activities such as cell growth, differentiation and migration and they 
have been found to influence tissue development and repair (Couchman & Woods, 1993; 
Aumailley & Krieg, 1996; Timpl, 1996; Aumailley & Gayraud, 1998). Laminins, 
entactin-1/nidogen-1, collagen IV and HSPGs are contained within all BMs (Fitch & 
Lisenmayer, 1994; Timpl & Brown, 1996). The electron dense region of the BM, called 
the lamina densa, predominantly consists of polymeric networks of collagen and laminin 
integrated by crosslinkers like nidogen and perlecan (Ghohestani et al., 2001). Assembly 
of the BM depends on the polymerization of two independent networks. The first type of 
assembly involves collagen IV, which becomes covalently stabilized (Yurchenco & 
Schittny, 1990). The second type involves polymerization of laminin, and this assembly 
is non-covalent and calcium-dependant. These two networks are connected by entactin 
(Yurchenco et al., 1992).  
 
Laminin proteins are large (400-900 kDa), four armed, heterotrimeric glycoproteins that 
are composed of various combinations of α, β, and γ chains (Figure 15; Miner & 
Yurchenco, 2004). The four arms consist of three shorter arms that can bind other laminin 
molecules forming sheets, and one longer arm that can bind to cells and thus help anchor 
the actual organs to the membrane. There are 16 known laminins in mammals and these 
proteins play a significant role in BM architecture and function (Aumailley et al., 2005; 
reviewed Tzu & Marinkovich, 2008). Laminins bind cells via high affinity receptors and 
mediate attachment, migration and organization of cells into tissue during development 
by interacting with other ECM components (Nurcombe et al., 1989; Tzu & Marinkovich, 
2008). During embryogenesis, laminin-111, previously called laminin-1 (Aumailley et 
al., 2005), is the first synthesized component of the BM and plays an important role in 
embryonic development (Miner et al., 1997; Aumailley et al., 2000; Colognato & 
Yurchenco, 2000). Serum IgG anti-laminin-111 autoantibodies have been associated with 
recurrent first-trimester miscarriages and studies reported a significant association of 
these antibodies with endometriosis in infertile patients. It seems that the presence of 
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anti-laminin autoantibodies results in abortion (Inagaki et al., 2003, 2001, 2005). The 
ability of laminin-111 to promote migration of neural crest cells enables the preferential 
migration of these cells along the basal lamina. The interaction of neural crest cells with 
laminin-111 involves two major cell binding domains that are both recognized by the 
α1β1 integrin and it was found that α1β1 integrin is able to elicit different cellular 
responses depending on the laminin-111 domain it interacts with (Desban & Duband, 
1997).  
 
Laminin is able to self-assemble into a polymer via a reversible, entropy-driven and 
calcium facilitated process, in vitro. This self-assembly is dependant upon the short-arm 
globular domains (Yurchenco et al., 1992). Polymerisation was shown to require the 
interaction of all three ligands, one from each short arm, through calcium activated 
assembley (Yurchenco & Cheng, 1993). Ligands identified for laminin include nidogen 
(entactin), fibulin, thrombospondin, HSPG (heparin), perlecan, agrin, and collagen IV 
(Tzu & Marinkovich, 2008; Chen et al., 1999; Schneider et al., 2006; Mecham, 1991). 
The induction of AChR clustering is an important step during the development of the 
neuromuscular junction (Fertuck & Salpeter, 1976). Laminin is able to induce AChR 
clustering; however, it was found that laminin-111 induces AChR clustering by a 
pathway independent of that used by neural agrin (Sugiyama et al., 1997).  
 
 
Figure 15. Laminin molecule. Structure of 
the laminin-111 molecule showing the α1 
chain, containing the G binding domains; the 
β1 and γ1 chains. 
 
 
 
 
Laminin is induced by brain injury and 
colocalizes with Aβ-deposits in AD brains 
(Engel, 1992; Liesi et al., 1984, 1989; 
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Murtomaki et al., 1992). Through a binding site on the α chain, laminin is able to bind Aβ 
with relatively high affinity (Castillo et al., 2000), and its binding with APP has also been 
reported (Koo et al., 1993). It was found that laminin is able to inhibit the formation of 
amyloid fibrils (Bronfman et al., 1996; Castillo et al., 2000). Related findings suggest 
that laminin may be effective as a therapeutic agent in AD (Monji et al., 1998).  
 
 
1.8 Work leading up to the thesis 
 
1.8.1 Non-Classical AChE Binding Partners and Binding Sites  
 
Interactions of AChE with a number of proteins and peptides have been reported. Our 
own as well as other evidence show that AChE is able to interact with laminin-111, 
(Johnson & Moore, 2003; Paraoanu & Layer, 2004). AChE is also able to interact with 
collagen IV and this interaction, along with the laminin-111 interaction, was shown to 
involve electrostatic mechanisms associated with the PAS (Johnson & Moore, 2003). By 
use of the yeast two-hybrid method, Paraoanu and Layer (2004) identified an interaction 
between the globular IV (G4) domain of laminin chain β1 and the amino acids 240-503 
of mouse AChE. Results suggested that through this interaction, AChE is able to exert 
changes in adhesion signalling pathways (Paraoanu & Layer, 2004). AChE was shown to 
modulate neurite outgrowth through interactions with fibronectin (Giordano et al., 2007). 
Associations of asymmetric AChE with glycosaminoglycans and fibronectin have also 
been suggested to bind AChE to the basal lamina (Massoulie & Bon, 1982). Interactions 
of AChE with the nicotinic ACh receptor (Greenfield et al., 2004) as well as with Aβ (De 
Ferrari et al., 2001b) have been reported. Pera et al. (2006) identified that AChE is able 
to bind and initiate the aggregation of prion protein (PrP) (Pera et al., 2006). The collagen 
tail of the asymmetric forms of AChE has been found to bind heparin, supporting the 
proposed concept that the asymmetric AChE forms are immobilized on the synaptic basal 
lamina via interactions with heparin-like molecules probably related to HSPGs (Brandan 
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& Inestrosa, 1984). Bigbee and Sharma (2004) observed an association of AChE with 
four as yet unidentified proteins of MW 200, 100, 35 and 33 kDa, respectively. 
 
Studies have shown that the AChE site that mediates cell adhesion is localized to the PAS 
(Johnson & Moore, 1999; Munoz et al., 1999; Olivera et al., 2003). Johnson and Moore 
(2004) have recently identified the site more precisely using synthetic peptides. The site 
was defined as a discontinuous (conformational) structure involving the participation of 
residues from a number of surface loops in the area of the PAS. Its most striking 
characteristic is its strong negative charge (supporting the “electrotactin” 
characterization) and its high degree of flexibility, caused by movement of the loops 
(Johnson & Moore, 2004).  
 
Greenfield and colleagues also proposed an important role for the C-terminal peptide of 
AChE. It was reported that this site promotes outgrowth of neurites in low concentrations 
and apoptosis in higher concentrations (Day & Greenfield, 2003). The C-terminal peptide 
seems to interact with the nicotinic AChE receptors (Greenfield et al., 2004; Zbarsky et 
al., 2004). This peptide also shares sequence similarities with APP (Greenfield & Vaux, 
2002) and have been found to be amyloidogenic (Cottingham et al., 2003). The 
physiological relevance of this peptide, as well as Greenfield’s proposal that monomers 
alone promote non-classical functions, could possibly need some revision as it is located 
in the part of the AChE sequence involved in oligomerisation. 
 
1.8.1 The AChE Knockout and Functional Redundancy 
 
Although the in vitro evidence, particularly the studies using anti-AChE antibodies which 
induced apoptosis in treated cells, suggests that AChE is essential for the survival and 
normal development of neural precursors, the AChE knockout mouse survives. 
Investigation showed that BChE compensates for the lack of AChE in cholinergic 
synapses and neuromuscular junctions, taking over its synaptic function (Xie et al., 
2000). However, BChE has not generally been observed to promote non-cholinergic cell 
adhesion (Johnson & Moore, 2000; Mack & Robitzki, 2000), and so is unlikely to replace 
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AChE in this context. Nevertheless, the knockout has severe developmental 
abnormalities: it is largely immobile, with defects in muscle structure and function 
(Vignaud et al., 2008), it requires a liquid diet in order to survive, has significant 
behavioural abnormalities, and has nervous system defects, in particular, in the 
development of the eye (Bytyqi et al., 2004). Abnormalities associated with eye 
development, in particular, suggest the presence of non-classical functions, and that 
AChE is indispensable in this context.  
 
Another in vivo study using catalytically inactive, but otherwise structurally intact, AChE 
in the zebrafish showed little evidence for non-cholinergic developmental functions as 
the zebrafish does not have compensating BChE. AChE activity was found to be 
necessary for development and maintenance of the axial muscle apparatus as well as for 
survival of primary sensory neurons, providing evidence of cholinergic non-classical 
functions (Behra et al., 2002).  
 
Cousin et al. (2005) published a highly critical paper on the non-classical functions of 
AChE stating that neither the invertebrate (C. elegans, D. melanogaster) nor the 
vertebrate models (zebrafish and mouse) provide strong enough evidence in favor of 
these functions. It was proposed that in all aspects so far studied, in vivo, the loss of 
function of AChE in these systems is responsible for the appearance of several 
phenotypes and that these phenotypes can be explained by an excess of the undergraded 
substrate, ACh, resulting in loss of function and pathological alterations. Furthermore, the 
observed phenotypes could solely be a consequence of the lack of AChE catalytic activity 
in the mutants as none of them appears to require the postulated adhesive or other non-
catalytic functions (Cousin et al., 2005). 
 
An obvious discrepancy exists between the in vivo evidence of the knockouts and the 
documented interactions and effects in vitro. Presuming that AChE is indeed capable of 
producing said effects in vitro, a possible explanation, reconciling both sides of the 
debate, could be that of functional redundancy. The number of knockouts reported with 
no associated phenotype suggests that redundancy is fairly common in higher organisms. 
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Redundancy seems to appear more frequently in proteins expressed in developmental, 
rather than ‘houskeeping,’ context, possibly because these proteins tend to be expressed 
in precise spatiotemporal pattern with a relatively smaller margin for error. Here 
redundancy may promote robustness by providing a back-up or fail-safe device. The fact 
remains that AChE is evolved almost perfectly to fulfil another function (ACh 
hydrolysis), and it may be that the adhesion function may have developed fortuitously as 
a back-up for a critical interaction.  
 
1.9 Aims of the Thesis   
 
The overall aim of this thesis was the characterisation of the AChE-laminin interaction, 
relating specifically to both cell adhesion and neurite outgrowth in neural development, 
and amyloidosis in neurodegeneration. A further problem that was addressed was the 
apparent discrepancy between the evidence suggesting the importance and necessity of 
AChE for neural development, and the largely normal phenotype of the AChE knockout 
mouse. The hypothesis that AChE in its non-classical role as a cell adhesion molecule is 
functionally redundant was proposed. 
 
Specific Aims: 
1. Demonstration of the interaction between AChE and laminin-111 (using ELISA 
and Co-IP); 
2. Definition and characterisation of the laminin-binding site on AChE (using phage 
display, peptide array, molecular modelling and docking); 
3. Definition and characterisation of the AChE-binding site on laminin-111 (using 
phage display, molecular modelling and docking); 
4. Identification of molecules that are expressed during the migration and 
differentiation of neural precursors and also the Alzheimer’s-affected brain, which 
structurally mimic characteristics of the AChE-laminin interaction, and thus with 
which this interaction may show functional redundancy (using bioinformatics). 
Stellenbosch University http://scholar.sun.ac.za
 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
 65 
2. Materials and Methods   
 
2.1 Materials   
 
2.1.1 Instruments 
Autoclave: Speedy autoclave HL-340 HLMC Co., Taipei, Taiwan 
Balances: Sartorius Weighing Instrument Cape Scientific, Cape Town, SA 
Cell culture hood: Bio-Flow  Hospital & Lab Solutions, Cape Town, SA 
Centrifuge: Sorvall® RC-5B Refrigerated 
Superspeed Centrifuge 
Du Pont Instruments, West Virginia, USA 
Centrifuge: Eppendorf Centrifuge 5417R Merck, Germiston, SA 
Dounce homogeniser Cole-Parmer, Vernon Hills, USA 
Electrophoresis tank/SDS gel tank: Mini-
PROTEAN® Tetracell 
BioRad Laboratories Ltd., Johannesburg, 
SA 
Electrophoresis and blotting power supply Consort E844, Belgium  
Hägar HB2 Dry Block Heater Hägar Designs HB2, Wildernis, SA 
Incubator for neuroblastoma cells (CO2) Thermo Electron Corp., Ohio, USA 
Laminar flow hood: Class II Biohazard VividAir, Durban, SA 
Magnetic stirring plates FMH Instruments, Lasec, SA 
Multipipette Nichipet EX, Nichiryo, Japan 
Microscope Nikon, SA 
Oak Ridge centrifuge tubes Nalgene Centrifuge Ware, USA  
pH meter: Orion 3star porTable  Thermo Scientific, Johannerburg, SA 
Pipettes  Gilson Pipetman, Middleton, Wisconsin, 
USA 
Pipetting device: Pipetteboy Integra Biosciences, Zürich, Switzerland 
Polyallomer SW41 tube Beckman Coultier, Cape Town, SA 
Rocker: 25 MainLab Services, Labnet, Cape Town, SA 
Spectrophotometer: Ultraspec LKB Biochrom, Cambridge, UK 
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Vortex VELP Scientifica, Usmate, Italy 
Waterbaths: Labcon MainLab Services, Cape Town, SA 
Western blotting tank: Mini Trans-Blot® 
Cell 
BioRad Laboritories Ltd., Johannesburg, 
SA 
 
2.1.2 Reagents/Chemicals  
ABTS (2,2'-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid)) 
Sigma, St Louis, Missouri, USA 
Acrylamide/Bis solution BioRad Laboratories Ltd., Johannesburg, 
SA 
Agar bacteriological (Bacto agar) Merck, Darmstadt, Germany 
Ammonium persulfate Sigma, St Louis, Missouri, USA 
BSA (Albumin, bovine serum) Sigma, St Louis, Missouri, USA 
Bacto-tryptone Sigma, St Louis, Missouri, USA 
Biotin, NHS (N Hydroxysuccinimido ester) Sigma, St Louis, Missouri, USA 
Bromophenol blue Sigma, St Louis, Missouri, USA 
Butanol  Sigma, St Louis, Missouri, USA 
BW284c51 (1,5-bis [4-
allyldimethylammoniumphenyl] pentan-3-
one dibromide) 
Sigma, St Louis, Missouri, USA 
Chloroform Merck, Darmstadt, Germany 
DMF  (N,N-Dimethylformamide) Fluka Chemika, Johannesburg, SA 
DMSO (Dimethyl sulfoxide) Fluka Chemika, Johannesburg, SA 
DTT (Dithiothreitol) Fluka Chemika, Johannesburg, SA 
EDTA (Ethylenediaminetetraacetic acid) Sigma, St Louis, Missouri, USA 
EMEM (Eagle’s minimum essential 
medium): HyClone 
Thermo Scientific, Waltham, 
Massachusetts, USA 
FCS (Fetal calf serum) Biowhitaker, Lonza Walkersville Inc., 
Walkersville, Maryland, USA 
Gallamine triethodide Sigma, St Louis, Missouri, USA 
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Gelatin Sigma, St Louis, Missouri, USA 
L-Glutamine Sigma, St Louis, Missouri, USA 
Glycerol Sigma, St Louis, Missouri, USA 
Glycine Merck, Darmstadt, Germany 
HCL  Merck, Wadeville, SA 
Hydrogen peroxide (H2O2) Sigma, St Louis, Missouri, USA 
Imperial™ protein stain Pierce, Rockford, Illinois, USA 
IPTG (Isopropyl β-D-1-
thiogalactopyranoside)  
Merck, Darmstadt, Germany 
Isopropanol Sigma, St Louis, Missouri, USA 
Kanamycin Fluka Chemika-Biochemika, 
Johannesburg, SA 
KCL  Merck, Darmstadt, Germany 
KH2PO4 Merck, Darmstadt, Germany 
K2HPO4 Merck, Darmstadt, Germany 
D(+) – Maltose monohydrate Fluka Chemika-Biochemika, 
Johannesburg, SA 
β-Mercaptoethanol Research Organics, Inc., Cleveland, Ohio, 
USA 
Methanol Sigma, Schnelldorf, Germany 
MgSO4 BDH Laboratories Supplies, Kampala, 
Uganda 
NaCl Fluka, Chemika-Biochemika, 
Johannesburg, SA 
NaF Sigma, St Louis, Missouri, USA 
NaHCO3 Sigma, St Louis, Missouri, USA 
Na2HPO4 Merck, Darmstadt, Germany 
NaN3 Sigma, St Louis, Missouri, USA 
NaOH Sigma, St Louis, Missouri, USA 
Na3VO4 Sigma, St Louis, Missouri, USA 
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NP40 Sigma, St Louis, Missouri, USA 
NZ amine A Sigma, St Louis, Missouri, USA 
PEG8000 Sigma, St Louis, Missouri, USA 
Penicillin/Streptomycin Biowhitaker, Lonza Walkersville Inc., 
Walkersville, Maryland, USA 
Phenol red Sigma, St Louis, Missouri, USA 
PMSF (phenylmethanesulfonylfluoride) Sigma, St Louis, Missouri, USA 
Poly-L-lysine Sigma, St Louis, Missouri, USA 
PI (Propidium iodide) Sigma, St Louis, Missouri, USA 
Protease inhibitor cocktail Sigma, St Louis, Missouri, USA 
Protein A - sepharose  Sigma, St Louis, Missouri, USA 
Pyridostigmine bromide (reversible 
cholinesterase inhibitor) 
Sigma, St Louis, Missouri, USA 
Sarkosyl (sodium lauroyl sarcosinate) Sigma, St Louis, Missouri, USA 
SDS (Sodium dodecyl sulfate) BDH Laboratories Supplies, Kampala, 
Uganda 
Streptavidin from Streptomyces avidinii Sigma, St Louis, Missouri, USA 
Streptavidin-peroxidase conjugate Sigma, St Louis, Missouri, USA 
Spectra™ multicolour brood range protein 
ladder 
Fermentas, Glen Burnie, Maryland, USA 
TEMED (N,N,N’,N’ – 
tetramethylethylenediamine) 
USB® Corporation, Cleveland, Ohio, USA 
Tetracycline Fluka Chemika-Biochemika, 
Johannesburg, SA 
TMB (3,3’,5,5’ tetramethylbenzidine liquid 
substrate system for membranes)  
Sigma, St Louis, Missouri, USA 
Trizma base Merck, Darmstadt, Germany 
Triton X100 Sigma, St Louis, Missouri, USA 
Trypsine/Versene Biowhitaker, Lonza Walkersville Inc., 
Walkersville, Maryland, USA 
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Tween 20 Fluka Chemika, Johannesburg, SA 
Yeast extract Merck, Darmstadt, Germany 
 
2.1.3 Consumables  
Blotting filter paper, mini transblot BioRad, BioRad Laboritories Ltd., 
Johannesburg, SA 
Cellstar tissue culture flasks Greiner Bio-One, Germany 
Centricon 30kDa ultrafilter Amicon, Millipore, St. Charles, Missouri, 
USA 
Disposable filter unit Lasec, Cape Town, SA 
Disposable nitrile examination gloves Hi-Care, Kolkata, India 
Eppendorf tubes (1ml, 1.5ml, 2ml) Quality Scientific Plastics (QSP), 
Whitehead Scientific, Cape Town, SA 
Immobilon-P transfer membrane Millipore, St. Charles, Missouri, USA 
Microtiter plates/ELISA plates Costar, Corning Inc., NY, USA 
Parafilm Lasec, Cape Town, SA 
Petridishes (35mm, 90mm) Lasec, Cape Town, SA 
Pipettes (1ml, 5ml, 10ml, 25ml) Lasec, Cape Town, SA 
Pipette tips Lasec, Cape Town, SA 
Plastic tubes, sterile,15ml: Cellstar Greiner Bio-One, Frickenhausen, Germany 
Plastic tubes, sterile, 50ml: Polypropelene 
Conicol tubes 
Becton Dickinson Labware, NJ, USA 
Slide-A-Lyzer Pierce, Rockford, Illinois, USA 
Snakeskin® pleated dialysis tubing Pierce, Rockford, Illinois, USA 
Syringes Promex, Johannesburg, SA 
24-well plates Greiner Bio-One, Frickenhausen Germany 
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2.1.4 Proteins  
AChE, amphiphilic from human 
erythrocytes 
Sigma, St Louis, Missouri, USA 
AChE, recombinant, from human Sigma, St Louis, Missouri, USA 
Laminin, from Engelbreth-Holm-Swarm 
murine sarcoma 
Sigma, St Louis, Missouri, USA 
Non-specific anti-human IgG (biotinylated) Sigma, St Louis, Missouri, USA 
 
2.1.5 Primary antibodies 
Anti-AChE, produced in goat, polyclonal, 
100µg/200µl 
Sigma, St Louis, Missouri, USA 
Anti-laminin, rabbit, produced in rabbit, 
polyclonal, 1mg/ml  
Sigma, St Louis, Missouri, USA 
 
2.1.6 Secondary antibodies 
Anti-goat IgG (whole molecule)-biotin, 
produced in rabbit, conjugated, 0.2-2 mg/ml 
Sigma, St. Louis, Missouri, USA 
Anti-rabbit (whole molecule)-biotin, 
produced in goat, polyclonal, solution in 0.01 
M PBS pH 7.4, containing 15 mM sodium 
azide  
Sigma, St Louis, Missouri, USA 
 
2.1.7 Kits 
Phage display peptide library kit New England BioLabs® Inc., Ipswich, 
Massachusetts, USA 
Wizard® genomic DNA purification kit Promega, Madison, Wisconsin, USA 
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2.1.8 Antibodies 
 
Prior to the work described in this thesis, a network of idiotypic (Ab1), anti-idiotypic 
(Ab2) and anti-anti-idiotypic (Ab3) antibodies was developed. The initial monoclonal Ab 
(MAb), E8, was raised in Balb/c mice against human erythrocyte AChE (Sigma). This 
MAb was found to have esterolytic activity (Johnson & Moore, 1995). Subsequently, two 
more catalytic MAbs (C2 and 43B4C) were raised against the same antigen (Johnson & 
Moore, 2000). Fusions and cloning of these Ab1s were performed according to standard 
protocols (Harlow & Lane, 1988). SDS/PAGE confirmed the purity of the Ag and the 
Abs were screened against both erythrocyte and recombinant human AChE. No 
significant differences in reactivity were observed. Purification of Abs was done by 
Protein A-Sepharose 4B affinity chromatography using low-salt buffers, according to 
standard protocols (Harlow & Lane, 1988). Another MAb, E12C8, was raised against 
Torpedo AChE and also block cell adhesion. MAb E12C8 was a gift from the Walter 
Reed Army Institute (Washington, DC, USA). It was observed that all three MAbs were 
able to block the ability of cultured neuroblastoma cells to adhere to the substratum. 
Neuroblastoma cells (cell line N2α) are normally flattened and adherent. If the MAbs 
were added to the cells at the time of plating, the cells remained in suspension without 
adhering, and subsequently died. When the MAbs were added to already adherent cells, 
the cells rounded up, floated, and subsequently died. This effect was dose-dependent. It 
was concluded that these MAbs were interfering with an AChE-mediated cell adhesion 
process.  
 
The MAbs showed very similar enzyme kinetics (Johnson & Moore, 2000) and this, 
together with the similarity of their effects on cells (quantitated by both the timing and 
percentage of adhesion loss) suggested that they recognised a common epitope on AChE. 
It was found, using competition ELISA and fluorometry, that the MAbs competed with 
the PAS-binding inhibitors propidium, gallamine, BW284c51 and fasciculin-2, which 
indicated that this epitope lay at or near the PAS. The results also confirm the association 
of AChE’s adhesion-mediating ability with the PAS. Subsequent work showed that the 
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MAbs blocked the interaction between AChE and laminin-111. It was therefore 
concluded that the MAbs’ epitope and the laminin-interaction site on AChE have 
structural features in common, and are possibly identical. Two more anti-AChE Abs, 9H 
and AE-2, appeared to bind near the PAS but did not inhibit cell adhesion or laminin 
binding. These were used as controls. MAb 9H was raised in our laboratory and MAb 
AE-2 was also a gift from the Walter Reed Army Institute (Washington, DC, USA). 
 
Anti-idiotypic (Ab2) MAbs were raised against the original catalytic and adhesion-
inhibiting MAb, MAb E8. Several of these Ab2s were found to be capable of promoting 
neurite outgrowth in neuroblastoma cells, and also of binding to laminin-111, suggesting 
that their idiotope was mimicking the adhesion-mediating site on AChE (Johnson & 
Moore, 2004). These Ab2s were not catalytic. Anti-anti-idiotypic (Ab3) MAbs were 
similarly raised against an Ab2. These were 13B9F and 13B9C. These Ab3s resembled 
the original MAb E8 in being both catalytic and adhesion-inhibiting. 
 
While the Ab1s showed both relatively similar enzyme kinetics and adhesion-inhibiting 
ability, more variation was seen among the Ab2s and Ab3s. Thus, it was thought that the 
Abs, especially as they are not exactly similar to AChE or its binding partner(s), would 
provide a “variation on a theme” that might prove useful in determining the relative 
importance of specific aspects on the adhesion-mediating site, both on AChE and on its 
interaction partner(s). A further consideration is the “localisation” of the site of interest 
on the Ab to a very specific area, namely the complementarity-determining regions 
(CDRs). A moderately-sized protein such as AChE could conceivably have a number of 
interaction sites; the C-terminal region, in particular, is noted for its ability to interact 
with membrane anchoring proteins and structures, which would confuse the issue. This 
consideration would apply even more to laminin, which is a very large molecule with a 
multiplicity of interaction sites.  
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2.1.9 Biotinylation 
 
The resultant number of biotins per AChE molecule was not determined; however, 
previous results from the laboratory had shown that biotinylation had no significant effect 
on AChE’s enzyme activity, inhibitor binding (inhibitors pyridostigmine, edrophonium 
BW284c51 and propidium), nor was MAb-AChE binding affected. These results suggest 
two things: firstly, as both BW284c51 and propidium are cationic PAS-binding 
compounds, this suggests that the charge of the PAS has not been significantly affected; 
it also suggests that steric hindrance effects are not significant. The MAb binding to 
AChE is also not affected, suggesting that the epitope is not restricted by biotinylation. 
 
AChE (human and mouse) contains 10 Lys residues (K23, K53, K332, K348, K470, 
K495, K538, K554, K568 and K576). Of these, only 3 lie on the gorge opening “face” of 
the molecule (Figure 16). These 3 residues are K23, K53 and K348. The others all lie 
away from this region, largely in AChE’s C-terminal domain; 4 lie in the distal part of the 
domain in the T-peptide oligomerisation domain. A high concentration of acidic residues 
(Asp and Glu) on the gorge opening “face” is also found. Because of this high 
concentration of acidic charge, the neutralisation of several positively charged residues 
may not have a drastic effect on the overall charge distribution. The experimental results 
support this. The biotinylated peptides used in this study were biotinylated at the NH2 
terminal only. 
 
Figure 16. The 
structure of mouse 
AChE molecule 
(1J06.pdb). The three 
Lys residues at the 
gorge opening are 
colored in cyan. The 
PAS residues are shown 
in yellow. The arrow 
shows the entrance to 
the ASG.  
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2.1.10 General buffers and solutions 
 
Phosphate buffered saline (PBS): A 10X stock solution was made up by dissolving 80g 
of NaCl, 2.0g of KCl, 14.4g of Na2HPO4 and 2.4g of KH2PO4 in 800ml of dH2O. The pH 
was adjusted to 7.4 after which the volume was increased to 1L with additional dH2O. 
The solution was sterilised by autoclaving and stored at room temperature (RT). A 1X 
working solution was made up by adding 100ml of the 10X stock solution to 900ml of 
dH2O. 
 
PBS/Tween (wash buffer): Tween 20 was added to a 1X PBS solution to give a final 
concentration of 1% (v/v). The solution was stored at RT. 
 
PEG/NaCl precipitation buffer: 110g of PEG 8000 and 116.9g of NaCl were added to 
475ml of dH2O and the mixture was stirred and heated to 65°C until solute dissolved. 
The solution was stored at 4°C. 
 
Tris-buffered saline (TBS) 1X solution: 8g of NaCl, 0.2g of KCl and 3g of Trizma base 
was dissolved in 800ml of dH2O. 0.015g of phenol red was added as a pH control. The 
pH was adjusted to 7.4 with HCl, until the red colour cleared. The total volume was 
increased to 1L with addition of dH2O. The solution was sterilised by autoclaving and 
stored at RT. 
 
TBS/Tween (wash buffer): Tween 20 was added to a TBS solution at a final 
concentration of 0.5% (v/v). The solution was stored at RT. 
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2.2 Methods 
 
2.2.1 ELISA 
 
Enzyme-linked immunosorbent assay (ELISA) is a powerful method of determining the 
presence as well as concentration of a particular protein in a sample. In “direct ELISA”, 
the antigen-containing sample is immobilised on a polystyrene microtitre plate and a 
specific antibody coupled to an enzyme (usually horseradish peroxidase or alkaline 
phosphatase) is added. The bound antibody is then detected by the addition of substrate 
together with a colour reagent that develops according to the amount of enzyme/antibody 
bound. There are a number of variations on this technique. In the “indirect” ELISA, both 
a primary (anti-antigen) and a secondary (anti-primary antibody) antibody are used. The 
secondary antibody may be coupled to the enzyme, or, as is frequently used, coupled to 
biotin. In the latter situation, an additional step using an avidin-enzyme complex is 
included. The use of the secondary antibody, as well as the biotin-avidin step, help to 
augment the final signal obtained.  
 
In the “sandwich” ELISA (also called the “capture” ELISA), the microtitre plate is coated 
with primary antibody, instead of the antigen. This antibody coating “captures” the 
antigen in the sample. This is followed by incubation with primary and secondary 
antibodies, as above. As with the indirect ELISA, this additional step helps to augment 
the final signal.  
 
A fourth type of ELISA is the “competition” or “competitive” ELISA. In a competitive 
ELISA used to quantitate antigen in a sample, the sample is incubated beforehand with 
the antibody to produce an antigen-antibody complex. The complex is then added to a 
microtitre plate which is coated with the antigen. The two “antigens” (antigen in the 
sample and antigen on the plate) thus compete for antibody binding. As a result, the 
higher the concentration of the antigen in the sample, the lower will be the final signal, as 
this is a measure of the amount of coated antigen that binds to the antibody. Competitive 
ELISAs are useful for the detection of antigen in crude samples.  
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In this thesis, several types of ELISA were used: indirect, sandwich, and a variation of 
the competitive ELISA described above.  
 
 
AChE synthetic peptides: Peptides corresponding to the following sequences of human 
AChE were synthesised by Bio-Synthesis Inc, Lewisville, Texas, USA, except for 
peptides 37-53 and 340-353 which were synthesised by PepMetrics:  
 
Table 2. Peptide sequences 
Residue Corresponding 
region 
Sequence 
28-53 (or 37-53) Surface loop adjacent 
to the PAS 
ISAFLGIPFAEPPMGPRRFLPPEPKKP 
55-66 Surface loop adjacent 
to the PAS 
PWSGVVDATTFQ 
 
69-96 Omega loop CYQYVDTYPGFEGTEMWNPNRELSEDC 
 
275-290 Part of large loop on 
the opposite side of 
the PAS and 
including PAS 
residue W286 
RPAQVLVNHEWHVLP 
340-353 Including PAS 
residue Y341 
VYGAPGFSKDNESL 
 
 
Peptides were purified by HPLC to > 95% purity and lyophilised. Lyophilised peptides 
were dissolved in double distilled water at a concentration of 2mg/ml, and frozen in 
aliquots. Aliquots that had been thawed were used immediately and not refrozen. 
 
Purified erythrocyte AChE was used in all assays. 
Stellenbosch University http://scholar.sun.ac.za
 77 
 
Peptides binding to laminin: Binding proteins, AChE and BSA, were biotinylated by 
the method of Bhakdi et al (1989) using the N-hydroxysuccinimide biotin ester. 
Biotinylation had no significant effect on AChE’s enzyme activity and MAb-AChE 
binding was also unaffected. The binding of biotinylated BSA and non-specific anti-
human IgG served as controls. Biotinylated non-specific anti-human IgG was used as its 
pI (5.4) is very close to that if AChE (pI 5.3) and BSA (pI 4.7) was used as a neutral 
control unlikely to bind. 96-well microtiter plates were pre-coated with 5µg/ml poly-L-
lysine in water (50µl per well) and incubated for 1 h at RT. After incubation, the plates 
were washed twice with 1X PBS and a laminin of 100µg/ml in 1X PBS, were added. The 
plates were covered and left to incubate for 2 h at RT. The remainder of the binding sites 
in the coated wells were then blocked by adding 200µl of 1% BSA/PBS blocking buffer. 
The plates were covered and left to incubate for 2 hours at RT. After blocking, 50µl/well 
of the biotinylated proteins were added at dilutions of 0-35 nM and the plates were 
incubated for 4 h at RT. The amount of biotinylated protein bound was probed with 
streptavidin-peroxidase and H2O2/ABTS, and the absorbance was measured at 405nm. 
Binding data was analysed by nonlinear regression using SigmaPlot™. 
 
Parallel experiments using non-poly-L-lysine coated microtiter plates were run to allow 
for differences in peptide acidity and hydrophobicity. Here the peptides were dissolved in 
50mM NaHCO3 (pH 9.0) and incubated overnight at 4°C before blocking. Non-specific 
binding was determined in the absence of peptide coating, and these values were 
subtracted from readings.  
 
Laminin synthetic peptide: An unbiotinylated version of the laminin peptide, AG-73, 
Arg2719-Lys-Arg-Leu-Gln-Val-Gln-Val-Ser-Ile-Arg-Thr2730 (mouse sequence, Swiss-Prot 
accession number NP_032506), along with a scrambled version, Leu-Gln-Ile-Thr-Arg-
Ser-Arg-Gln-Arg-Val-Lys-Leu, were obtained from PepMetric Technologies 
(Vancouver, British Columbia, Canada). The free N-terminal amines of the peptides 
alone were biotinylated. The peptides underwent HPLC purification to >95% purity and 
lyophilised. The lyophilised peptides were dissolved in double distilled water at a 
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concentration of 2mg/ml and frozen in aliquots. Thawed aliquots were used immediately 
and not refrozen. 
 
Proteins binding to laminin peptides: AChE and BSA were biotinylated as above. 
Recombinant human AChE was used in this assay, instead of the erythrocyte AChE 
species against which the MAbs were raised (no significant differences in reactivity of 
the MAbs towards the two species was observed). Biotinylated non-specific anti-human 
IgG and BSA was used as controls (reasons mentioned above). Proteins and peptides 
were absorbed on high-binding microtiter plates in 50mM NaHCO3 (pH 9.0) overnight at 
4°C. The concentrations used were 10µg/ml for proteins and 20µg/ml for peptides. After 
incubation, the plates were washed with washing buffer (0.2% Tween 20 in 1X PBS) and 
blocked with 1% BSA/PBS blocking buffer for 2 h at RT. Serial dilutions of biotinylated 
proteins or peptides were added (0-20µg/ml) and incubated for 4 h at RT. Bound 
biotinylated proteins was probed with streptavidin-peroxidase and H2O2/ABTS. 
Absorbance was measured at
 
405nm. Non-specific binding was determined in the 
absence of absorbed protein or peptide and the binding data was analysed by nonlinear 
regression by SigmaPlot™. 
 
Whole molecule binding of AChE and laminin: Binding proteins, AChE and BSA, 
were biotinylated as above. Laminin was diluted to 10µg/ml working dilution in 50mM 
NaHCO3 (pH 8.0). The plates were coated with 10µg/ml of laminin. The plates were 
blocked with PBS/BSA and washed as above. Biotinylated AChE was added at serial 
dilutions of 20, 10, 5, 2.5, 1.25, 0.625, 0.312, and 0.156µg/ml. The amount of 
biotinylated protein bound was probed with streptavidin-peroxidase and H2O2/ABTS and 
the absorbance was measured at 405nm. Binding data was analysed by nonlinear 
regression using Prism 5. The controls BSA and anti-human IgG, as well as AChE, were 
added at concentrations of 0.00, 0.625, 1.25, 2.5, 5, and 10µg/ml and binding was 
observed as above. 
 
Competition ELISA: The microtiter plates were coated as above. Biotinylated AChE or 
laminin (20µg/ml) was pre-incubated with various concentrations of either the AG-73 
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peptide or its scrambled version. Incubation proceeded for 1 h at RT before adding the 
protein mixtures to the pre-coated plates. Bound proteins were detected as above. Due to 
similarities in the AChE-laminin binding site and the heparin-laminin binding site, the 
question of whether AChE competes with heparan sulfate in binding to laminin, was put 
under investigation. Microtiter plates were coated with 10µg/ml laminin-111, blocked, 
and washed as above. Serial dilutions of AChE (0-20µg/ml; 0-286nM) were added 
together with 10µg/ml heparan sulfate and binding was determined as above. 
 
Inhibitors: PAS-binding inhibitors, propidium and gallamine, as well as active-site 
binding inhibitor, pyridostigmine, were used at concentrations of 0-500µM. Prior to 
addition to microtiter plates, inhibitors were incubated with 20µg/ml (286nM) 
biotinylated AChE (biotinylation had no significant effect on its reaction with the 
inhibitors) for 1 h at RT. The amount of biotinylated AChE bound was probed and 
measured as above. 
 
Effects of NaCl: The effect of the salt concentration of the buffer on the binding of 
AChE and laminin, as well as on the binding of AChE and AG-73, was investigated. The 
different buffer NaCl concentrations used were: 500nM, 250nM, 125nM and 62.5nM. 
Protein binding was probed and measured as above. 
 
2.2.2 Phage display 
 
Often in molecular biology one requires information on the binding partners of 
molecules. This may be needed, for example, in identifying a ligand for a particular 
receptor or characterising antigen-antibody or enzyme-substrate or enzyme-inhibitor 
interactions. In the earlier days of molecular biology, candidate molecules would have to 
be purified or synthesised, and their binding to the molecule of interest determined and 
analysed. This is a very time-consuming and laborious process.  
 
There are a number of methods that are used to investigate protein-protein interactions. 
The two major approaches are the yeast two-hybrid system and phage display. Mass 
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spectrometry may also be used, but is not common, probably due to availability of the 
equipment that is required. In this thesis, phage display was chosen over yeast two-
hybrid. In yeast two-hybrid, the protein of interest is expressed in yeast cells. A 
mammalian protein must be able to fold correctly and exist in a sTable state inside the 
yeast cell. Furthermore, posttranslational modifications, such as disulfide bonding, 
glycosylation and phosphorylation, may not occur at all, or may occur inappropriately, in 
the yeast (Van Criekinge & Beyaert, 1999). Previous results from the laboratory had 
localised the adhesion-mediating site of AChE to the PAS area. This area is associated 
strongly with the Cys 69-Cys 96 omega loop, and thus dependent on correct disulfide 
bond formation. The PAS as well as AChE’s catalytic activity are very sensitive to 
conformational changes (Shi et al, 2003), and previous results (unpublished) have 
indicated that imperfectly glycosylated AChE has reduced catalytic activity, attributed to 
altered conformation.  
 
Phage display, introduced by Smith (1985), is a way of greatly speeding up the process of 
ligand identification. Genes encoding peptides or proteins can be introduced into the 
genome of filamentous bacteriophage in such a way that the gene product is expressed 
(“displayed”) on the bacteriophage surface as a fusion product of a phage coat protein. 
Phage expressing these peptides or proteins can then be incubated with the receptor 
molecule of interest and their ability to bind determined. The phage binders can be used 
to infect bacterial cells, and thus amplified. Because of the link between phenotype (the 
“displayed” peptide or protein) and genotype, the DNA of the binders can be sequenced 
and the peptide sequence of the peptide or protein determined.  
 
Phage libraries of up to 1010 different sequences can be developed, allowing for rapid 
screening of potential binding partners. The most commonly used phage is filamentous 
phage and phagemid (based on M13, fl or fd). T7 (Houshmand et al, 1999) and lambda 
(Mikawa et al, 1996) phage have also been used. Phage display is a robust method and is 
probably the most commonly used in vitro technique for the selection of peptide and 
protein binders. Initially, it was used for peptides and epitope mapping (e.g. Scott & 
Smith, 1990), and subsequently for antibody identification, hormone affinity optimisation 
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(Lowman & Wells, 1993) and for identifying the binding partners for many proteins (e.g. 
Bradbury & Marks, 2004 for review).  
 
Proteins and Abs: Phage display selection was performed against AChE and the three 
MAbs E8, C2, and 43B4C. 
 
Phage display libraries: Random peptide libraries of filamentous phage in the Type 88 
Vector f88-4 was used (obtained from Professor George Smith of the University of 
Missouri; protocols available at: 
http://www.biosci.missouri.edu/smithgp/PhageDisplayWebsite/PhageDisplayWebsiteInd
ex.html), specifically the f88-4/CysO library. This library contained 5.6 x 108 primary 
clones and has a DNA size of 9267 bases. The concentration of physical particles was 
1.48 x 1014 virions/ml and the approximate infectivity 10.7%. The Cys-linked library was 
used because the peptides displayed on the phage surface are Cys-Cys linked, these were 
more likely to yield information about nonlinear recognition sites. The peptides used 
were thus linear peptides that were cyclized. 
 
Blocking buffer: The buffer contained 0.1M NaHCO3, 5mg/ml dialyzed BSA, 0.1µg/ml 
streptavidin and 0.02% NaN3. 1.26g of NaHCO3, 0.75g of dialyzed BSA, 1µl of a 
5mg/ml streptavidin solution and 0.03g of NaN3 were dissolved in dH2O to give a final 
volume of 150ml. The solution was filter sterilized and stored at 4°C. The buffer was re-
used until it showed evidence of microbial growth or accumulation of insoluble matter. 
 
TTDBA: 0.2g of BSA and 0.2g NaN3 were dissolved in ~200ml TBS/Tween to a final 
concentration of 1mg/ml and 0.02% (m/v), respectively. Solution was stored at RT. 
 
Elution buffer: The buffer contained 0.1N HCl (pH adjusted to 2.2 with glycine) and 
1mg/ml BSA. The glycine.HCl buffer was made and adjusted as a 4X stock, filter 
sterilized, and stored at RT. The glycine.HCl buffer, along with the other components, 
was made up in autoclaved water and was filter sterilized. The solution was stored at 4°C. 
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Bacterial strain: E. coli bacterial strain K91Blukan (obtained from Professor George 
Smith of the University of Missouri). 
 
LB medium (1X): 10g of bacto-tryptone, 5g of NaCl and 5g of yeast extract were added 
to 800ml of dH2O and the pH was adjusted to 7.0 with NaOH after which the volume was 
increased to 1L with additional dH2O. The mixture was autoclaved and stored at RT. 
 
LB agar plates: Bacto agar was added as 15g/L to the 1X LB medium described above 
and autoclaved. Once mixture had cooled to about 50°C, the antibiotics (tetracycline 
and/or kanamycin) were added for antibiotic-resistance selection. The solution was 
poured onto petri-dishes (85mm) and left at RT to allow agar to solidify. The solid plates 
were sealed and stored at 4°C. 
 
NZY medium (1X): 10g of NZ amine A, 5g of yeast extract and 5g of NaCl was 
dissolved in 1L of dH2O and the pH was adjusted to 7.5 with NaOH. The solution was 
autoclaved and stored at RT. 
 
NZY agar plates: 15g of bacto-agar was added to the NZY medium and the solution was 
autoclaved. Once solution had cooled down to about 50°C, tetracycline and kanamycin 
was added at concentrations of 40µg/ml and 100µg/ml respectively. The solution was 
poured onto petri-dishes and left at RT to solidify after which the plates were sealed and 
stored at 4°C. 
 
Terrific broth: 12g of bacto-tryptone, 24g of yeast extract and 4ml of glycerol were 
dissolved in 900ml of dH2O. 90-ml portions in 125-ml polypropylene bottles were 
autoclaved. When cooled, 10ml of separately autoclaved potassium phosphate buffer 
(containing 0.17M KH2PO4 and 0.72M K2HPO4: 2.31g of KH2PO4 (anhydrous) and 
12.54g of K2HPO4 (anhydrous) were dissolved in 90ml of dH2O, volume was adjusted to 
100ml and buffer was autoclaved) was added to each bottle. 
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Tetracycline stock solution, 20mg/ml: 40ml glycerol was autoclaved in a 100ml bottle. 
After the glycerol cooled down, 40ml of a 40mg/ml tetracycline solution filter sterilised 
in water, was added to it. The solution was mixed thoroughly and stored at -20°C, away 
from light 
 
Kanamycin stock solution, 100mg/ml: Kanamycin sulphate was dissolved in dH2O to a 
final concentration of 80mg/ml. The pH was adjusted to 6-8 with NaOH or HCl where 
necessary. The solution was autoclaved, filter sterilized using a syringe and disposable 
filters, and stored at 4°C. 
 
Preparation of starved cells: K91BluKan cells were grown by shaking at 37oC in 20ml 
NZY medium to log phase (OD600 ~0.45). The cells were then incubated with gentle 
shaking for an additional 5min, to allow any sheared F pili to regenerate. Cells were 
centrifuged in a 50ml tube at 2.5 Krpm for 10 min at 4oC. Cells were then gently 
resuspended in 20ml 80mM NaCl. Resuspended cells were then poured into a sterile 
125ml flask and shook gently at 37oC for 45 min. The centrifuging step was repeated 
after which the cells were resuspended gently in 1ml cold NAP buffer (80mM NaCl, 
50mM NH4H2PO4 pH 7 with NH4OH). The concentration of viable cells was ~5 x 109ml 
and cells remained infectible for 3-5 days. 
 
Preparation of terrific broth cultures: A few ml of NZY medium was inoculated with 
K91Blukan cells and left to shake overnight at 37°C. 100µl of this overnight culture was 
used to inoculate 10ml of terrific broth in a 125-ml flask and allowed to shake vigorously 
at 37°C. Once culture became turbid, OD600 of 1/10 dilutions were read until 1/10 
dilution reached 0.1-0.2 on the spectrophotometer after which the shaking was slowed 
down to allow sheared F-pili to regenerate. Cells were used within 1 h and the 
concentration of viable cells was ~5 x 109ml. 
 
Protein biotinylation: (see section 2.1.9) AChE and the mAbs were biotinylated to 
enable biotin/avidin-detection. Biotin (long-arm) N Hydroxysuccinimide ester (BNHS) 
reacts with amino groups in proteins. Biotin was dissolved in DMF at a final 
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concentration of 25mg/ml and was prepared prior to use. AChE was dissolved in sodium 
bicarbonate at a concentration of 2mg/ml. AChE was biotinylated by adding 1/10th of the 
protein weight biotin and incubating at room temperature for 2 h, stirring occasionally. 
The biotinylated protein was then dialyzed against three changes of 2L of 1X TBS buffer 
 
2.2.2.1 Affinity selection 
 
One-Step selection: In one-step selection phage, contained in the library, are captured by 
a biotinylated selector (AChE, MAbs) that has been pre-immobilized on the surface of a 
streptavidin-coated petri dish. 35mm petri dishes were coated with 400µl 10µg/ml 
streptavidin in 0.1M NaHCO3 for at least 1 h at RT. The solution was aspirated out and 
dishes were filled to the brim with blocking buffer and allowed to sit with the lid off for 2 
h at RT. The blocking solution was poured off and the dishes were washed five times 
with TBS/Tween. 10µg of the biotynilated receptor (bAChE), diluted in 400µl TTDBA 
buffer, was added and the petri dishes were allowed to react for 2 h at 4oC. This was 
followed by another wash step, five times with TBS/Tween, in order to remove unbound 
selector. The dishes were filled to the brim with TTDBA and 4ul 10mM biotin was added 
to block unoccupied biotin-binding sites on the immobilized streptavidin. The dishes 
were rocked for 10 min at RT. The input phage (f88/4-CysO library for 1st round 
selection, and 1st and 2nd round eluates for 2nd and 3rd round selection, respectively) was 
then added and the dishes were rocked at 4oC for 4 h (removal of excess biotin was 
unnecessary as it won’t displace the bound biotinylated selector). After 4 hours, the 
bound phage was eluted from the dish by adding 400ul elution buffer and rocking it for 
10 min. The eluate was then transferred to a microtube and neutrilized by mixing it with 
50µl 1M Tris-HCL (pH 9.1).  
 
Two-step selection: In two-step selection phage are reacted with biotinylated selector in 
solution prior to addition to strepavidin-coated plates. Such selectors can serve as an 
internal indicator of non-specific backround yield during affinity selection.  
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Quantifying yield and amplifying eluates: The entire first round eluate was 
concentrated and washed once with TBS on a Centricon 30kDa ultrafilter by centrifuging 
at 5 Krpm in a Sorvall SS34 rotor to give a final volume of ~ 100µl (this step is only 
applicable in 1st round eluates as eluates from subsequent rounds, in which every clone is 
represented by many thousands or millions of phage particles, are used without 
concentrating). 100µl of the eluate (1st and 2nd round) was mixed with 100µl starved 
K91BluKan cells and incubated for 10-30min at RT. The infected cells were pipetted into 
a 150ml culture flask containing 40ml NZY medium with 0.2µg/ml tetracycline and left 
to shake for 30-60 min at 37oC. 200ul portions of appropriate serial dilutions of the 
culture (10-1 - 10-4, diluent = NZY) was spread on NZY plates containing 40µg/ml 
tetracycline and 100µg/ml kanamycin to enable quantification of the output of affinity 
selection (a high phage yield is very important in 1st round eluates as the input phage is 
the whole library and it is thus necessary that each specific phage be represented a few 
times). 20mg/ml tetracycline was added to the 40ml culture to bring the antibiotic 
concentration up to 20µg/ml after which the solution was left to shake further overnight 
at 37oC. The next day the culture was poured into a 50ml tube and cleared of cells by two 
rounds of centrifugations at 5 and 8 Krpm at 4oC. The doubly-cleared supernatant, at a 
final volume of ~35ml, was poured into a fresh tube. 5.25ml PEG/NaCl precipitation 
buffer was added to the cleared culture and mixed by many inversions, allowing the 
phage to precipitate overnight at 4oC. The precipitated phage was collected the next 
morning by centrifuging at 12Krpm for 15 min at 4oC. The pellet was dissolved in 1ml 
TBS and the solution was transferred to a 1.5ml Ep tube. The solution was then 
centrifuged at 15K rpm to clear insoluble material and the supernatant was transferred to 
a second 1.5ml Ep tube. 150ml PEG/NaCl was then added and vortexed, and the mixture 
was left for at least 1 h at 4oC after which it was microfuged for 5 min at 15K rpm . The 
pellet was once again dissolved in 400µl TBS. This was followed by another microfuge 
step for 1 min at 15K rpm to clear undissolved material. The supernatant was then 
transferred to a 500µl Ep tube and stored in the refrigerator. This supernatant is the 
amplified eluate and the physical partical concentration at this point should be ~5 x 1013 
virions/ml3. Selection proceeded for 3 rounds after which the 100µl of 1st round eluates 
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was used as 2nd round “input phage”, and 100µl of 2nd round eluates were used as 3rd 
round “input phage”. 3rd round eluate (last round) = final eluate. 
 
Propagating clones from final round eluate: Using TBS/gelatin (0.1g of gelatine was 
autoclaved in 100ml 1X TBS) as diluent, serial dilutions was made of the final eluate 
(dilutions ranged from 10-1 to 10-5) in 15-ml disposable tubes (tubes were held at an angle 
and a 10µl droplet of each dilution was deposited on the inner wall of the tube). 10µl 
starved cells were added to each sample and the mixtures were incubated for 10 min at 
RT to allow for infection. 1ml of NZY containing 02ug/ml tetracycline was added and 
each mixture was left to incubate while shaking for 40 min at 37°C. The infected cells 
were spread (200ul/plate) on NZY plates containing 40µg/ml tetracycline and 100µg/ml 
kanamycine. Plates were incubated for ~24 h at 37°C. The yield was monitored.  
 
Phage purification: The Wizard® genomic DNA Purification System kit and protocol 
(Promega) was used. A single, well isolated, phage plaque was picked from the agar plate 
using a sterile toothpick. The plaque was expelled into a 1.5-ml microcentrifuge tube 
containing 100µl phage buffer (containing 150mM NaCl, 40mM Tris-HCl (pH 7.4) and 
10mM MgSO4) and left overnight at 4°C. In the meantime a fresh culture was started by 
inoculating a single colony into 5ml of LB medium containing 50µl 20% maltose and 
50µl 1M MgSO4 and leaving it to shake overnight at 37°C. The next day, 500µl of the 
overnight culture was added to the tube containing the plaque/phage buffer mixture from 
the first step and the solution was left to incubate for 20 min at 37°C. 500ul of the 
infected culture was transferred to a 250-ml Erlenmeyer flask containing 100ml pre-
warmed (37°C) LB with 1ml 1M MgSO4. The solution was left to shake until lysis 
occurred (for about 5 h). The medium should appear turbid at first, but then clear upon 
lysis. After cell lysis, 500µl chloroform was added and the mixture was left to shake for a 
further 15 min. The lysate was centrifuged at 8 000 x g for 10 min to remove cellular 
debris after which the supernatant was transferred to a sterile tube. 10ml of this lysate 
was transferred to an appropriate centrifuge tube. The Nuclease Resuspension Solution 
was added to the lyophilized Nuclease Mixture (both provided by kit), and the solution 
was resuspended very gently. 40ml of this resuspended Nuclease Mixture was added to 
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the 10ml of lysate and left to incubate for 15 min at 37°C. 4ml of the provided Phage 
Precipitant was added, the solution mixed gently, and placed on ice for 30 min. After 30 
min the mixture was centrifuged at 10 000 x g for 10 min. The pellet was resuspended in 
500µl of phage buffer and transferred to a 1.5-ml microcentrifuge tube. Centrifugation 
proceeded at 10 000 x g for 10 seconds to remove insoluble particles. The supernatant 
was transferred to a new tube and 1ml of thoroughly mixed Purification Resin (provided 
by kit) was added to it and the solution was mixed by inverting the tube. A Wizard® 
Minicolumn was prepared by attaching the syringe barrel to the Luer-Lok® extension of 
each minicolumn and inserting the tip of the minicolumn/syringe barrel assembly into 
each vacuum manifold. The resin/lysate was pipetted into the syringe barrel and a 
vacuum was applied to draw the mix into the minicolumn. 2ml of 80% isopropanol was 
added to the syringe barrel to wash the column after which the vacuum was re-applied to 
draw the solution through the minicolumn. The vacuum was continued for 30 sec to dry 
the resin after the solution was pulled through. The syringe barrel was removed and the 
minicolumn was transferred to a 1.5-ml microcentrifuge tube and centrifuged at 10 000 x 
g for 2 min to remove any residual isopropanol. The minicolumn was transferred to a 
fresh tube and 100ul pre-warmed (80°C) water was added and the minicolumn was 
immediately centrifuged at 10 000 x g for 20 sec to elute DNA. The minicolumn was 
removed and discarded leaving behind the purified DNA.  
 
Alternative phage purification protocol: This protocol was adapted from Wickner et al. 
(1975). A well separated colony from the overnight plates was used to innoculate 1L of 
NZY containing 20µg/ml tetracycline and 1mM IPTG in a Fernbach flask and the 
solution was left to shake overnight at 37°C. The next day the mixture was cleared by 
two centrifugations in three 500-ml centrifuge bottles at 5 and 8K rpm for 10 min. The 
final supernatants were poured into tared 500-ml bottles (volume of each was ~300ml). 
0.15 volume PEG/NaCl was added to each and mixed thoroughly by ~100 inversions. 
The mixture was allowed to precipitate overnight at 4°C. The bottles were centrifuged at 
8K rpm for 20 min after which 10ml of 1X TBS was added to each. The bottles were left 
to shake at RT to resuspend phage. The phage was pooled (30ml altogether) in an Oak 
Ridge tube and centrifuged at 10K rpm for 15 min to pellet insoluble matter. The 
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supernatant was poured and pipetted into a fresh Oak Ridge tube. 3.3ml of a 1:9 v/v 
mixture of triton-X100:water was added and the tube was rocked on its side for 1 h at RT. 
5ml PEG/NaCl was added and the solution was mixed by many inversions after which it 
was immediately centrifuged at 10K rpm for 15 min. The phage pellet was dissolved in 
15ml 1X TBS and the centrifuged at 10K rpm for 10 min. The supernatant was poured 
into a fresh Oak Ridge tube. 15ml 1X TBS containing 2% sarkosyl was added and the 
solution was mixed gently by inversion. The tube was then rocked on its side for 1 hr at 
RT. 4.5ml PEG/NaCl was added and the solution was mixed by many inversions. 
Immediate centrifugation proceeded at 10K rpm for 10 min. The pellet was dissolved in 
10ml 1X TBS by pumping and scraping with a 5-ml pipette tip. The mixture was left to 
shake for 1 h at RT. Centrifugation proceeded at 10 Krpm for 10 min to clear insoluble 
matter. The supernatant was poured into a 15-ml centrifuge tube (phage was stored at 4°C 
at this point). 4.83g of CsCl was put into a tared beaker after which the beaker was tared 
again. The cleared supernatant was added to bring the net weight of aqueous phage to 
10.75g. The mixture was stirred gently to dissolve the salt. The final solution was 12ml of 
a 31% w/w (1.30g/ml) with a density of 1.29-1.31 g/ml. The phage suspension was 
loaded into a polyallomer SW41 tube and centrifuged for 36-48 h at 37 000 rpm. Using a 
sterile transfer pipette, the solution above the phage band (a very light, clean, translucent 
band should be visible towards the middle of the tube) was removed, trying as much as 
possible to keep the tip at the meniscus. A fresh transfer pipette was the used to remove 
the phage band into a clean 60Ti bottle. The bottle was filled to shoulder with 1X TBS 
and centrifuged at 50 Krpm for 4 hours in a 60Ti rotor. RRR. 3ml of 1X TBS was added 
to the bottle. The top of the bottle was wrapped in parafilm and left to rotate overnight at 
4°C to dissolve phage. The next day the solution was re-vortexed and centrifuged briefly 
to drive solution to the bottom. The dissolved phage was transferred to a 4-ml tube. The 
mixture was dialyzed in a 3-ml Pierce Slide-A-Lyzer against three changes of ~1L cold 
1X TBS. the dialyzed phage was transferred into a clean polyallomer 10-ml Oak Ridge 
tube and centrifuged at 10 Krpm for 5 min. The supernatant was removed to a clean 4-ml 
vial. The undiluted physical particle concentration was calculated by making 300µl of a 
1/50 dilution and scanning the absorption from 240-320nm. 
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Sequencing phage: Oligonucleotide primers specific for the phage DNA sequence were 
purchased (Whitehead Scientific, Cape Town, SA). The primers were specific for the 
f88-4 vector clones (5’ –AGTAGCAGAAGCCTGAAGA-3’). Sequencing was 
performed by the sequencing facility of the Division of Molecular Biology and Human 
Genetics, University of Stellenbosch Faculty of Health Sciences. 10µl of f88-4 primer 
was needed for each sample and the final primer concentration was 1.1pmol. The sample 
concentration for sequencing had to be 100ng/µl.  
 
2.2.2.2 Micropanning 
 
In order to confirm binding, micropanning was applied. 40µl 10µg/ml streptavidin in 
0.1M NaHCO3 was pipetted into each well of a 96 well polystyrene ELISA dish. The 
protein was left to absorb to the plastic for at least 1 h at room temperature. The 
strepavidin solution was aspirated out and the wells were filled to the brim with blocking 
buffer (~400µl/well). The dish was allowed to sit with the lid off for 2 h at RT. The dish 
was then washed 5X with TBS/Tween. The desired amount of biotinylated receptor 
(bAChE, bE8, bC2, b43B4C) was added at about 500ng in 200µl TTDBA and allowed to 
react for at least 2 h at 4oC in a humidified box. This was followed by another wash step, 
5X with TBS/Tween. The wells were filled with 100µl TTDBA. 30µl of the input phage 
(f88-4/CysO, at a physical particle concentration of up to ~107 virions/ml for qualitative 
binding conformation) was added and the dish was rocked for 2 h at RT in a humidified 
box. The wells were washed 10X with TBS/Tween. 20µl elution buffer was pipetted into 
each well and allowed to sit for ~10 min at room temperature. The eluate in each well 
was pipetted into the corresponding well of a second microtiter dish already containing 
3.75µl 1M Tris.HCL (pH9.1). Into each well starved K91BluKan cells were pipetted and 
transfection proceeded at RT for 10 min. 200µl NZY medium, containing 0.2µg/ml 
tetracycline, was then pipetted into each well and dishes were put in the 37oC incubator 
for 30 min. This was the gene expression period, during which the tetracycline resistance 
gene on the incoming phage has a chance to be expressed before the infected cells are 
challenged with a high concentration of the antibiotic. 20µl portions from each well was 
spotted onto a NZY plate containing 40µg/ml tetracycline and 100µg/ml kanamycin. 
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Single standard 100mm petri dishes were able to accommodate 19 spots in a hexagonal 
array. The colonies were counted after ~12 h at 37oC. Excellent binding (10% yield) 
corresponds to ~100 colonies/spot. Good binding (~1% yield) correspond to ~10 
colonies/spot. Background should be 0. 
 
2.2.2.3 Antibody phage display   
 
 
In this thesis, two different types of phage libraries were used: peptide and antibody 
libraries. The principle behind them and the methods of selection, amplification and 
sequencing are the same. 
 
Antibody phage display has been described by Bradbury and Marks (2004) as “arguably 
the most successful use of phage display”. The technique involves the use of single-chain 
Fv (scFv) immunoglobulin fragments rather than the short linear peptides used. ScFvs are 
approximately 225 residues long and are made up of the single chain variable region of 
the immunoglobulin molecule. The variable region contains the 6 hypervariable 
complimentarity-determining regions (CDRs), which are primarily responsible for 
antigen recognition, and therefore vary dramatically in sequence, and the framework 
regions that occur in between the CDRs. The framework regions are largely a beta-sheet 
structure that supports the CDRs, and they are far more conserved. 
 
Two kinds of Ab library can be used: naïve or immune. Naïve libraries are derived from 
natural unimmunised human rearranged V genes (Marks et al., 1991; Vaughan et al., 
1996; Sheets et al., 1998; de Haard et al., 1999; Sblattero and Bradbury, 2000), synthetic 
human genes (Griffiths et al., 1994; Nissim et al., 1994; de Kruif et al., 1995; Knappik et 
al., 2000) or shuffled V genes (Soderlind et al., 2000). Immune libraries are developed 
from the V genes of humans (Barbas et al., 1991; Zebedee et al., 1992; Williamson et al., 
1993; Amersdorfer and Marks, 2000; Amersdorfer et al., 2002) or mice (Orum et al., 
1993; Ames et al., 1994, 1995), and thus are biased towards antibodies of a particular 
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specificity (Bradbury & Marks, 2004), although their use in selecting antibodies against 
antigens not used for immunisation has been reported (Williamson et al., 1993).  
 
The Ab phage display was contracted out (Creative Biolabs Inc., NY, USA) for the 
catalytic MAbs (not for AChE). A naïve human scFv library was used. This approach 
gives a 3D structure made up of CDRs of the Ab rather than the linear peptide sequences 
obtained from ordinary phage display. From the sequences obtained from the scFv, 
homology modelling and docking can be done with AChE in order to identify specific 
sequences that bind to the PAS and its motifs. The first part of the Ab phage display 
focused on selecting human scFv binders against rHuAChE (recombinant human AChE) 
from the HuNSL® naïve ScFv phage display library. Six rounds of selection proceeded. 
During the first three rounds, the original library as well as the derived sub-libraries was 
pre-absorbed with pre-blocked panning tube to remove non-specific binders. In the 
following three rounds, the biotinylated peptide 18 was used as the target. Capturing 
proceeded using streptavidin conjugated magnetic beads to remove non-specific binders. 
In order to increase the screening stringency, the subtracted phages from the 1st and 2nd 
round of screening were incubated with decreased concentrations of rHuAChE protein. 
At the same time, specifically-bound phages from the first three rounds were eluted using 
0.25% Trypsine, while in the last three rounds of screening, specific binders were eluted 
with high concentrations of the non-biotinylated peptide competitively. Final round 
clones were amplified and assayed by phage ELISA, among which 23 positive clones 
were subjected to DNA sequencing.  
 
The top two positive binders obtained from the Ab phage display were subjected to three 
dimensional modelling using Swiss-Model and RASMOL. The models produced were 
used to dock with mouse AChE (see 2.2.4.1). The scFv sequences produced were also 
BLASTed in order to identify additional molecules with which AChE could be 
redundant. 
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2.2.3 Peptide array/microarray 
 
Peptide array or microarray is the rapid and quantitative cyclization of multiple peptide 
loops onto synthetic scaffolds for the structural mimicry of protein surfaces. Structure-
based design of synthetic peptides mimicking the functional site of natural proteins, serve 
as important tools for discovering biochemical interactions, profiling cellular activities, 
and discovery of novel drugs (Timmerman et al., 2005). Even though a wide variety of 
structural mimics exist, including mimics for α-helices (Venkatraman et al., 2001; Karl, 
1999), β-turns (Venkatraman et al., 2001; Cochran et al., 2001; Burgess, 2001) and β-
sheets (Venkatraman et al., 2001; Nowick, 1999), often more complex topologies like 
four-helix bundles (Hill et al., 2000; Floegel & Mutter, 1992) are needed to adequately 
mimic protein function (Reineke et al., 1999). The principle involves the immobilization 
of peptides, previously designed by chemical or by recombinant methods, to a solid 
surface such as glass chip, paper or monolayers, followed by assaying the bound peptide 
through protein binding, enzyme activity or cell adhesion. Specific binding can be 
detected using fluorescence, radioactivity, surface Plasmon resonance or mass 
spectrometry.  
 
Previous work suggest that the AChE site is clearly conformational (e.g. Johnson & 
Moore, 2004), involving residues from different loops drawn together by folding as well 
as the formation of a salt bridge. A precise and detailed mapping of conformational 
structures is necessary for rational design as well as to compliment results obtained from 
the phage display which would yield linear as well as conformational binders. A 
microarray of 500 overlapping peptides of varying length (9-25 amino acids) and residue 
combinations for the AChE sequence 30-110 was designed in such a way as to represent 
conformational structure as present in the native protein. Synthesized and execution of 
the array was done by PepScan Systems (Lelystad, The Netherlands). Using CLiPS™ 
technology, the microarray was constructed with each peptide containing two cysteine 
residues. Variation in the position of these residues allows different degrees of constraint 
and enables reconstruction of conformational epitopes. The immobilization of peptide 
loops onto a synthetic scaffold is an extremely fast and clean reaction running very well 
with linear peptides that are 2-30 amino acids long. The reaction is compatible with all 
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possible side-chain functionalities except for free cysteine. PepScan’s CLiPS™ epitope 
mapping (http://www.pepscan.com.) used high-throughput synthesis of overlapping 
peptides on microarrays that completely covered the sequence and structure of the 
protein. The peptides representing the protein interaction site of interest was identified 
through antibody binding studies using fully automated ELISA-type read-out. The 
protein-protein interaction sites were defined at the level of individual amino-acids. For 
more information on the technique see Timmerman (2007). 
 
2.2.4 Bioinformatics 
2.2.4.1 Homology modelling 
 
The three-dimensional structure of a protein is necessary for the understanding and 
prediction of many of its functions, including ligand interactions. Crystallisation and X-
ray diffraction is the gold standard, but is a difficult and time-consuming process. An 
alternative is nuclear magnetic resonance (NMR), but this is limited to relatively small 
proteins. Homology modelling is a method that allows the rapid determination of a three-
dimensional structure from sequence data, provided a suiTable template is available. This 
technique is sometimes referred to as “comparative modelling” or “knowledge-based 
modelling”, terms that may be more accurate as “homology” implies a common 
evolutionary origin of the modelled structure and the template, which may not always be 
the case. 
 
The first step in the modelling of a protein sequence is the identification of a suiTable 
template. This is done by identifying similar or homologous sequences, and whether they 
have structures available, on the Basic Local Alignment Search Tool for proteins 
(BLAST-P; Altschul et al., 1997), National Centre for Biotechnology Information 
(NCBI), followed by alignment of the sequence to be modelled with that of the proposed 
template. Following this, the steps in model construction are the identification of 
structurally conserved and structurally variable regions, the generation of coordinates for 
the structurally conserved residues of the unknown structure using the coordinates of the 
known structure, the generation of the conformations of the structurally variable regions 
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in the unknown structure, building the side-chain conformations, and, finally, the 
refinement and evaluation of the unknown structure.  
 
In this thesis, modelling was done by the automated web server, Swiss-Model at the 
Swiss Institute of Bioinformatics (http://swissmodel.expasy.org; Arnold et al., 2006) and 
RASMOL. 
 
2.2.4.2 Protein-protein docking 
 
The goal of protein-protein docking is the prediction of how two individual protein 
structures may bind and form a complex. There are two different approaches to 
automated protein-protein docking: rigid-body docking and flexible docking.  
 
In rigid-body docking, both proteins are considered to be completely rigid. This type of 
docking thus does not consider either conformational changes or interfacial solvation that 
occur on binding. This reduces the docking problem considerably. Docking is geared 
towards optimising the geometric and chemical fit of the two surfaces. Flexible docking, 
on the other hand, takes both conformational changes and solvation into account. This 
type of docking is therefore much more complex, and tends to be demanding of both time 
and computing hardware. As a result, it is less frequently used than its rigid-body 
counterpart. 
 
Docking algorithms use a range of search and scoring methods, including fast Fourier 
transform correlations, geometric hashing, and Monte Carlo techniques. There are two 
parts to the docking problem: firstly, developing a scoring/energy function that is able to 
discriminate between correctly docked orientations and incorrectly docked orientations, 
and, secondly, developing a method of searching that can pick out a correctly or nearly 
correctly docked orientation with reasonable accuracy (Ritchie, 2008). The simplest 
scoring function is shape complementarity, which requires a description of the surface of 
the protein. Thermodynamic considerations, particularly the free energy change, also 
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need to be taken into account. Interactions such as electrostatic, Van der Waals and 
water-mediated interactions are also considered (Richie, 2008). 
 
Docking was carried out by using the programs Hex 4.5 (D. Ritchie, University of 
Aberdeen, Aberdeen, Scotland,U.K) as well as GRAMM-X (Tovchigrechko et al., 2006). 
This kind of docking gives both a visualization of the receptor-ligand interaction, as well 
as a detailed analysis of the fit and types of bonding (e.g. hydrogen bonds, Van der Waals 
interactions, etc.). Hex 4.5 uses rigid-body docking and is distinguished from other 
docking software by its use of spherical polar Fourier correlations to accelerate docking. 
Hex also, uniquely, uses an expansion of the molecular surface and electric field in 
spherical harmonics, which improves the efficiency of docking (Ritchie & Kemp, 2000). 
It performs a six-dimensional search over the full ranges of both receptor and ligand. The 
specific parameters used were full rotation plus electrostatics where the contribution of 
electrostatics to the interaction is calculated during the final search phase. The structures 
used were: mouse laminin α1 G4-5 domains (PDB code 2JD4); mouse AChE, apo form, 
chains A and B (PDB code 1J06); mouse AChE dimer-propidium complex (PDB code 
1N5R); mouse AChE dimer-gallamine complex (PDB code 1N5M); mouse AChE 
dimmer-fasciculin-2 complex (PDB code 1KU6); Torpedo AChE (PDB code 2ACE); 
human BChE (PDB code 1P0I); and the laminin α2 G4-5 domain pair (PDB code 
1DYK). The Torpedo AChE (PDB code 2ACE) and human BChE (PDB code 1P0I) are 
monomers. Analysis of structures, in particular, measurement of distances between 
residues, was done with DeepView/Swiss PDB Viewer (Guex & Peitsch, 1997). RasMol 
was used for visualizing structures and for graphics used in illustrations (Sayle & Milner-
White, 1995). 
 
2.2.4.3 Identification of Motifs 
 
As mentioned, results from previous studies indicated that laminin-111 binds to AChE 
through an interaction with the PAS region involving electrostatic mechanisms (Johnson 
& Moore, 2003). Seeing as the PAS region is anionic, a complementary site would very 
possibly be cationic. In order to identify such a cationic site, the sequence of the mouse 
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laminin α1-chain (Swiss-Prot accession number NP_032506), as well as the β1 
(accession number P02469) and γ1 (accession number P02468) chains were put under 
investigation. Potential cationic sites were defined as clusters of three or more basic (Arg, 
Lys, His) residues. A number of sites promoting cell attachment and spreading on 
laminin-111 have previously been identified (Nomizu et al., 1995).This information was 
taken into account when identifying potential interaction sites. In addition, docking of 
AChE with the LG4-5 domain pair of laminin α2 (which has 63% identity to laminin α1) 
was investigated. This was the only laminin structure available at the time.  
 
For motif searches, both BLAST-P and Prosite were used. Prosite is a protein database 
curated by the Swiss Institute of Bioinformatics (http://expasy.org/prosite/). It contains 
entries describing protein families, domains and functional sites, as well as information 
on motifs and signatures. Short amino acid sequences or novel motifs can be scanned 
against the Swiss-Prot database 
 
2.2.4.4 Other Bioinformatics Methods 
 
Through the use of bioinformatics and in silico docking, the possibility of functional 
redundancy was investigated. The premise behind this analysis was that the MAbs appear 
to define a site that is critical for neural development, as treatment of developing neural 
cells with these Abs, blocked cell adhesion and induced apoptosis in neuroblastoma cells 
in vitro (Johnson & Moore, 2000). As the MAbs were raised against AChE, this would 
suggest that AChE is essential for neural development. However, the AChE knockout 
mouse does not show the degree of abnormality that the MAbs results would indicate 
(Xie et al., 2000). The postulation of functional redundancy is a way of reconciling these 
observations: that the site recognized by the MAbs is present, not only on AChE, but on 
another molecule or molecules and that these Abs may be cross-reacting. Defining the 
MAbs epitope and using bioinformatic methods to investigate the presence of a similar 
epitope in other molecules, could indicate which molecule or molecules might be 
functionally redundant with AChE.  
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The analysis was done in two contexts: firstly, the migration and differentiation stages of 
neural crest cells, outside the CNS, and, secondly, in the CNS and especially in the 
context of neurodegeneration. The AChE-laminin interaction was used as a template for 
defining the search. This was done as AChE and laminin were onserved to interact in 
vitro, and the MAbs, furthermore, interfere with this interaction (Johnson & Moore, 
2003).  
 
2.2.5 Coimmunoprecipitation 
 
Immunoprecipitation is one of the most widely used methods for Ag detection and 
purification. The process involves allowing an Ab (monoclonal or polyclonal) against a 
specific target Ag (AChE or laminin in this study) to form an immune complex with that 
target in sample such as a cell lysate. This is followed by the capturing of this complex on 
a solid support to which either Protein A or Protein G has been immobilized. Protein A or 
Protein G is able to bind the Ab which is in turn bound to the Ag, thus extracting or 
precipitating the complex from the solution. Coimmunoprecipitation (Co-IP) is conducted 
in the same way; however, the target Ag precipitated by the Ab “co-precipitates” a 
binding partner/protein complex from a lysate. The components of the bound immune 
complex can then be analyzed through sodium dodecyl sulphate (SDS) gel 
electrophoreses, separating the different components according to size/weight. SDS gel 
electrophoreses is followed by western blot detection, using a secondary Ab, in order to 
verify the identity of the Ag. 
 
For this study, anti-AChE and anti-laminin Abs were used to extract AChE and laminin, 
respectively, from cell lysates obtained from neuroblastoma cells. AChE is expressed in 
primitive neural cells from quite an early stage. In the embryo, the cells are formed in the 
neural crest where they stay during the early stages of development. At some point these 
cells start migrating and AChE expression is initiated, limited largely to soluble isoforms. 
When the cells reach their destinations, after adhering to the ECM, they start to 
differentiate. It is at this point that expression is very high and the expression form 
changes to membrane-associated forms. Neuroblastoma cells are, effectively, primitive 
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neural cells at the proliferation stage. Neuroblastoma is a cancer that shows up in very 
young children and the general cause seems to be something that goes wrong during the 
transition from proliferation to differentiation in the embryo. Shifting these cells from 
proliferation to differentiation can make them benign. There is also the possibility that 
AChE in undifferentiated cells and AChE in differentiated cells react with different 
ligands. Therefore both situations of using undifferentiated/proliferating vs. differentiated 
cells should be taken into account.  
 
Co-IP enabled the investigation of molecules identified by preliminary experiments as 
possible AChE and laminin ligands (which “co-precipitates” with AChE and laminin), 
such as heparin sulphate proteoglycans (Battaglia et al., 1992), agrin (Denzer et al., 
1997), beta-neurexin (Sugita et al., 2001), etc., as well as enabling the confirmation of the 
AChE-laminin interaction (Johnson & Moore, 2003; Paraoanu & Layer, 2004).  
 
 
2.2.5.1 Cell culturing 
 
Versene (EDTA in buffered saline): 650mg of Na2EDTA, 500mg of KCL, 20g of NaCl, 
2.85g of Na2HPO4 and 500mg of KH2PO4 was dissolved in 400ml of dH2O. The pH was 
adjusted to 7.2-7.4 after which the volume was increased to 500ml with dH2O. The 
solution was autoclaved and stored at 4°C. 
 
Cell line and culture conditions: Neuro-2α cells (N2α, neuroblastoma cells) were 
obtained from the ATCC (The global bioresource center™, Manassas, Virginia, USA). 
The cells were stored in a liquid nitrogen freezer. The growth medium contained 10% v/v 
FCS, 1% Penicillen/Streptomycin and 89% v/v Eagle’s Minimum Essential Medium 
(EMEM) containing L-glutamine. Cells cultured directly from frozen were first grown in 
a medium containing 20% FCS for two nights after which the media was replaced with 
the 10% FCS medium. The cell culture media was stored at 4°C. The freezing media 
contained 8% DMSO in 20% FCS medium. It was important to maintain adequate frozen 
stocks of cell lines throughout the project.  
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Subculturing: The culture media was removed and discarded. The cell layer was briefly 
rinsed with 3ml of Trypsine/versene solution to remove all traces of serum that contains 
trypsine inhibitor. 5ml of Trypsine/versene solution was added to each flask and the flask 
was left (occasionally swirling slightly) until the cell layer was dispersed (usually within 
5-15 min). The cells/trypsine mixture was pipetted into a 15-ml tube and lightly 
centrifuged for a few minutes after which the Trypsine/versene solution (supernatant) 
was removed and discarded. Fresh culture medium was added to new, sterile, culture 
flasks. 2ml of fresh culture media was added to the cells (pellet) and pipetted up and 
down to mix the cells into the media. 1ml of each cell solution was added to each new 
culture flask. The cells were left to grow in the CO2 incubator until 100% confluency was 
reached. 
 
Determining the amount of AChE and laminin per cell: Microtitre plates were coated 
overnight with 1/2000 anti-laminin Ab (L9393) and blocked. Laminin (L2020) was added 
at various dilutions ranging from 0-50ng. This was followed by secondary Ab-biotin 
binding. The amount of biotinylated protein bound was probed with streptavidin-
peroxidase and H2O2/ABTS, and the absorbance was measured at 405nm. The data was 
used to produce a standard curve with which the cell lysate assay can be compared. For 
the cell lysate assay, the microtitre plates were coated as above, but instead of using pure 
laminin, the cell lysate was added in various dilutions (1/10, 1/50, 1/100). The resulting 
A405 readings, taking the dilution factor into account, were then converted to laminin 
concentration using the standard curve.  
 
2.2.5.2 Coimmunoprecipitation 
 
Cell lysis buffer: The buffer contained 20mM Tris-HCl (pH 8), 100mM NaCl, 0.5% NP-
40, 0.5mM EDTA, 0.5mM PMSF (proteolytic inhibitor) and 0.5% protease inhibitor 
cocktail. 1ml of a 1M Tris-HCl solution (60.57g Tris dissolved in 500ml dH2O, pH 
adjusted to 8 with HCl), 0.29g NaCl, 0.25ml NP-40, 0.007g of EDTA, 0.025ml of a 0.1M 
PMSF stock solution (1.74g PMSF dissolved in 100ml DMSO) and 0.25ml of protease 
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inhibitor cocktail was dissolved in dH2O to give a final volume of 50ml. The buffer was 
then divided into 2ml aliquots and stored at -20°C. The proteolytic inhibitors contained 
within the protease inhibitor cocktail had a broad specificity for serine, cysteine,  and acid 
proteases, and aminopeptidases. 
 
NETN buffer: The buffer contained 20mM Tris (pH 8), 1mM EDTA, 900mM NaCl and 
0.5% NP-40. 2.42g of Tris (pH 8), 0.29g of EDTA, 52.60g of NaCl and 5ml of NP-40 
was dissolved in 1L dH2O and stored at 4°C. An alternative NETN buffer containing 
100mM NaCl was also used.  
 
Precipitating the proteins: N2α cells were grown in 10% culture medium in four 250-
ml culture flasks until 100% confluency was reached for each flask. The cells from each 
of the four flasks were removed with 5ml of Trypsine/versene solution and pipetted into 
15-ml sterile tubes as described above (two flasks worth of cells per tube, thus 10ml per 
tube). Each of the tubes were lightly centrifuged in order to remove the Trypsine/versene 
solution. (At this point the cells was either used immediately or stored in 2ml 1X PBS, 
pH 7.4, per tube, at -20°C). To lyse the cells, 1ml of ice cold lysis buffer was added to 
each of the two 15-ml tubes (if cells were used from frozen, the tubes were lightly 
centrifuged first in order to remove the PBS) and pipetted vigorously up and down. The 
mixture was left to sit on ice for 10 min after which the cells were homogenized as 
described above. After lysis, the mixture was centrifuged at maximum speed at 4°C for 
15 min. The supernatant of each tube was pooled and the antibodies were added to 
precipitate the proteins: For AChE, 20µl of the goat polyclonal anti-AChE (sigma) was 
added to one tube (sample A); For laminin, 20µl of the rabbit polyclonal anti-laminin 
(sigma) was added to the other tube (sample L). At this point 10µg of AChE and 1µg of 
laminin was added to samples A and L, respectively. The immunoprecipitate was left to 
rock at 4°C for 1-2 h. In the meantime, the protein A-Sepharose slurry was prepared by 
washing 0.1g of protein-A beads in 1ml 1X PBS for 1 h at RT. The bead-mixture was 
centrifuged and the PBS discarded. 1ml of PBS/BSA 1% (w/v) was added to the beads 
and the mixture was left to rock for 1 h at RT. After 1 h the bead-mixture was 
centrifuged, rinsing twice with 1ml PBS, followed by a final centrifugation step. The last 
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PBS was discarded and 400µl of lysis buffer was added to the beads. The slurry was 
ready for use. After ~2 h, 100µl of the protein-A slurry mixture was added to each of the 
samples (lysate/antibody solution), and they were left to rock at 4°C for 1 h. The samples 
were centrifuged and the beads were washed, five times in NETN buffer containing 
900mM NaCl), and once with NETN buffer containing 100mM NaCl. The leftover beads 
contained the precipitated protein. 
 
2.2.5.3 SDS-PAGE 
 
Running buffer for SDS gels: A 10X buffer was made up as a stock solution. The buffer 
contained 150mM Tris, 1.92M glycine and 1% SDS. 60.4g of Tris base, 288g of glycine 
and 20g of SDS was dissolved in dH2O to give a final volume of 2L. A 1X buffer 
solution was made up prior to running the gels by adding 100ml of the 10X stock solution 
to 900ml of dH2O to make up 1L of working buffer. 
 
Sample loading buffer (laemli): 1ml of a 1% bromophenol blue solution was added to 
4ml of 1.5M Tris-HCl, pH 6.8. 10ml of glycerol was added to the mix. 2g of SDS was 
added and left to dissolve. 5ml of β-mercaptoethanol was then added and mixed. The 
buffer was aliquoted and stored at -20°C. 
 
Preparing and running the gels: SDS-polyacrylamide gel electrophoresis enables the 
separation of proteins according to their molecular weight. SDS can stop proteins 
aggregating and precipitating after the thermal denaturing step and provide proteins with 
a negative charge, irrespective of their isoelectric point. ~20µl sample loading buffer, 
containing SDS and β-mercaptoethanol which breaks disulfide bonds and separates 
multisubunit proteins to their monomers, was added to each of the samples from the Co-
IP and they were boiled for 4 min at 100°C. The SDS gel consists of a separating gel of 
high concentration and a pH of 8.8, and a stacking gel of lower concentration and a pH of 
6.8.  
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The gel compositions are shown below: 
 
 Separating gel (10%, for 
2X 0.75 mini-slab gels) 
Stacking gel (3%, X4 gels) 
Acrylamide/bisacrylamide, 
30% 
3.33ml 1.3ml 
Tris-HCl 2.5ml (1.5M, pH 8.8) 1.25 (1M, pH 6.8) 
10% SDS 0.1ml 0.1ml 
dH2O 4ml 7.4ml 
TEMED 10µl 20µl 
10% ammonium persulfate 50µl 50µl 
 
The separating gel was prepared, loaded into the running cassette and overlaid with 
butanol. Once the separating gel had set, the butanol was poured off and the stacking gel 
was prepared and loaded on top of the separating gel. After polymerization, the cassette 
was placed into the gel chamber and covered with running buffer. Each sample (A and L) 
was loaded onto a separate 10% gel, along with a protein ladder as well as 3 controls for 
the AChE sample (C1A, C2A, C3A)  and 3 controls for the laminin sample (C1L, C2L, 
C3L). C1A and C1L represented the cell lysate prior to Ab addition and should contain 
all the proteins of interest. C2A and C2L represented the supernatants after extraction of 
precipitated proteins with the protein A-Sepharose slurry and should be free of any AChE 
or laminin, respectively. C3A and C3L represented the recombinant human AChE 
(Sigma) and Engelbreth-holm-swarm murine sarcoma laminin (Sigma), respectively, and 
serve as indicator of successful blotting with antibodies. The gels were run in 1X running 
buffer for ~1 h at 200V in an SDS tank. Two control gels were also run and subjected to 
protein staining in order to confirm the presence of the proteins in the gels. Western 
blotting followed for the two sample gels. 
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2.2.5.4 Western blotting 
 
When an Ab against an epitope of a particular protein is available, western blotting can 
enable high sensitivity detection of that specific protein in a protein mixture. The proteins 
separated by the SDS-PAGE gel are transferred to a nitrocellulose membrane which in 
turn is subjected to immunodetection. In order to identify optimal concentrations, a dot-
blot was performed by directly pipetting the lysate samples from the Co-IP onto a 
nutricellulose membrane and then proceeding with the normal western blot detection 
procedure, description followes.  
 
Blocking buffer: The buffer contained 3% BSA and 0.05% Tween 20 diluted in 1X PBS. 
15g of BSA was dissolved in 1X PBS to give a final volume of 500ml. The solution was 
filter sterilized followed by addition of 250µl Tween 20. The buffer was stored at 4°C. 
For long term storage, 0.02% NaN3 was added. 
 
Blotting (transfer) buffer: A 10X stock solution was made up by dissolving 30.3g Tris 
and 144.1g glycine in 1L of dH2O. A 1X solution, made up by adding 100ml of the 10X 
stock solution and 200ml of methanol to dH2O to a final volume of 1L, was made up 
prior to blotting each time. The transfer buffer was stored at 4°C. 
 
Transfer of proteins to a nitrocellulose membrane:  While the gels were running, the 
blotting apparatus was prepared. The membranes were soaked in methanol for ~30 min 
on a rocker at RT. After 30 min, the membranes, along with the fibre pads and blotting 
filter papers, were pre-soaked in 1X blotting buffer. After SDS-PAGE, the gel was 
carefully removed from the cassette and assembled into a “sandwich” containing the fibre 
pads and filter papers on both sides. The gel is placed directly on top of the membrane in 
the middle of the “sandwich”. The “sandwich” cassette was placed into a western blotting 
transfer tank and the proteins were transferred electrophoretically at 300 mA for 1-2 h.  
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Immunodetection: After the proteins were transferred to the membranes, the two 
membranes (membrane A for the AChE sample, and membrane L for the laminin sample) 
were incubated overnight at 4°C with blocking buffer. This buffer contained a rich source 
of natural proteins that allow unspecific binding to all the proteins transferred onto the 
membrane. The next day, the membranes were washed three times with TBS/Tween 
wash buffer. Each membrane was incubated with primary Ab: Membrane A with a 
1/1000 dilution of the goat anti-AChE Ab (sigma); and membrane L with a 1/1000 
dilution of the rabbit anti-laminin Ab (sigma). Abs were diluted in washing buffer. 
Incubation proceeded on a rocker for 1 h at RT or overnight at 4°C. After incubation, the 
membranes were washed five times with TBS/Tween. Incubation with secondary Abs 
followed. Membrane A was incubated with a 1/10 000 dilution of anti-goat IgG (sigma) 
and membrane L with a 1/10 000 dilution of anti-rabbit IgG (sigma). Incubation 
proceeded for 1 h at RT. This was followed with another wash step (5X TBS/Tween). 
The membranes were then incubated with a 1/ 2000 dilution of streptavidin-peroxidase in 
blocking buffer for 15 min on the rocker at RT followed by another wash step (5X 
TBS/Tween). After washing, the membranes were sealed in a plastic cover and ~7ml 
TMB detection fluid containing 1% hydrogen peroxide was added to each sealed “bag”. 
Detection proceeded for 10-15 min (or once bands become visible) by rocking the 
membranes at RT. The membranes were then washed five times with purified H2O. The 
visible protein bands were analysed.  
 
Stripping and reprobing of blot: Membranes A and L were incubated in preheated 
stripping buffer at 50°C in a shaking water bath for 30min. The membranes were then 
washed twice in TBS-tween buffer at RT. This was followed by blocking the membranes 
in 10% blocking buffer for 1 h at RT. Immunodetection followed. 
 
Immunodetection using opposite Abs: In order to confirm the co-precipitation of AChE 
with laminin, and laminin with AChE, the membranes A and L were then blotted with 
opposite Abs: membrane A with anti-laminin primary Ab (followed by incubation with 
appropriate secondary Ab); and membrane L with anti-AChE Ab (followed by incubation 
with appropriate secondary Ab). The respected concentrations used were as given above. 
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Where immunodetection with opposite Abs, following stripping of the membranes, 
produced weak signals, new samples were run from the start and membranes were blotted 
with opposite Abs, i.e. where anti-AChE Abs were used in the Co-IP, anti-laminin was 
used for western detection and vice versa. 
 
 
 
 
 
 
 
 
 
 
.  
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3. Results 
 
3.1 Demonstrating the interaction between AChE and laminin-111 
 
In order to demonstrate the binding of AChE with laminin-111, ELISA and Co-IP 
methods were used. The ELISA demonstrates interaction of the two molecules in a 
controlled in vitro environment, while the Co-IP shows interaction under more 
physiological conditions. The in vitro ELISA experiments are a repeat of previously 
published work (Johnson & Moore, 2003).  
 
3.1.1 Whole molecule binding: ELISA 
 
Consistent with results previously shown (Johnson & Moore, 2003; Paraoanu & Layer, 
2004), biotinylated AChE was observed to bind to laminin-111 (Figure 17). The 
measured Kd value was 4.866 ± 0.3717 nM, and Bmax = .5136 ± 0.008021 A405 units (n = 
6). Non-specific binding was measured by using plates that were coated with buffer only. 
The non-specific binding has been subtracted from the values used for the graph. Purified 
erythrocyte AChE (Sigma) was used in all assays in preference to the recombinant 
protein; this was done in order to avoid possible problems with posttranslational 
modifications, especially glycosylation, that might influence the protein's conformation 
and binding to ligands. 
 
Neither of the two controls, biotinylated BSA and non-specific anti-human IgG was 
found to bind laminin-111 (Figure 18). IgG was used because it has a pI value similar to 
AChE, and BSA was used as a neutral control unlikely to bind. This confirms the specific 
binding of AChE to laminin-111.  
 
Stellenbosch University http://scholar.sun.ac.za
 107 
0 5 10 15 20 25
0.0
0.2
0.4
0.6
[AChE] (micrograms/ml)
A
40
5
 
Figure 17. Whole molecule binding between AChE and laminin. Microtitre plates 
were coated with 10µg/ml laminin in 50mM NaHCO3 buffer (pH 8.0). Biotinylated 
AChE was added (0.156-20µg/ml) and binding was observed at A405. Error bars reflect 
standard deviation (SD) and an average of 6 replicas was used to produce each data point.  
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Figure 18. Binding of the controls BSA and IgG to laminin-111. Microtitre plates 
were coated with 10µg/ml laminin in 50mM NaHCO3 (pH 8.0). Biotinylated AChE, BSA 
and IgG was added in serial dilutions of 0-10µg/ml, and binding was observed at A405. 
Error bars reflect SD and an average of 5 replicas were used to produce each data point. 
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In order to investigate the role of electrostatics in the binding between AChE and 
laminin-111, the NaCl concentration of the buffer was altered and binding was measured 
as above. It was clear that high concentrations of salt in the buffer disrupted binding 
(Figure 19), indicating that electrostatics may play a role in the binding of AChE and 
laminin-111. This was also previously shown (Johnson & Moore, 2003). 
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Figure 19. The effects of NaCl on the binding of AChE to laminin. Plates were coated 
with 10µg/ml laminin in 50mM NaHCO3 (pH 8.0). Biotinylated AChE was added at a 
concentration of 10 µg/ml in PBS containing a different concentration of NaCl for each 
data point (500, 250, 125 and 62.5 mM). n = 6 for each data point.  
 
Pre-incubation of AChE with the PAS-binding inhibitors (BW284c51, propidium, and 
gallamine), as well as the active site inhibitor, pyridostigmine, was also found to affect 
AChE-laminin binding (Figure 20), indicating that the PAS as well as the active site may 
be involved in AChEs binding to laminin.  
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Figure 20. Effects of AChE inhibitors on AChE-laminin binding. Microtitre plates 
were pre-coated with 10 µg/ml laminin. 20µg/ml biotinylated AChE was pre-incubated 
for 1 h in the presence of BW284c51 (●), propidium (■), pyridostigmine (▲) or 
gallamine (▼), before addition to plates. Inhibitors were used at concentrations of 0-
500µM. Absorbance was calculated as a percentage of total AChE binding at each 
concentration. 
 
 
3.1.2 AChE peptides binding to laminin: ELISA 
 
Peptides corresponding to the PAS-associated sequences of human AChE were 
synthesized. Figure 21 depicts the different positions on mouse AChE (1J06.pdb) of each 
of the peptides used. Demonstration of the binding of laminin to each of these peptides 
gives an indication as to the involvement of specific sites on AChE in the binding. 
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Figure 21. Position on mouse AChE (1J06.pdb) of the peptides used in this study. 
Residues 39-50 are shown in purple; 55-66 are shown in yellow; 69-96 are shown in 
green; 275-290 are shown in orange; and 340-353 are shown in cyan. The PAS residues 
(Y72, D74, Y124, W286 and Y341) are shown in spacefilling mode. 
 
 
The following peptides showed highest binding to the laminin immobilized on the plates: 
the omega loop (69-96), 55-66 and the 37-53 peptides (Figure 24). Peptides 275-290 and 
340-353 showed lowest binding to laminin. Once again non-specific binding was 
measured by coating wells with buffer only (without laminin), adding the biotinylated 
ligands and then subtracting the A405 values from the readings used for representation of 
the graph in Figure 22. 
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Figure 22. AChE peptides binding to laminin. Microtitre plates were coated with 
100µg/ml laminin. The biotinylated peptides were added at dilutions of 0-35mM.  
 
 
3.1.3 Demonstration of the interaction between AChE and laminin: Co-IP  
 
Coimmunoprecipitation was performed in order to investigate the AChE-laminin 
interaction in a more physiological context as well as to indicate the possibility of other 
binding partners for AChE. Previous results from the laboratory had shown that the 
inclusion of proteolytic inhibitors had no effect on Ab recognition of AChE. Seeing as 
the experiment was not focused on measuring AChE’s enzyme activity, using proteolytic 
inhibitors (such as PMSF, which inhibits AChE), would not matter. Figure 23 shows the 
basic principle behind the Co-IP method. (Unfortunately some of the protein bands on the 
immunoblots were less visible after scanning as the resolution of the available scanner 
was not ideal, and even. The protein bands were also clearer in the electronic copy vs. the 
printed out hard copy).  
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Figure 23. Coimmunoprecipitation. The Ab-protein complex is extracted from the cell 
lysate using Protein A-Sepharose beads. Any molecules attached to the protein of interest 
will be extracted along with it.  
 
 
In Sample A (Figure 24), AChE was extracted from the cell lysates of neuroblastoma 
cells using goat polyclonal anti-AChE Ab (Sigma). It is important to note that, unlike the 
MAbs used in the other experiments, this polyclonal Ab did not interfere with the AChE-
laminin interaction (results not shown). Immunodetection followed using the same Ab. In 
theory, only AChE should be visualized here, either on its own, or as part of a complex 
(with the Ab or another molecule) that did not separate under the denaturing conditions. 
Results show (lane titled Sample A; Figure 24) that the goat polyclonal anti-AChE Ab 
was able to successfully extract AChE from the cell lysate (indicated by an arrow in the 
Sample A lane, represented as a monomer corresponding to the ~70kDa area according to 
the protein ladder). At around 52kDa, a protein band can be seen. Another light band 
corresponding to ~30-40kDa can also be seen. These two bands probably represent the 
IgG light and heavy chains of the Ab molecule. There were no higher molecular weight 
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bands (possible AChE-complexes) visible in sample A. The first control, C1A, 
represented the complete neuroblastoma cell lysate prior to precipitation. Protein bands 
visible in the C1A control corresponded to ~52, 60, 80, 95, 135, and 200Da. The second 
control, C2A, is the supernatant after extraction of precipitated AChE. No AChE was 
detected in this lane of the immunoblot indicating successful extraction of protein. The 
lack of visible bands in this lane also eliminates the possibility of non-specific binding. 
The final control, C3A, contained the pure AChE and is shown as a light band near the 
72kDa mark of the protein ladder (indicated by an arrow in the C3A lane). 
 
Figure 24. Sample A: 
Anti-AChE Ab used 
for detection. Anti-
AChE Abs were used 
for protein extraction 
as well as for 
immunodetection. 
Sample A is the AChE 
sample from the cell 
lysate. C1A is the 
complete lysate 
control. C2A is the 
supernatant after 
AChE extraction 
control. C3A is the 
pure AChE. 
 
 
 
 
 
 
 
 
The visible IgG heavy and light chains could be the result of excess Ab that was left 
behind from the extraction, i.e. all the Ab may not have been removed from the cell 
lysate by the protein A. If this was the case, the secondary Ab (anti-goat IgG) would pick 
it up during immunodetection. This would also happen if the Ab was originally added in 
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fairly high stoichiometric ratios (compared to AChE). The Ab-AChE complex would 
probably be split by the SDS, thus showing as separate bands on the membrane, as can be 
seen in Figure 24.  
 
Although it is likely that the presence of SDS would dissociate complexes, higher 
molecular weight bands could indicate AChE in complex with a binding partner. It has 
been shown that certain protein complexes are sTable enough to survive SDS degradation 
(e.g. the investigation of SDS-resistant complexes by Otto et al., 1997). Unfortunately it 
is not known whether SDS would break up an AChE-complex or if such a complex 
would survive degradation. However, unless non-specific binding occurred (an absence 
of non-specific binding is suggested by the lack of protein bands in C2A), anti-AChE 
immunodetection would only pick up AChE or AChE-associated complexes. Cross-
reaction of anti-AChE Abs has been observed (e.g. Mappouras et al., 1995), thus higher 
molecular weight bands could also be due to the Abs cross-reacting with another, 
irrelevant entity.  
 
Sample A, containing the precipitated AChE, was also blotted with anti-laminin Ab in 
order to confirm the AChE-laminin interaction. The sample showed (Figure 25) a protein 
band once again near the 52kDa region that could represent the IgG heavy chain of the 
Ab (i.e. Ab left over after Protein A extraction). One or two lighter bands were also 
visible in the 150-260kDa area (2 very light bands were visible on the membrane, 
however, these are not as visible on the membrane scan showed in Figure 27; the arrows 
indicate to where these bands were seen). If visualization of these bands is correct, it may 
indicate that the laminin molecule separated into its separate chains (α = 338kDa, β = 
202kDa, γ = 177kDa) during electrophoreses. Control C1A showed similar bands in the 
high molecular region (150-260kDa; indicated by arrows). The higher molecular weight 
bands seen in this lane could indicate AChE oligomers, AChE complexes, or antibody 
cross-reaction with other proteins. As a reducing agent, β-mercaptoethanol, was used in 
the sample buffer, the presence of AChE oligomers, which are linked by disulfide bonds, 
is unlikely. Complexes are likely to be split by the presence of SDS in the sample buffer 
and gel, although whether this has occurred in this case is obviously not known. 
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Similarly, the potential for cross-reaction by the antibody is also not known. Control C2A 
did not show any protein bands. Seeing as C2A represents the cell lysate after AChE was 
extracted from it, no bands could indicate that most of the laminin present in the cell 
lysate may have been extracted along with AChE, thus being in complex with AChE. The 
control containing the pure AChE (C3A) presented no protein bands indicating no 
interference of non-specific binding. 
 
 
Figure 25. Sample 
A: Anti-laminin Ab 
used for detection. 
Sample A is the 
AChE sample from 
the cell lysate. C1A 
is the complete cell 
lysate control. C2A 
is the cell lysate 
after extraction of 
AChE. C3A is the 
pure AChE control. 
 
 
 
 
 
 
 
 
 
 
In Sample L, laminin was extracted from the cell lysate using a rabbit polyclonal anti-
laminin Ab (Sigma). Immunodetection followed using the same Ab. The immunoblot 
shows (Figure 26) a dark band near the 52kDa region, possibly the IgG heavy chain 
again. Two lighter bands can be seen in the same area (150-260kDa; once again these 
bands were quite clear on the original membrane; shown by the two arrows) where the 
laminin chains could be residing as in Figure 25. Similar two light bands are visible in the 
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complete cell lysate control, C1L (shown by the arrows in lane C1L). The control 
containing the pure laminin (C3L) shows a very dark, thick band in the same area. It 
would appear that the C3L sample was overloaded on the gel, and the consequent lack of 
definition may obscure minor bands present in the same area. If there is more than one 
band represented there, it could possibly again indicate the separate chains of the laminin 
protein. This would suggest that laminin separates into its individual chains during 
electrophoresis. Control C2L did not show any protein bands, indicating that the protein-
Ab extraction was successful. 
 
 
 
 
 
 
Figure 26. 
Sample L: 
Anti-laminin 
Ab used for 
detection. 
Sample L is the 
laminin sample 
from the cell 
lysate. C1L is 
the complete 
cell lysate 
control. C2L is 
the cell lysate 
after extraction 
of laminin. C3L 
is the pure 
laminin control. 
 
 
 
Sample L was also probed with the anti-AChE Abs for immunodetection to confirm the 
AChE-laminin binding. Sample L very clearly shows (Figure 27) the presence of AChE 
corresponding to the 72kDa mark on the protein ladder, as well as two lighter bands near 
the 45 and 52kDa areas. These two bands again most probably represent the two IgG 
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chains (heavy and light). C1L showed a similar dark band at 72kDa representing the 
AChE in the complete cell lysate. C2L also contains the AChE indicating that not all the 
AChE in the cell lysate was extracted along with the laminin (thus bound to laminin) 
during the precipitation step. As the pure laminin control, C3L showed no protein bands, 
it is safe to exclude the possibility of non-specific binding in this experiment. Differences 
in the intensities of the bands corresponding to AChE on the laminin (Figure 27) and 
AChE (Figure 24) membranes (although the same anti-AChE was used) could possibly 
be attributed to differences in experimental conditions as well as differences in cellular 
concentrations of AChE and laminin (e.g. higher concentrations of laminin extracted 
would lead to higher concentrations of AChE extracted along with it).  
 
 
Figure 27. Sample 
L: Anti-AChE Ab 
used for detection. 
Sample L is the 
laminin sample 
extracted from the 
cell lysate. C1L is 
the complete cell 
lysate control. C2L 
is the cell lysate 
after laminin 
extraction. C3L is 
the pure laminin 
control. 
 
 
 
 
 
 
A few drawbacks need to be taken into account when considering the Co-IP procedure. 
During the homogenisation and lysis processes, the protein of interest can come into 
contact with proteins it would not normally come into contact with and these proteins 
may even bind to each other. A protein expressed on the cell surface may, for example, 
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meet up with a protein that is always found in the cytosol and discover an affinity for this 
protein that would not normally happen in the cell, thus creating artefactual results. 
Lability of protein complexes is also a problem. The complex formed between AChE and 
laminin may be inherently labile and may split during homogenisation and lysis. It may 
also split when it encounters SDS. The AChE-laminin complex most probably is a labile 
one as it is strongly dependant on electrostatic interaction which can very easily be 
broken by altered ionic conditions. Also, seeing as electrostatics play such a big role in 
AChEs binding to laminin, the ionic/salt concentrations of the buffers (NETN and wash 
buffers) used in the experimental procedures could have possibly affected binding. 
 
The use of protein cross-linkers could possibly resolve the issue. Protein cross-linkers are 
chemical compounds used to covalently bind, or conjugate, biomolecules together. When 
such cross-linkers are added to the homogenate, they will chemically link two proteins 
that are bound or close enough to each other. This would increase the likelihood of 
visualising a complex of interest as well as lead to the formation of complexes that are 
more sTable. However, the issue of the protein of interest reacting with unlikely partners 
during homogenization and lysis comes into play even more so when cross-linkers are 
concerned. Normally non-interacting proteins may then be chemically attached to each 
other by these cross-linkers. This would increase the risk for false positives and high 
backgrounds, making interpretation of results very difficult. It thus seems to be a trade-
off between potentially losing the complex (when excluding the use of cross-linkers), or a 
false positive and high backgrounds when including cross-linkers. Neither scenario is 
ideal. The decision to exclude cross-linkers in this study was based on previous findings 
that demonstrated the interaction between AChE and laminin without the use of cross-
linkers (Paraoanu & Layer, 2004).  
 
The findings described in this section confirm the AChE-laminin interaction in the 
controlled in vitro environment of the ELISA, and also in the more physiological context 
of the neuroblastoma cell. Interference in AChE-laminin binding by PAS-binding 
inhibitors confirms previous findings (Johnson & Moore, 2003) of the interaction 
between the proteins occurring at or near the PAS. The lesser interference with binding 
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by the carbamate pyridostigmine, which binds to AChE’s active site and choline-binding 
sites, could feasibly be due to conformational changes within the gorge that affect 
binding at the PAS. The Co-IP results indicate binding of AChE and laminin. It is 
unfortunate that the resolution of Figure 25, in particular, did not demonstrate the 
interaction more clearly.  
 
3.2 Definition and characterization of the binding sites involved in the 
AChE-laminin interaction 
 
3.2.1 Phage display using peptide libraries 
 
The peptide phage display technique appeared to work well. Adequate yields from the 
selections as well as adequate growth of clones were observed. The DNA yields from the 
final round of selection also appeared adequate. However, the results of the sequencing 
were very disappointing. In many cases the sequencing was unsuccessful, due to 
insufficient DNA, and, where successful, a variety of sequences with little consensus was 
seen. It is probable that the insufficient amounts of DNA found on the sequencing is a 
consequence of the apparently large number of sequences present, so that each sequence 
is encoded by a relatively small proportion of the total DNA. The selection procedure 
was repeated, with attempts to optimise different parameters, but with the same result. It 
was concluded that this was a genuine, albeit negative, result, and that, to obtain 
information about interaction sequences, different techniques would have to be used. 
 
Although the issue will be discussed more thoroughly in the Discussion (section 4), it 
appeared possible at this stage that the use of peptide libraries could have been the source 
of the problem. If the AChE site is strongly three-dimensional, these peptides may not be 
adequate, as they may only bind to a small section of the site. This could also at least 
partly account for the multiplicity of peptide binders obtained in the sequencing. A 
solution to the problem would be to use a method that would provide three-dimensional 
information. A way to do this would be to use the same technology i.e. phage display, but 
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a library of three-dimensional binders. The only such libraries available are antibody 
libraries. Antibody libraries, unfortunately, are not readily available; at the time this work 
was done (2008/2009), no antibody libraries were available for purchase, and the 
development of a library would not have been feasible in the time frame of research for a 
degree. The antibody phage display work was thus contracted out to Creative Biolabs 
Inc., who has a library and do the selections against it.  
 
The different sites on the AChE molecule to which the MAbs bind is shown in Figure 28. 
 
 
Figure 28. Position on mouse 
AChE (1J06.pdb) of the 
principle MAb recognition 
motifs. Recognition site 40-48 is 
shown in yellow; 78-85 is shown 
in purple; and 86-92 is shown in 
green. The PAS residues (Y72, 
D74, Y124, W286 and Y341) are 
coloured cyan and shown in 
spacefilling mode 
 
 
3.2.2 Phage display using antibody libraries 
 
Work that was contracted out: 
Both AChE whole molecule (rHuAChE) and an AChE peptide (PS18; 
PPMGPRRFLPPEPKQPWS; corresponding to the human AChE sequence starting at 
P40) were used. During the first three rounds of panning, rHuAChE was used. The 
targets were then switched from rHuAchE to biotinylated PS18 in the rounds that 
followed and these specific binders were eluted by a high concentration of non-
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biotinylated PS18. The basic method used in the Ab phage display was the same as that 
used in the peptide phage display.  
 
Single clones were prepared from the elution of the 6th round screening followed by 
colony PCR using primers H1 and L1 in order to exclude the clones harbouring the 
empty vector. For the phage ELISA, the biotinylated target was immobilized indirectly 
by coated streptavidin. The top 23 positive clones were subjected to DNA sequencing of 
which a total of 15 clones were sequenced successfully. Sequence analysis showed that 
these sequences encoded two unique Abs (clone 7 and clone 21; sequences shown in 
Figure 29) (Table 3). Sequence alignment showed the VL sequences of the two scFv 
clones to be very similar, although their VH sequences seemed to differ (Figure 30; 
sequence alignment work was not contracted out). Overall the two clones showed a 95% 
identity. Phage ELISA with AChE coated plates also demonstrated that the positive clone 
no. 21 is able to bind AChE as expected. Solid evidence from the Creative Biolabs Inc. 
laboratory showed that this clone is doubly positive against both the target protein as well 
as the target peptide.  
 
 
Table 3. Grouping of the antibody clones based on their amino acid sequences 
 
Sequences Clone Number Total 
1 7, 18, 25, 39, 52, 60, 6 
2 21, 35, 43, 49, 51, 56, 74, 
78, 83 
9 
 Total clone number 15 
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Figure 29. Sequences of clone no.7 and clone no. 21 
 
 
MAEVQLLESG  GGLVQPGGSL  RLSCAASGFT  FSSYAMSWVR  QAPGKGLEWV      50 
MAEVQLLESG  GGLVQPGGSL  RLSCAASGFT  FSSYAMSWVR  QAPGKGLEWV      50 
 
SKISRDGYRT  WYADSVKGRF  TISRDNSKNT  LYLQMNSLRA  EDTAVYYCAK     100   
SSIS PS GRST   KYADSVKGRF  TISRDNSKNT  LYLQMNSLRA  EDTAVYYCAK     100 
 
VGHKFDYWGQ  GTLVTVSSGG  GGSGGGGGSG  GGGSTDIQMT  QSPSSLSASV     150 
RPMRFDYWGQ  GTLVTVSSGG  GGSGGGG-  SG  GGGSTDIQMT  QSPSSLSASV     149 
    
GDRVTITCRA  SQSISSYLNW  YQQKPGKAPK  LLIYAASSLQ  SGVPSRFSGS           200 
GDRVTITCRA  SQSISSYLNW  YQQKPGKAPK  LLIYAASSLQ  SGVPSRFSGS           199 
 
GSGTDFTLTI   SSLQPEDFAT  YYCQQSYSTP  NTFGQGTKVE  IKRAAA                     246 
GSGTDFTLTI   SSLQPEDFAT  YYCQQSYSTP  NTFGQGTKVE  IKRAAA                     245  
 
Figure 30. Sequence alignment of clone no. 7 and clone no. 21. Sequence 7 is shown 
on top of sequence 21. The CDRs are shown in bold and fall between residues 51-61, 95-
112, 175-187 and 224-232. Sequence 117-135, containing repeating Gly and Ser 
residues, is the linker sequence. 
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It is important to note that there is an amber stop code “TAG” in both of these validated 
clones. This always occurs in Ab phage display screening (information supplied by 
Creative Biolabs). This codon does not stop translation in suppressor strains used in this 
project (i.e. XL-Blue and ER2738 E. coli host strain). However, in other protein 
expression bacterial strains, site-mutation of the amber stop code is necessary to express 
the soluble scFv fragments.  
 
Work that was not contracted out: 
The sequences of the two top binders clone no. 7 and clone no. 21, were used for 3D 
modelling with Swiss-Model (Figure 31). The models produced were used to dock with 
mouse AChE (1J06.pdb), using the GRAMM-X webserver. The interaction sites on both 
clones are shown in Figures 32 and 33. Docking of clone no. 7 with AChE is shown in 
Figure 34. Docking of clone no. 21 with AChE is shown in Figure 35.  
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a) 
 
b)  
 
Figure 31. 3D modelling of sequences 7 and 12. Clone no. 7 is shown in a) and clone 
no. 21 in b). For both sequences: CDRs are shown in cyan; Basic residues (Arg, Lys, His) 
within the CDRs are shown in blue; Acidic residues (Asp, Glu) within the CDRs are 
shown in orange.  
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Figure 32. Residues on scFv sequence 7 that interact with AChE in the docking 
simulations. VH residues are coloured yellow, and VL residues are coloured cyan. The 
residues involved in the interaction are: VH CDR1 = S32, S33; VH CDR2 = S54, P55, 
D56, R58, S59; VH CDR3 = K100, V101, H103, K104; VL CDR1 = R158, S163, I164, 
S165; VL CDR2 = K177, I183, Y184, A185, A186, S187; VL CDR3 = Y227. 
 
 
 
 
 
Figure 33. Residues on 
scFv sequence 21 that 
interact with AChE in 
the docking simulations. 
VH residues are coloured 
yellow, and VL residues 
are coloured cyan. The 
residues involved in the 
interaction are: VH CDR1 
= S32, S33; VH CDR2 = 
S54, S56; VH CDR3 = 
R101, P102, M103, 
R104; VL CDR1 = R158, 
S163, I164, S165; VL 
CDR2 = K177, A178, 
I183, Y184, A185, A186, 
S187; VL CDR3 = Y227. 
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Figure 34. ScFv sequence 7 model docking with AChE (1J06.pdb). The RELSED 
motif is shown in magenta and the VLDATT motif is shown in cyan. 
 
 
 
Figure 35. ScFv sequence 21 model docking with AChE (1J06.pdb). The RELSED 
motif is shown in magenta and the VLDATT motif is shown in cyan. AChE is the 
molecule in the left and the scFv is shown on the right. 
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The docking program that was used for generating these docking simulations was the 
GRAMM-X webserver (Tovchigrechko & Vakser, 2006). The output is given as a protein 
database (pdb) file containing the multiple simulations (as many as requested; 10 is the 
minimum). Unfortunately no additional information or confidence in the particular 
docking poses is provided. It is observed that, using a multiplicity of simulations 
(minimum of 20), that one particular pose occurs with a significantly greater frequency, 
and that a number of slight variations on the pose are observed. The poses representing 
the above docking was selected as being most likely.  
 
The scFv sequences obtained from the Ab phage display were also used to identify other 
molecules, containing similar epitopes, with which AChE could possibly be functionally 
redundant (see section 3.3). By applying the BLAST-P alignment tool to the sequences, 
molecules with similar sequences to AChE, can be identified (Tables 4 & 5). 
 
 
Table 4. BLAST results for sequence no. 7. 
 
Hit E value 
anti-TREM1 1e-131 
anti-α-synuclein 4e-130 
anti-laminin 4e-128 
anti-factor VIII 4e-116 
anti-IFN-G 6e-116 
anti-fibronectin 1e-114 
anti-tenascin-C 2e-114 
anti-tetanus toxin 8e-114 
anti-botulinum toxin 3e-100 
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Table 5. BLAST results for sequence no. 21. 
 
Hit E value 
anti-TREM1 1e-131 
anti-α-synuclein 3e-130 
anti-laminin 5e-130 
anti-IFN-G 6e-118 
anti-tenascin-C 2e-117 
anti-factor VIII 9e-117 
anti-tetanus toxin 2e-116 
anti-fibronectin 2e-115 
anti-botulinum toxin 2e-99 
 
 
The E value, in Tables X and Y, refers to the “expected” value, i.e. the chances of a hit 
occurring by chance alone. The smaller the E value, the smaller the chance of the hit 
occurring by chance. The hits produced by the BLAST search are other scFvs. Therefore, 
the population from which the hits were taken is limited to other scFvs that have been 
developed.  
 
It can be seen from the Tables that many of the E values are extremely low. There are 
several factors that contribute to this very high similarity. The first is the structure of the 
scFv itself, which is made up of framework and hypervariable (CDR) regions of the 
immunoglobulin variable domain. Although part of the variable region, the framework 
sections are relatively conserved; the hypervariable CDR regions, on the other hand, will 
differ according to the structures of the individual antigens recognised. Antibody libraries 
are usually derived from a single individual, immune or non-immune. The antibody 
library that was used by Creative Biolabs in selecting these scFv is derived from the so-
called Tomlinson library (Nissum et al., 1994). scFv derived from the same library, even 
though they are panned against different antigens, are likely to be highly similar in their 
framework regions, although not in the CDRs. The BLAST-P algorithm, when assessing 
similarity, considers the entire sequence of the protein. As the framework regions make 
Stellenbosch University http://scholar.sun.ac.za
 129 
up a relatively large proportion of the scFv compared to the CDRs, the similarity scores 
will be artificially skewed, resulting in artefactually low E values. Because of this, the 
hits obtained in Tables 4 and 5 were analysed according to the libraries used in their 
generation. Table 6 shows the sequence 21 BLAST-hits arranged according to the 
libraries used in generating the scFvs 
 
Table 6. Sequence 21 BLAST-hits. Only sequence 21 BLAST-hits are shown as the two 
sequences obtained from the Ab phage display show similar hits, though with different E 
values. %ID refers to the percentage identity between the scFvs obtained from the Ab 
phage display and the ones obtained from the BLAST-search.  
 
Hit Acc. No. % ID E value Library 
used 
anti-TREM1 ABD59020 92 1e-115 human; 
Tomlinson 
anti-laminin ABS57273 89 4e-114 human; 
Tomlinson 
anti-fibrillar 
α-synuclein 
ACN56324 92 83-114 human; 
Tomlinson 
anti-HSP70 AAM77686 86  human; 
Tomlinson 
anti-IFN-G CAA06870 80 5e-98 human; other 
anti-HCS CAA06868 80 9e-98 human; other 
anti-
tenascinC 
CAA06867 80 1e-97 human; other 
anti-amyloid 
β 
AAS10497 82 1e-97 mouse 
anti-tetanus 
toxin 
CAO79114 81 1e-97 human; other 
anti-Factor 
VIII 
CAA06869 79 5e-97 human; other 
anti-
fibronectin 
CAA06862 79 2e-96 human; other 
anti-rabies 
glycoprotein 
AAY33413 71 2e-85 mouse 
anti-
botulinum 
toxin 
AAT35553 64 8e-84 mouse 
anti-guinea 
pig C5 
CAB60132 68 6e-86 mouse 
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As expected, the scFvs derived from the Tomlinson libraries show very high similarities 
to the anti-AChE scFv, with very low E values (Table 6). A second group of scFvs were 
also derived from the same library, a constructed human library (Pini et al., 1998). These 
scFvs (against IFN-G, HCS, tenascin-C, fibronectin and Factor VIII) were also very 
similar to each other in sequence. Hits from several  mouse libraries were also produced. 
 
As a control, sequence similarities in random scFvs (where the Ag has no relation to 
AChE) were investigated (Table 7). It was once again found that the scFv from the 
Tomlinson library have high similarity to the scFv produced in this study. Those scFvs 
from human and mouse libraries showed less similarity.  
 
 
Table 7. ScFv control BLAST. Random scFvs were identified by searching for “scFv” 
on NCBI Protein. The libraries used in raising the scFv were from the publications 
describing the scFvs. The randon scFv sequences were BLASTed against the anti-AChE 
scFv sequence 21, and E values and percentage identities determined. 
 
 
Antigen scFv Acc. no %ID to 
Seq.21 
E value Library 
replicase of plant 
(+) RNA virus 
CAG24081 79 1e-108 human; 
Tomlinson 
malonyl CoA 
decarboxylase 
AAQ95595 62 1e-81 human; other 
disialoganglioside 
2 
AAC16042 58 1e-74 mouse 
IL-6 CAC69950 47 3e-59 mouse 
 
 
The antigens against which the “hit” scFv shown in Tables 4 and 5 were aligned with 
human AChE (P22303), using BLAST-P. The results are shown in Table 8. Sequences 
and motifs shown in bold are those associated with the PAS, and potentially associated 
with the AChE-laminin interaction. 
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Table 8. ScFv antigen alignments with AChE. Sequences and motifs shown in bold are 
those associated with the PAS, and potentially associated with the AChE-laminin 
interaction. 
 
 
BLAST hit Antigen 
accessio
n 
number 
Alignment with human AChE % 
ID 
% 
pos. 
TREM1 Q9NP99 79PGFEGTEMWNPW 
331VKDEGSYFLVYGAP 
55 
43 
55 
50 
Laminin P25391 no significant alignment   
Fibrillar α-
synuclein 
P37840 no significant alignment   
Factor VIII AAA524
84 
74DTLYPGFEGTEMWNPNRELS 33 56 
IFN-G NP 
000610 
no significant alignments   
Fibronectin P02751 89NRELSEDCLYLNVWPTYPR 
27GPVSAFGIPFAEPPMGPRRFLPPEPPKQ 
72PPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTL 
42 
29 
31 
 
63 
50 
42 
HCS BAA133
32 
309SDTPEALINAGDFHGLQVLVGVVKDEGSYFLVY 
529CAFWNRFLPKLLSATDTLDEAERQWKAEF 
36 
28 
55 
38 
Tenascin-C P24821 279-404 
450-479 
539LLSATDTLDEAERQWKAEFHRWSSYMMVHWKNQ 
24 
30 
25 
39 
47 
50 
 
Tetanus 
toxin 
AAA232
82 
59VVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDC 
       ….130 
253HLVGCPPGGTGGNDTELV 
506GAQQYVSLDLRPLEVRR 
26 
 
33 
32 
36 
 
56 
44 
 
gp120 AAF694
92 
100-114 
409-438 
540LSATDTLDEAERQWKAEFHRWSSYMVHWKNQFDH 
47 
27 
24 
53 
40 
50 
Botulinum 
toxin 
P10845 49PPEPKQPWSGVVDATT 
281LVNHEWHVLPQESVFRFSFVPVVD 
454-463 
47 
25 
40 
53 
67 
90 
Amyloid β-
peptide 
1IYT 254LVGCPPGG 
555AEFHRWSSYMVH 
38 
58 
63 
58 
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It is clear that several of these antigens, in particular, laminin and α-synuclein, although 
their scFv generated very low E values compared to the anti-AChE scFv, bear no 
significant resemblance to AChE. Both these scFv were derived from the Tomlinson 
libraries, and it is therefore concluded that these hits are false positives. The remaining 
hits, however, do align with AChE, and an examination of the alignments shows a 
preponderance of four sequences: the PGFEGTE motif; the PPMGPRRF motif; the short 
omega loop, especially the PPMG motif; and the C-terminal peptide. These results tie in 
very strongly with the peptide array results (section 3.2.3), and will be discussed in depth 
in the discussion (section 4).  
 
3.2.3 Conformational epitope mapping of adhesion-inhibiting anti-AChE MAb: 
Peptide Arrays 
 
 
Not only have the anti-AChE MAb been shown to block cell adhesion and neurite 
outgrowth to varying degrees, they also interfere with the binding of laminin-111 to 
AChE in vitro. For these reasons, it appeared probable that the common epitope of the 
MAbs and the site on AChE to which laminin binds may be one and the same. Thus, the 
epitope mapping was undertaken to identify this common epitope and, hopefully, as a 
consequence, to identify the laminin-binding site on AChE. Table 9 show the different 
recognition motifs of the MAbs. 
 
The results of the conformational epitope mapping showed that the MAbs did, indeed, 
recognise a common epitope, and, furthermore, that this epitope was associated with the 
PAS. Table 6 shows the MAbs’ major recognition sites, ranked in order of reactivity.  
 
It was found that the MAbs that most effectively inhibit cell adhesion recognize the 
40PPMGPRRFL motif. This motif is linked by a salt bridge to the omega loop; the 
residues involved in the salt bridge are 46Arg and 94Glu on the omega loop. Because of 
this linkage, the 40PPMGPRRFL sequence is brought into close proximity to both the 
omega loop and the PAS (Figure 36). These Abs however, also showed a strong 
recognition of the motifs 85WNPNRE and 78PGFEGTE, both situated on the omega loop 
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(Figure 36). It was found that the reactivity of the Ab towards a specific peptide in the 
array was immediately increased following addition of a proline residue to that peptide 
sequence. This not only indicates that the primary epitope of these Abs is the proline-rich 
40PPMGPRRFL sequence, but that these Abs also respond to other proline-containing 
sequences. As stated, the MAb E12C8 was raised against Torpedo AChE. Here the 
equivalent sequence is PPVGNMRFR (Figure 37). E12C8 was found to also respond 
strongly to the presence of proline and also inhibit cell adhesion. All the MAbs that 
recognize the WNPNRE motif inhibit cell adhesion effectively. MAbs AE-2 and 29H, 
which do not react with WNPNRE, do not inhibit cell adhesion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. AChE structure (1J06.pdb) showing the position of the Arg 46-Glu 94 
salt bridge. The 90RELSED motif is shown in yellow. The 40PPMGPRR motif is shown 
in cyan. The PAS residues (Y72, D74, W286 and Y341) are shown in violet. The arrow 
indicates the direction of the active site gorge. The two residues comprising the salt 
bridge (Arg 46 and Glu 94) are shown in spacefilling mode. 
Table 9. Recognition of motifs by MAb. Inhibition of cell adhesion is a measure of the 
effects of the MAbs (at 40µg/ml) on neuroblastoma cells in vitro after 48h. Motifs are 
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ranked in order of their recognition by MAb. Cell adhesion data are from Johnson and 
Moore (2000). 
 
 
MAb Inhibition of 
adhesion 
Motif 1 Motif 2 Motif 3 
C2 94.0 PPMGPRRFL WNPNREL PGFEGTE 
E8 92.0 PPMGPRRRFL PGFEGTE WNPNREL 
43B4C 87.2 VVDATT PPMGPRRFL YQYVD 
13B9F 85.0 PPMGPRRFL PGFEGTE WNPNREL 
E12C8 81.4 PPMGPRRFL WNPNREL PGFEGTE 
13B9C 49.0 PPMGPRRFL YQYVD WNPNREL 
9H 0.0 VVDATT PPMGPRRFL - 
 
AE-2 
0.0 VVDATT PPMGPRRFL YQYVD 
 
 
 
Figure 37. Comparison of mouse and human AChE (residues 40-96), Torpedo AChE 
(residues 38-94), and the human BChE sequence (residues 36-92). The two disulfide-
linked cysteine residues (69 and 96 in mouse and human; 67 and 94 in Torpedo; 65 and 
92 in BChE) at the ends of the omega loop, along with the PAS residues Y72 and D74 
(mouse and human AChE), Y70 and D72 (Torpedo AChE) and D70 (BChE), are shown 
in boldface. The shaded parts represent motifs recognized by the adhesion-inhibiting 
MAbs (Johnson et al., 2008a). 
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These results, therefore, indicate that the epitope of the MAbs is the 40PPMGPRFFFL 
motif adjacent to the omega loop, and that they also recognize the Pro-containing 
sequences  85WNPNRE and 78PGFEGTE on the omega loop itself. It is possible that the 
site on AChE that binds laminin and promotes cell adhesion and neurite outgrowth is 
identical to this epitope. It is also possible, however, that the site is not identical, but 
close by with perhaps common features. The observation that the MAbs prevent AChE-
laminin binding is compatible with both possibilities: Abs are large molecules (the 
molecular weight of IgG is approximately 150 kDa), and steric hindrance could play a 
significant role. The specific identification of the site on laminin that interacts with AChE 
is addressed in the following sections. 
 
It is interesting that the epitope/s identified by the peptide array agree very closely with 
the common sequences identified by the BLAST alignments of AChE with the scFv 
antigens (Table 8). The scFv antigen alignments produced four common motifs: 
 
1. the 40PPMGPRRFL motif 
2. the large (69-96) omega loop, containing the 78PGFEGTE and 85WNPNRE motifs 
3. the short omega loop 257-272. 
4. the C-terminal T-peptide. 
 
Common features of points 1-3 are the high concentrations of Pro and Gly residues. As 
discussed above, cross-recognition of Pro-Gly motifs on the 69-96 omega loop and its 
immediate surrounds (such as the 40PPMGPRRFL motif) was observed with the MAbs. 
Thus, it would appear that these motifs are structurally very similar. 
 
There is likewise structural similarity between the 78PGFEGTE motif and the Pro and 
Gly-containing initial section of the short omega loop (257-272). Structural overlay of 
these two motifs was shown (Johnson & Moore, 2009). This short omega loop is also of 
interest because of its interaction with the PAS: in the crystal structure of the mouse 
AChE tetramer (Bourne et al., 1999), it was observed that the 257-272 omega loop 
interacts with the PAS of an adjacent AChE subunit. This interaction appears to be useful 
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in stabilising the tetrameric assembly. Bourne et al. (1999) furthermore demonstrated a 
structural similarity between the short omega loop and both the amyloid beta-peptide and 
the prion protein. Both the beta-peptide and the prion protein have been shown to interact 
with the PAS: the beta-peptide at the hydrophobic 274-308 sequence on AChE, which 
contains the PAS residue W286 (De Ferrari et al., 2001); and the prion protein at an 
unspecified site at the PAS (Clos et al., 2006). 
 
Yet more structural similarities emerge. The amyloid beta-peptide, apart from being an 
AChE ligand, also aligns with a part of the AChE sequence: part of the C-terminal T-
peptide (Greenfield & Vaux, 2002). Cottingham et al. (2002; 2003), furthermore, showed 
this AChE peptide to be capable of assuming beta-sheet conformation and assembling 
into amyloid-like fibrils, as does the beta-peptide.  
 
Thus, it is possible to say that the four sites – the 40PPMGPRRFL motif, the 
78PGFEGTE/85WNPNRE motif, the 253PPGGTGG motif and the C-terminal T-peptide – 
are structurally similar, and that they appear to be recognized as such by the hybridoma-
derived MAbs as well as the scFv. It should be noted that the docking of the scFv with 
AChE produced only docking at the large omega loop region: the adjacent 
78PGFEGTE/85WNPNRE motifs (W84 lies within the gorge, forming the major 
component of the choline-binding site), and the 40PPMGPRRFL (or 40PPVGPRRFL in 
the mouse pdb structure 1J06.pdb) which is linked to the 90RELSED motif by a salt 
bridge between Arg46 and Glu94. Docking did not occur at either the short omega loop 
or the C-terminal peptide: neither of these structures is present in the crystal structure. 
 
3.2.4 Identification of potential binding sites on laminin α1 through sequence 
analysis.  
 
Previous results show binding of AChE to laminin-111 (Johnson & Moore, 2003), which 
is the isoform expressed during development. These results had shown that PAS-binding 
inhibitors and PAS-binding Abs interfered with the AChE-laminin binding, suggesting 
that the AChE PAS was involved in the interaction. It was also demonstrated that binding 
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occurred through an electrostatic mechanism, indicating that the anionic PAS, 
theoretically, should attract a cationic complimentary site. Identification of such a site 
called, first of all, for the investigation of the mouse laminin α1-chain (Swiss-Prot 
accession number NP_032506) sequence. Nomizu et al. (1995) have previously identified 
a number of sites involved in cell attachment and spreading, many of which are cationic. 
Five of the laminin peptides showed cell attachment activities with cell-type specificities: 
AG-10, AG-22, AG-32, AG-56 and AG-73 (Nomizu et al., 1995). 
 
Potential cationic sites on the mouse laminin α1 chain (accesion number P19137): 
 
144
 RYKITPRRGPPTYR 
204
 RYIRLRLQRIRT 
364
 RPHK 
1719
 RFQKPQEKLK 
1844
 KRRAR 
1942
 RRKQ 
1988
 REKGRKAR 
2086
 KLLISRAKAR 
2155
 RRGK 
2378
 RNRK 
2426
 KAVRKGVSSR 
2718
 RKRLQVQ      (AG-73) 
2764
 KGRTK 
2790
 KRKAFMDKDR 
 
Cationic sites in laminin β1 and γ1 chains: 
 
Laminin β1 (mouse laminin, accession number P02469) 
 
213RIKFVK 
1175RTHK 
1554KRASK 
1695RRK 
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Laminin γ1 (mouse laminin, accession number P02468): 
 
129KRTR 
291RPWRR 
550RRDTR 
1098RARSR 
1441KRK 
1469RKAK 
 
3.2.5 Docking with laminin α2, and identification of AG-73 as likely site. 
 
At the time when this aspect of the study was commenced, the structure of the laminin α1 
chain (the component of laminin-111 which was used in the binding assays) was not 
available. The only laminin structure available was the laminin α2 G4 and G5 domain 
pair, the component of laminin-211 (merosin). The α1 and α2 chains are, however, 
strongly homologous (45% identity; Figure 38), and the G4 and G5 domain pair – the 
region of the laminin molecule where most ligands, including heparin and integrins, bind 
– show 63% identity between the α1 and α2 chains. Thus, the initial docking studies were 
done with the laminin α2 G4 and G5 domains (1DYK.pdb).  
 
 Docking of AChE with laminin α2 G4/G5 domain pair was found to take place between 
regions of the AChE PAS and the 2769KVKNRLTIELEVRT sequence (Figure 39). This 
sequence was found to correspond to AG-73 (2718RKRLQVQLSIRT) of the laminin α1-
chain (in the nomenclature of Nomizu et al. (1995)), making this site a top candidate. 
Docking was done by GRAMM webserver, producing 10 docked simulations. These 
were visualised and analysed on DeepView. Residues within 5Å of each other on the two 
molecules were determined. On AChE these were: the PAS containing sequences 72-78, 
279-293 and 340-347. On laminin these were: 2769-2782 (incorporates part of the AG-73 
sequence equivalent) I2880, Y2882, P2887, I2888.  
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    *      * * * * *   *   * *                            *      * *         *        * *  *   * * * 
2697    GAHQFGLSQN   SHLVLPLNQS     DVRKRLQVQL   SI RTFASSGL   
2739    GSKQFGLSRN    SHI AI VFDDT     KVKNRLTI EL   EVRTEAESGL  
 
                 *            *          *       *   * *      *           *      * * *       *   *           * 
2737    IYYVAHQNQM   DYATLQLQEG   RLHFMFDLGK   GRTKVSHPAL    
2739    LFYMGRI NHA   DFGTVQLRNG    FPF F SYDLGS   GSTRTMIPTK     
 
                * * *     * *         *          *                       * *         *                        *      * 
2777    LSDGGKWHTV   KTEYIKRKAF     MTVDGQESPS   VTVVGNATTL   
2769    INDGGQWHKI    KIVRVKQEGI      LYVDDASSQT    ISPK-  KAD  IL       
 
            * *         * *   * *   **      *      *    *     *      *   *        *                       
2817    DVERKLYLGG   LPSHYRARNI      GTI THS IPAC    IGEIMVNGQQ    
2808    DVGGILYVGG   LP I NYTTRRI      GPVTYSLDGC   VRNLHMEQAP   
 
              *    *    *  *            *       *         *          * *   *  *    *                *              * 
2857    LDKDRPLSAS    AVDRCYVVAQ   EGTFFEGSGY    AALVKEGYKV    
2848    VDLDQPTSSF    HVGTCFANAE     SGTYFDGTGF   GKAVGG-  FIV     
 
              * * *          **      * **        * ***      * ***   *    *           *   *    *    *   
2897    RLDLNITLEF     RTTSKNGVLL     GISSAKVDAI      GLEIVDGKVL    
2887    GLDLLVEFEF    RTTRPTGVLL     GISSQKMDGM   GIEMIDEKLM     
 
            ** *    * * * * *      * *   *                          *    *   *               *   *   *    * 
2937    FHVNNGAGRI    TATYQPRAAR   ALCDGKWHTL   QAHKSKHRIV    
2927    FHVDNGAGRF   TAIYDAEIPG     HMCNGQWYKV  TAKKIKNRLE    
 
            *   * * * *  *    *       **        * ***      *****        ** *       *          *      * 
2977    LTVDGNSVRA    ESPHTHSTSA    DTNDPIYVGG   YPAHIKQNCL     
2967    LVVDGNQVDA   QSPNSASTSA    DTNDPVFVGG   FPGGLNQFGL     
 
                        * ***        *   *    *      *                       *   *          
3017    SSRASFRGCV    RNLRLSRGSQ   -VQSLDLSRA   FDLQGVFPHS   CPGPEP 
3007    TTNIRFRGCI      RSLKLTKGTA   NRWRLILPRP  WN-------------- 
 
          
Figure 38. Sequence alignment of laminin α1 and α2. Laminin α1 is shown on top with 
laminin α2 below it.  
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Figure 39. Docking of mouse AChE (1J06.pdb) with mouse laminin α2 G4 and G5 
domains (1DYK.pdb). AChE is shown in grey and laminin is shown in cyan. Interaction 
sites (Y72-78, 279-293, 340-347 on AChE and 2769-2782 on laminin) are coloured 
yellow and orange, respectively. 
 
 
 
3.2.5 In vitro binding of the PAS of AChE to AG-73 
 
Binding of biotinylated AChE to the AG-73 peptide occurred with a Kd value of 276.9 ± 
38.77 nM and a Bmax of 1.371 ± 0.2326 (A405 absorbance units) (Figure 41a). Figure 40 
shows the AG-73-associated interaction on the laminin molecule. AChE did not bind to 
the scrambled version of AG-73. Neither of the two controls, biotinylated BSA and non-
specific mouse IgG (with a similar pI value as AChE), was found to bind to any of the 
two peptides (normal and scrambled version). In the reverse situation, biotinylated AG-
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73 was observed to bind to AChE. Here, no binding occurred with either of the controls. 
The biotinylated scrambled version of the AG-73 peptide did not bind. The AG-73 
peptide was also found to have a significant interfering effect on the binding of AChE 
and laminin (Figure 41b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. The G4 and G5 domains of the laminin molecule showing the AG-73 
interaction site. The site on laminin G4 that was found to interact with AChE is shown 
in cyan and spacefilling mode. The interaction residues are 2718VRKRL, 2738YY, 
2789YIKRK and 2817VERK. Structure is 2JD4.pdb. 
 
 
The presence of salt in the buffers once again disrupted binding (Figure 42), indicating 
the electrostatic significance in the reaction. Pre-incubation of AChE with inhibitors 
showed varying results (Figure 43). Propidium (PAS-binding inhibitor) showed to have a 
strong effect, significantly reducing binding (P<0.001). The effects of gallamine were 
somewhat less, but still significant (P<0.001). The binding of AChE to AG-73 was 
unaffected by the active-site inhibitor pyridostigmine. The role of the PAS in this binding 
is once again highlighted. 
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Figure 41. Binding of AChE to the AG-73 laminin peptide. (a) Binding of biotinylated 
AChE to AG-73. Microtitre plates were coated with either 20µg/ml AG-73, or the 
scrambled version. Biotinylated proteins included AChE, BSA and IgG. ♦ = Biotinylated 
AChE; AG-73 as plate-coating. ■ = Biotinylated AChE; scrambled version of peptide 
AG-73 as plate-coating. ▲ = Biotinylated BSA; AG-73 as plate-coating. ● = Biotinylated 
IgG; AG-73 as plate-coating. (b) Interference with AChE-laminin binding by AG-73. 
Microtitre plates were coated with 10µg/ml laminin-111. Biotinylated AChE (20µg/ml or 
286 nM) was pre-incubated with various concentrations (0-10 µM) of either AG-73 or its 
scrambled version. ♦ = Pre-incubated with AG-73. ■ = Pre-incubated with scrambled 
version of AG-73. ▲ = AChE only, no added peptide (Johnson et al., 2008a). 
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Figure 42. Effects of NaCl on AChE-AG-73 binding. The different buffer NaCl 
concentrations used were: 500, 250, 125, 62.5 mM. 
 
 
 
Figure 43. Effects of AChE inhibitors on AChE binding to AG-73. The microtitre 
plates were coated with 20µg/ml AG-73. Biotinylated AChE (20µg/ml) was pre-
incubated for 1 h in the presence of propidium (■), gallamine (●), or pyridostigmine (▲) 
inhibitor. Absence of inhibitor is shown as = ♦ (Johnson et al., 2008a). 
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3.2.7 AChE competing with heparan sulfate for binding to laminin-111 and AG-73 
 
The site on laminin that binds AChE has much in common with the heparin-binding site. 
The AG-73 peptide was initially identified as a heparin-binding site (Hoffman et al., 
1998). Competition ELISA was performed in order to investigate whether AChE 
competes with this molecule for binding to laminin. The presence of heparan sulfate was 
found to significantly reduced the binding of biotinylated AChE to laminin (P<0.001) 
(Figure 44). Pre-coating the microtitre plates with AChE or heparan sulfate showed 
similar results (results not shown).  
 
 
 
Figure 44. Competition between AChE and heparan sulfate for binding laminin-
111. Microtitre plates were coated with 10µg/ml laminin-111. Serial dilutions of 
biotinylated AChE (0-20µg/ml; 0-286nM) were added in the presence (■), or absence (♦) 
of 10µg/ml heparan sulfate (Johnson et al., 2008a). 
 
 
Competition ELISA confirmed the involvement of the AG-73 site on laminin in its 
binding with AChE. Seeing as AChE and heparin compete for binding to laminin, this 
could indicate the possibility of functional redundancy between AChE and heparin (see 
section 3.3 on functional redundancy). 
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3.2.8 Docking of AChE and laminin α1: Identification of interaction sites on both 
AChE and laminin. 
 
The laminin α1 G4-5 domain structure only became available towards the end of this 
aspect of the study (Harrison et al., 2007). The docking results are shown in Figure 45 (a-
d). One of the catalytic subunits of the AChE dimer was shown to dock with the G4 
domain of laminin where the laminin contribution to the docking was observed to come 
from four clusters of the residues: 2718VRKRL, 2738YY, 2789YIKRK and 2817VERK. The 
first group of residues, 2718-2722, form part of the AG-73 sequence. These residues 
seem to interact closely with R90 and E91 as well as the N61-Q66 sequence of AChE. 
The acidic sequence, 90RELSED, was found to be the major interaction site on AChE. 
Parts of this acidic sequence appear to interact with all three of the laminin basic 
sequences.  
 
a) The docked structures:  
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b) Interacting residues on AChE:  
 
 
c) Interacting residues on laminin: 
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d) Stereo view of the interacting structures:  
Figure 45. Docking of AChE (PDB code 1JO6) and laminin (PDB code 2JD4). (a) 
The docked structures: AChE (single catalytic subunit) is shown in cyan; the LG4 and 
LG5 domains (one domain of each) of laminin are shown in grey; the PAS residues (Y72, 
D74, Y124, W286 and Y341) are shown in black; and 90RELSED is in blue. (b) 
Interacting residues on the AChE molecule: the PAS residues on AChE are shown in 
yellow, and the interacting residues in blue. (c) Interacting residues on the laminin 
molecule (LG4 and LG5 domain): shown in red. (d) Stereo view of the interacting 
structures: the AChE molecule is shown in cyan and the laminin molecule in grey; the 
interacting structures on AChE are shown in blue and the interacting structures on 
laminin in red (Johnson et al., 2008a). 
 
 
In the docked structure, as illustrated in Figure 45 (a-d), R90 is observed to lie within 4 Å 
(1 Å = 0.1nm) of R2719, K2720, F2760, F2762 and K2793 and within 2 Å of L2722 and 
Y2789. E91 was found to lie within 4 Å of L2722, as does L92 with Y2738 and Y2739, 
and S93 with E2818, R2819 and V2740. E94 approaches E2818 and K2820, and D95 
approaches V2817, E2818 and R2819. Due to its salt bridge linkage with E94, R46 also 
interacts with this sequence, and lies within 4 Å of K2820, as well as L2862 and S2863 
on the laminin chain. P40, P41 and V42 and Y70 were also observed to associate V2817, 
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E2818, R2819 and K2820. Other laminin residues that appear to interact with AChE are 
2737IYY. These residues lie close to P88 and L92, as well as both Q71 and V72.  
 
Torpedo AChE did not dock with the mouse laminin G4 domain (results not shown). 
Sequence differences occur between mouse/human and Torpedo AChE (see Figure 37). 
These differences include: in the RELSED motif, L92 is replaced by methionine residue 
in Torpedo, a conservative replacement. The DATTFQ sequence, however, show even 
more variation: in Torpedo, the equivalent sequence is NASTT. The replacement of the 
acidic A61 with the uncharged N59 could thus possibly have a negative effect on the 
interaction. 
 
No docking was observed between the mouse AChE-inhibitor complexes (with 
propidium, gallamine and fasciculin-2) and laminin α1 (results not shown). Human BChE 
also did not dock (results not shown). In BChE, R90 is replaced by a threonine residue. 
The BChE sequence also contains a replacement of the non-polar T64 with a positively 
charged lysine residue (Figure 37).  
 
3.3 Functional Redundancy 
 
3.3.1 In neural development 
 
3.3.1.1 Clues from the laminin site 
 
On laminin, the AChE binding site overlaps the heparin-binding site (Harrison et al, 
2007). This site has previously been identified showing that the AG-73 peptide forms part 
of it (Hoffman et al., 2001). From the results it is evident that AChE competes with 
heparan sulfate for binding to laminin, suggesting heparin-containing molecules could 
possibly be functionally redundant with AChE. 
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An array of proteoglycans is expressed during neural development. This expression 
occurs both in the ECM and on the surfaces of cells (Hartmann & Maurer, 2001). Not a 
lot is known about proteoglycan expression patterns and function, but accumulating 
evidence show that these molecules portray important roles in development. They have 
been found to promote cell adhesion, cell-cell interactions as well as growth factor (GF) 
signalling (Bandtlow & Zimmerman, 2000; Selleck, 2000). The proteoglycan protein 
core can contain heparan, chondroitin, or less frequently, dermatan sulfate, alone or in 
combination. Intermolecular interactions have been shown to be a common occurrence 
both by the sugars and protein core (Hartmann & Maurer, 2001; Bandtlow & 
Zimmerman, 2000). A multiplicity of potential binding and signalling structures could 
result from the different variations in sugar composition and length together with the 
diversity of proteins to which they attach. In the developing nervous system, heparan 
sulfate containing proteoglycans (HSPGs) have been observed to bind a heterogeneous 
group of molecules. These include proteins such as NCAM, slit proteins, fibronectin and 
the thrombospondins; as well as GFs such as members of the fibroblast growth factor 
(FGF), Wnt, transforming growth factor β as well as the hedgehog families and 
pleiotrophin (Bandtlow & Zimmerman, 2000). Bindings like these may occur exclusively 
by the HS chains or alongside contributions from the protein core. HSPGs showing 
similar spatiotemporal expression to AChE include: the membrane-associated syndecans, 
glypicans and testicans; and the extracellular molecules perlecan, agrin and collagen 
XVIII (Table 10).  
 
Syndecans, a family of four transmembrane receptors, are expressed in a variety of 
tissues portraying multiple biological functions (Tkachenko et al., 2005). These HSPGs 
are capable of carrying both heparan and chondroitin sulfate chains. The extracellular 
domain of syndecans may be shed into the matrix as functional molecules (Kim et al., 
1994). Even though all four of these transmembrane receptors are expressed in the 
developing nervous system, they have different spatiotemporal distributions. It is thus 
likely that they also have different functions. Binding of syndecans with various GFs, 
ECM molecules, as well as with LDL, have been previously demonstrated (Bernfield & 
Sanderson, 1994). The syndecan knockout mouse showed no obvious phenotypes 
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(Hartmann & Maurer, 2001). Syndecan-1, a prototype HSPG first identified as a 
developmentally regulated type-1 transmembrane protein that bound ECM components to 
epithelial cells (Rapraeger & Bernfield, 1983; Koda & Bernfield, 1984; Saunders & 
Bernfield, 1988), has been shown to bind laminin-111. Interestingly, this binding occurs 
through an interaction of the heparan sulfate with AG-73 site in the LG4 domain of the 
laminin molecule (Hoffman et al., 1998). 
 
Table 10. HSPGs in the developing nervous system (the majority of the data from: 
Hartmann & Maurer, 2001; Bandtlow & Zimmerman, 2000; Selleck, 2000). Notes a-f 
indicate the other relevant references (see below). (Johnson et al., 2008b) 
 
 
a= Bernfield et al., 1999; b= Fuki et al., 1997; c= Ethell et al., 2000; d= Hienola et al., 2006; e= Song et 
al., 2005; f= Anderson et al., 2007 
 
The glypicans are distinctive cell surface HSPGs linked directly to membrane 
phospholipid (David et al., 1990). These glycosylphosphatidylinositol-linked (GPI-
linked) HSPGs appear to play important roles in cell growth and differentiation 
(Bernfield et al., 1999). Several additional structurally related glypicans have been 
identified. Like the syndecans, glypican gene products bear HS chains as a permanent 
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feature and individual glypicans have been known to show differences in their 
developmental expression patterns. These expression pattern variations once again 
suggest distinct functions. Glypicans also modulate GF signaling through their HS 
chains. Glypican-2, a HSPG exclusive to the nervous system, along with glypican-1, have 
been shown to bind laminin-111 in vitro (Stipp et al., 1994). None of the other members 
of the glypican family have been demonstrated to bind laminin. 
 
As a subgroup of the BM-40/SPARC/osteonectin family of modular proteins, the 
testicans have yet to demonstrate laminin binding. These proteins also seem to have an 
inhibitory effect on neurite outgrowth (Schnepp et al., 2005). These findings suggest the 
testicans are unlikely to show redundancy with AChE. 
 
Perlecan, a large multifunctional HSPG, is well known for its role in the formation of the 
BM by cross-linking many cell-surface and ECM molecules. In addition to its structural 
role, both the protein core and the HS constituents of perlecan have been shown to 
support various biological activities. These functions include cell adhesion, GF binding, 
as well as apoptosis (Farach-Carson & Carson, 2007). Perlecan expression occurs from 
very early stages of development and the molecule consists of five domains. Domain I 
contains the HS attachment site and domain II the LDL receptor repeats. Domain V is 
found to be homologous to the laminin G domains and laminin binding through the AG-
73 site have been demonstrated (Brown et al., 1997). In vitro and in culture binding 
studies, along with studies using genetically modified mice have indicated that perlecan 
is responsible for localizing AChE on the synaptic basal lamina (reviewed in Inestrosa & 
Perelman, 1989). Through interactions with the ColQ collagen-like tail associated with 
the asymmetric forms, perlecan has been shown to bind AChE in the NMJ (Kimbell et 
al., 2004). Unlike perlecan, these asymmetric isoforms of AChE are not expressed during 
early neural developmental stages. In a recent study, colocalization of AChE and perlecan 
was observed near membrane protrusion sites in fibroblasts and astrocytes (Anderson et 
al., 2007). Results from this study also indicated possible interactions of perlecan with 
amyloid precursor protein. Colocalization may indicate the presence of redundancy. 
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The multidomain HSPG, Agrin, is well known for its role in AChR clustering during 
synaptogenesis. Binding of agrin with various molecules, including laminin-111, have 
been demonstrated. Such binding can occur by both HS-dependant and HS-independent 
means (Hartmann & Maurer, 2001; Bandtlow & Zimmerman, 2000). The laminin 
interaction site does not, however, correspond to the heparin-binding site AG-73 in the 
G4 domain (Denzer et al., 1998). These findings, along with the demonstration that agrin 
inhibits rather than enhances neurite outgrowth; indicate that this molecule is unlikely to 
show redundancy with AChE.  
 
Collagens XVIII, along with its cleavage product endostatin, are both components of the 
BM. These molecules share structural characteristics with both proteoglycans and 
collagen. Collagen XVIII have been shown to play a physiological role in modulating 
axonal growth by acting as a ligand for neural receptor tyrosine phosphatase. Even 
though collagen XVIII binds laminin, the site does not correspond to the heparin-binding 
site. Binding of collagen XVIII with heparan sulfate on the cell surface have also been 
demonstrated (Marneros & Olsen, 2005). These findings suggest collagen XVIII unlikely 
to be functionally redundant with AChE.  
 
3.3.1.2 Clues from the AChE site 
 
3.3.1.2.1 Homologous proteins 
 
The 90RELSED site on AChE falls partly within the carboxylesterase type b signature 2 
(signature sequence EDCLYLNVWTP; prosite pattern PS00941), a signature strongly 
conserved throughout the α/β hydrolase fold family of proteins. As mentioned, the 
hydrolase fold family includes the cholinesterases (AChE and BChE), the 
cholinesterases-domain proteins (the neuroligins, neurotactin, glutactin, gliotactin, 
thyroglobulin and the Dictyolstelium crystal protein), the carboxylesterases and the 
lipases (Holmquist, 2000). The signature sequence occurs in the sequence surrounding a 
cysteine residue involved in a disulfide bond. Sequence conservation implies that at least 
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part of the 90RELSED site is conserved in the cholinesterase-domain proteins as well. 
Additional conserved residues are found in the 40PPMGPRRFL sequence where R46, 
which forms a salt bridge with E94, is conserved. Pro 40 and 41 are also conserved 
(Figure 37).  
 
BChE, although very closely homologous to AChE, does not promote cell adhesion nor 
does it bind laminin in vitro (Johnson & Moore, 2000, 2003; Mack & Robitzki, 2000). 
The two molecules were also unable to dock.  
 
As mentioned, the neuroligins are a group of four transmembrane proteins able to form 
adhesion complexes with β-neurexins in the presynaptic membrane where they promote 
synapse formation (Chubykin et al., 2005). The neuroligin-1 extracellular domain shares 
34% identity with AChE. Here a clear resemblances is seen in both the 90RELSED 
(147QDQSED) and the 40PPMGPRRFL (88PPTFERRFQ) sequences (Figure 46). Seeing 
as both AChE and neuroligin-1 bind to β-neurexin, functional redundancy between these 
two molecules has previously been proposed (Grifman et al., 1998). This redundancy was 
not confirmed in a subsequent study (Comoletti et al., 2003). Given that the neurexins 
show considerable alternative splicing, it is possible that isoforms other than those tested 
bind. Functional redundancy during early stages of development is unlikely as the 
neuroligins appear to be expressed only after synaptogenesis.  
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Figure 46. Sequence alignment of neuroligins 1-4, AChE and BChE. Asterisks 
indicate conserved residues. Dots indicate conservative replacements. The residues (and 
their equivalents) forming the laminin-binding site in AChE are shown in bold. Aligment 
was performed by using CLUSTALW (Johnson et al., 2008b). 
 
3.3.1.2.2 Searches for similar motifs in other proteins 
 
Searches were performed for the 40PPMGPRRFL and the 90RELSED sequences, along 
with equivalents and conservative replacements for both. 40PPMGPRRFL sequence 
searches only showed various AChEs and neuroligins from a number of species. Searches 
for the 90RELSED sequence in neural molecules yielded the syntaxins, ligatin, proto-
oncogene receptor tyrosine kinase Mer, perlecan and the LDL receptor. Of these, the only 
molecules expressed during migration and differentiation is Mer, perlecan and the LDL 
receptor. It is important to note that the motif search was not done for the exact sequence, 
but allowed for conservative replacements. The motif search on ProSite was [RK]-[ED]-
[LAIM]-[ST]-[ED]-[ED]. The hit on Mer was residue 428-433 KELSEE (mouse receptor 
tyrosine kinase Mer, accession number NP 032613). This sequence is found in the 
extracellular domain of Mer, in a fibronectin type 3 domain. 
 
Searches for the subsidiary 60VDATT sequence also involved in the AChE-laminin 
interaction, yielded a number of candidates. When the search was narrowed to 
developmentally-associated neural proteins containing both the 90RELSED and 40VDATT 
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motifs, the yielded subset was considerably smaller. This subset seems to consist of 
perlecan and Mer. In perlecan, it would appear from the position of the two motifs that 
they may be situated far apart. As the structure of perlecan has yet to be solved, this 
speculation could not be confirmed. For Mer the VDATT motif search was [VLI]-[DE]-
[LAIM]-[TS]-[TS], and the hit was residues 652-656. This falls within the tyrosine kinase 
domain, so is unlikely to associate with the KELSEE motif mentioned above. The 
structure of the relevant part of Mer has also not been solved. It appears, however, from 
the sequence that the motifs in Mer may be relatively close. Mer, belonging to the 
Ax1/Sky/Mer family of receptor tyrosine kinases, is expressed in both embryonic and 
mature nervous tissue (Graham et al., 1995). Reports show that Mer is able to induce cell 
adhesion and flattening. It has also been found to, in combination with interleukin-3, 
promote differentiation. In contrast with many receptor tyrosine kinases, Mer does not 
appear to stimulate proliferation (Guttridge et al., 2002). 
 
The receptor tyrosine kinases Mer, Sky and Ax1 are activated through binding with Gas6. 
Gas6 is the product of the growth arrest-specific gene 6 and belongs to the vitamin K-
dependant protein family characterized by the presence of γ-carboxyglutamic acid 
residues that mediate calcium-dependant phospholipid membrane binding. The receptor 
binding site is situated in two domains that are very similar to the laminin-G domains 
(Sasaki et al., 2002). When the docking of Gas6 with AChE was investigated, it was 
observed that docking occurs at the same position as laminin (Figure 47). The 90RELSED 
motif on AChE seems to lie within 2Å of the Gas6 residues 296-298 (YLG) and 306-309 
(VIRL). Interestingly, this site is identical to the site described for Gas6 binding to Ax1 
(Sasaki et al., 2002). It was also found that the 40PPMGPRRFL peptide lies within 2Å of 
Gas6 residues 339-345 (GMQDSW) along with F428 and D432. The 60VDATT motif 
lies within 2Å of G298 and R299, as well as 329-332 (DPEG), 350-351 (LR) and 437-
440 (IPR). However, the exact positions of the Gas6 binding site are unknown. This 
analysis is an indication only of molecules that may be similar to AChE in critical motifs. 
Mer came up as a hit. This does not necessarily suggest that it is definitely functionally 
redundant with AChE, but only that it is a possibility. Mer ligand binding would, 
Stellenbosch University http://scholar.sun.ac.za
 156 
presumably, trigger a signaling event of cascade; wich of course is a major difference 
between it and AChE, which cannot do this.  
 
 
 
Figure 47. Docking of AChE with Gas6. Details of the docking of the mouse AChE 
dimmer (1J06.pdb; shown in grey) with human Gas6 (1H30.pdb; shown in cyan). The 
PAS residues on AChE are shown in yellow. Residues 40-42, 46, 60-64 and 90-95 are 
represented in black (Johnson et al., 2008b). 
 
 
3.3.1.2.3 The LDL receptor pentapeptide DGSDE 
 
Although their function is unknown, a number of molecules, including perlecan, contain 
low-density lipoprotein repeats (LDLR). In the LDL receptor, these repeats play a role in 
the binding of LDL. The conserved pentapeptide DGSDE sequence has been found to be 
especially important (Noonan et al., 1991). Interestingly, this sequence is very similar to 
the AChE 90RELSED sequence. The LDL ligand that binds to DGSDE is also known to 
bind heparin. It appears that the AChE site resembles heparin as both these molecules 
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bind to the same site on laminin. Reports show that LDL is also able to bind syndecan-1 
(Fuki et al., 1997).  
 
As mentioned, lipoproteins are known to play roles in neurite outgrowth and plasticity. 
The role of the apoE4 allele in AD has also been discussed in previous sections 
(Strittmatter et al., 1993). Even though the specific mechanisms are still unclear, apoE3 
seem to promote neurite outgrowth where apoE4 inhibits it (Beffert et al., 2004). Both 
isoforms have been shown to bind amyloid β-peptide, apoE4 binds with greater avidity 
than apoE3. 
 
The docking of apoE isoforms with AChE was investigated (1LPE.pdb and 1LPE4.pdb; 
apoE3 and apoE4, respectively). It was found that AChE docked with apoE3 (Figure 48) 
again via the same site that laminin binding occurs. Residues of apoE lying within 2Å of 
the AChE 90RELSED motif were R142, K143, R145 and K146. Residues lying within 2Å 
of the 40PPMGPRR sequence were W34, R38, R145 and K146. Residues of apoE lying 
2Å of the 60VDATT motif were L43, Q48, W118, E131, L133, R134, V135 and R136. 
The receptor-binding region has previously been identified to lay between residues 135 
and 151 (Datta et al., 2000). This receptor-binding site is the same region that docks with 
the AChE site (many of these residues are basic). ApoE4 does not dock with AChE. 
 
 
Figure 48. Docking of 
AChE with 
apolipoprotein E3. 
Detailed docking of the 
mouse AChE dimmer 
(1J06.pdb; represented in 
grey) with human apoE3 
(1LPE.pdb; represented 
in cyan). The PAS 
residues are shown in 
yellow, and residues 40-
42, 46, 60-64 and 90-95 
are shown in magenta 
(Johnson et al., 2008b).  
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3.3.2 Potentially redundant molecules in Neurodegeneration: Alzheimer’s disease 
 
The RELSED (ELSED instead of RELSED in order to minimize restriction) and DGSDE 
motifs were also used to BLAST-search candidates for redundancy in neurodegeneration. 
This time around the focus was strictly on molecules associated with brain function and 
also molecules that have previously been connected to Alzheimer’s disease. The BLAST-
search was restricted to the Mus musculus genome.  
 
3.3.2.1 Searches for the ELSED motif 
 
The first BLAST-hit was for sickle tail protein. Sickle tail protein is involved in skeletal 
development, in particularly, the development of the invertebral disc (Semba et al., 
2006). This is a non-neuronal protein that is not connected to neurodegeneration and thus 
unlikely to be redundant. 
 
Another unlikely hit was for the guanine nucleotide factor, Son of sevenless (SOS). SOS 
proteins act on Ras and Rho subfamilies of small GTPases and functions downstream of 
many growth factors and adhesion receptors (Wing et al., 2003). Although they are 
expressed in neural cells, SOS proteins are not cell surface proteins.  
 
Integrin β7, also produced from the ELSED-motif search, is a protein involved in 
adhesive interactions in leukocytes. Here integrin β7 (α4β7 intergrin) acts as a receptor 
for fibronectin, MADCAM1, VCAM1 and E-cadherin (see Higgens et al., 2000 for 
review). Even though integrin β7 is found on cell surfaces, it does not appear to be 
involved in neural cell adhesion. 
 
Several proteasome proteins, such as Psmd2 and mCG49710, were also produced from 
the search, but none of these are involved in cell adhesion. In conclusion, searches for the 
ELSED motif did not produce any molecules with potential for functional redundancy 
with AChE.  
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3.3.2.2 Searches for the DGSDE motif 
 
As mentioned, the RELSED motif resembles the DGSDE motif that binds 
apolipoproteins on LDL receptors (see section 3.3.1.2.3). It was also shown that AChE is 
capable of docking with apoE at the RELSED site (Figure 48). ApoE, as well as LDL 
receptors and LDLR-containing molecules, have all been previously implicated in 
Alzheimer’s disease (AD). For these reasons, proteins involved in neurodegeneration 
containing the DGSDE motif, was also investigated.  
 
A number of significant hits were produced for the DGSDE motif: 
 
SCO-spondin, a member of the thrombospondin family, is secreted by the sub 
commissural organ. It is a multidomain protein expressed in the brain and is conserved in 
all mammals (Meiniel & Meiniel, 2007). SCO-spondin contains 8 LDLR domain repeats 
(Accesion numver NP_775604) and has been shown to be involved in the modulation of 
neural aggregation (Gobron et al., 1996). No specific involvement of SCO-spondin in 
AD has been documented making it an unlikely candidate for redundancy with AChE in 
neurodegeneration.  
 
The structurally-related LDL receptors are the main class of apoE receptors expressed in 
the CNS (reviewed in Strittmatter et al., 1993; Schmechel et al., 1993). These receptors 
themselves, along with their variations, are candidates for functional redundancy. All 
members of this family of receptors are able to bind and internalize apoE-containing 
lipoproteins and are specifically expressed in the brain, particularly in regions prone to 
amyloid deposition and AD-associated neuronal cell loss (Andersen & Willnow, 2006). 
For these reasons, much attention has focused on a possible role of LDLR-related 
receptors in AD. Seeing as these receptors are components of the cellular machinery that 
supplies cholesterol to neurons, their activities might be crucial for the regulation of 
cellular cholesterol homeostasis, thus affecting the rate of APP processing. This concept 
is supported by association of disorders of cholesterol metabolism with high risk of AD 
(Shobab et al., 2005). It is also possible that these receptors clear apoE or apoE-Aβ 
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complexes from the extraneuronal space, thereby modulating the extent of Aβ 
oligomerization and neurodegeneration (Kang et al., 2000).  
 
α-2 macroglobulin is a serum pan-protease inhibitor and its receptor also contains LDLR 
domain repeats (Borth, 1992; Strickland et al., 1990). α-2 macroglobulin is upregulated 
in the brain during injury and has been localized to senile plaques in AD (Rebeck et al., 
1995). α-2 macroglobulin seem to mediate Aβ degradation and clearance thereof via 
endocytosis (Narita et al., 1997). A common variant (29.5%) polymorphism in α-2 
macroglobulin has also been associated with an increased risk of AD (Saunders & Tanzi, 
2003).  
 
The ECM molecule perlecan (HSPG2), also containing LDLRs, has been shown to be 
associated with amyloid plaques and tau aggregation. Polymorphisms in this molecule, 
however, do not appear to confer risk for AD (Rosenmann et al., 2004). This indicates 
that perlecan is unlikely to be a candidate for redundancy with AChE in the prevalence of 
neurodegeneration. 
 
Sortilin-related receptor (SORL1) is a mosaic protein expressed predominantly in the 
CNS. SORL1 consists of an N-terminal portion resembling the vacuolar protein sorting-
10 (Vpsl10) receptor family and a C-terminal portion that has attributes of the LDLR 
family. This protein is capable of binding ligands ranging from receptor-associated 
protein (RAP) to apoE (Jakobsen et al., 2001) and has been termed a neuronal receptor. 
SORL1 has been associated with AD in that it was found to interact with APP in the 
Golgi and endosomes to reduce production of Aβ (Anderson et al., 2005; Offe et al., 
2006; Dodson et al., 2008). SORL1 expression was found to be decreased in the neurons 
of sporadic AD patients (Scherzer et al., 2004; Sager et al., 2007). It seems that SORL1 
variants that reduce SORL1 expression may increase risk for developing AD by 
increasing Aβ production (Grear et al., 2009). The many associations of SORL1 with 
neurodegeneration suggest that this protein could be functionally redundant with AChE. 
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It is important to note that a five amino acid motif will possibly produce random matches. 
However, by starting an investigation with a specific motif (DGSDE) that is known to be 
involved in a specific interaction, simply extends the exploration to a slightly different 
context and suggests an intriguing possibility. These findings thus do not provide a 
definite case for redundancy, but are purely suggestive and might be interesting to follow 
up on in future studies. 
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4. Discussion 
  
Apart from its primary function in the synaptic hydrolysis of acetylcholine, AChE has 
been shown through in vitro demonstrations to be able to promote various non-
cholinergic functions, including cell adhesion and neurite outgrowth. AChE was also 
shown to interact with laminin-111 in vitro (Johnson & Moore, 2003). As this interaction 
was blocked by both PAS-binding inhibitors and PAS-binding MAbs, it was concluded 
that laminin binding by AChE occurred at the PAS. Furthermore, the abrogation of cell 
adhesion, resulting in apoptotic cell death or anoikis, by the same PAS-binding inhibitors 
and MAbs strongly suggested that the AChE-laminin interaction promoted cell adhesion. 
The involvement of the PAS in cell adhesion and neurite outgrowth is supported by 
similar findings in neural cells from a variety of tissues and species (see section 1.6.2.4). 
The anionic nature of the PAS itself and of the area surrounding the gorge (Ripoll et al. 
1993; Porschke et al. 1996; Antosiewicz et al., 1996) contributes to the attraction of the 
cationic acetylcholine molecule, and may also, as suggested by the annular motif of 
negative charge seen in the adhesion-mediating AChE and the CLAMS, but not in BChE 
(Botti et al., 1998) be involved in mediating cell adhesion as well. Observations (Johnson 
& Moore, 2003; Bigbee & Sharma, 2004) that electrostatics play an important part in 
AChE-mediated cell adhesion support this. The project described in this thesis took these 
findings – the involvement of the PAS and electrostatic interactions – as its premise, and 
used as tools  the PAS-reacting MAbs and inhibitors that had been used before.  
 
Selection pressure on the PAS (the five residues constituting the substrate-binding site) 
has undoubtedly been directed towards catalysis and, specifically, acetylcholine 
hydrolysis, resulting in strong phylogenetic conservation of the structure. However, apart 
from this, there are several other features that contribute to structural conservation of its 
surrounds. One of these is the carboxylesterase type B signature 2 motif that surrounds 
Cys 96 of the omega loop (the 94EDCLYLN motif). The other is the salt bridge between 
Arg 46 and Glu 94. Both of these features are involved in maintaining AChE’s tertiary 
structure, and are very strongly conserved in all cholinesterases as well as the 
carboxylesterases from which they evolved. It is interesting that all these conserved 
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features – the anionic charge, the 94EDCLYLN motif and the Arg-Glu salt bridge – are 
implicated in the interaction site with laminin: anionic charge through the electrostatic 
nature of the interaction, the principal interaction motif, 90RELSED, forms part of the 
94EDCLYLN motif, as does the salt bridge, through Glu 94 and the Arg 46-associated 
40PPMGPRR motif.  
 
Not all PAS ligands, however, are cationic. Small inhibitors, such as propidium, 
BW284c51 and gallamine, are cationic. These compounds interact directly with the PAS 
residues. On the other hand, fasciculin 2, a 61 amino acid peptide from green mamba 
venom, is not cationic. Its interaction with AChE covers a relatively large surface area, 
involving non-electrostatic interactions with residues of the Cys69-Cys96 omega loop, 
and insertion into the gorge itself (e.g. Radic et al., 1994). In terms of ligands binding at 
the PAS, the amyloid beta peptide is hydrophobic. The beta peptide, however, does not 
bind on the 69-96 omega loop, or to the anionic regions of the PAS and its surrounds, but 
to the hydrophobic 274-308 sequence on the opposite side of the gorge (De Ferrari et al., 
2001). The prion protein has also been shown to bind AChE at the PAS, and, because of 
its structural similarity to the amyloid beta peptide (Bourne et al., 1999), it is likely that it 
binds to the same sequence.  
 
Paraoanu and Layer (2004) observed binding of AChE to laminin-111, and, using a yeast 
2 hybrid technique, identified an interaction between the laminin β1 chain and an 
unidentified site in the C-terminal domain (between residues 240 and 503) of AChE. 
They confirmed their results using Co-IP, using mouse brain extracts as their tissue 
source. Bigbee and Sharma (2004) also observed binding of AChE to laminin, but in this 
case, the γ1 chain (it was observed that the AChE binding partner ran in the laminin γ1 
position on the gel, but the identity of the band was not specifically confirmed). These 
authors used dorsal root ganglion cells; these cells extend axons into the central nervous 
system. The project described in this thesis used neuroblastoma cells, a tumour that is 
derived from the peripheral nervous system. There are distinct differences in the 
composition of the extracellular matrix between the central and peripheral nervous 
systems. In the peripheral nervous system, laminin and collagen IV are major constituents 
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of the extracellular matrix surrounding the neurons and neural precursors, but this is not 
the case in the central nervous system. These differences in tissue and extracellular 
matrix composition may play a significant role in the results obtained in the different 
studies. In this project, Co-IP, using whole molecule laminin was used, with no attempt to 
identify binding to the different laminin chains.  
 
The localisation by Paraoanu and Layer of the AChE interaction site to the C-terminal 
domain may represent, to reconcile with the findings here, binding to C-terminal domain 
parts of the PAS itself (W286, Y341 and associated sequences), mimicry of PAS-
associated structures (such as the short omega loop), part of the C-terminal T-peptide 
(findings by Greenfield’s group - e.g. Day and Greenfield, (2002) - implicate this in cell 
adhesion) or, most likely, and especially taking into account the different laminin chains 
involved, an entirely different interaction site. Again, this may be a consequence of the 
different tissue source used. 
 
The proteins and proteoglycans of the extracellular matrix (including the basement 
membrane) are frequently large and are characterised by an ability to interact with a 
variety of molecules. Many, like perlecan and fibronectin, are modular, and may be made 
up of multiple repeating domains. These multiple interactions serve a variety of 
functions, but a major one is the formation of a strong and sTable network supporting the 
cells. During the development of the peripheral nervous system, AChE (as a hydrophilic 
tetramer) is secreted by the cell into the matrix (Layer & Willbold, 1995). The function of 
this secreted form is not known. At a later stage, AChE expression shifts to the PRiMA 
anchored form in the cell membrane. Greenfield (e.g. Day & Greenfield, 2002) has 
suggested that the secreted AChE is of primary importance in developmental non-
classical functions. AChE appears to be capable of using different sites to interact with a 
variety of protein partners. It interacts, firstly, via the charged RELSED motif near the 
PAS with laminin α1 (this thesis), secondly, via the hydrophobic PAS sequence with the 
amyloid β-peptide (De Ferrari et al., 2001) and very likely with the prion protein also 
(Bourne et al., 1999; Clos et al., 2006), thirdly, with collagen IV (Johnson & Moore, 
2003) and fibronectin (Giordano et al., 2006) by as yet identified PAS-associated sites, 
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fourthly, with laminin β1 via an unidentified site in the C-terminal domain (Paraoanu and 
Layer, 2004), very likely with laminin γ1 by an unidentified site (Bigbee and Sharma, 
2004) and, fifthly via its C-terminal T-peptide with nAChR (Day & Greenfield, 2002) as 
well as  the anchoring proteins ColQ and PRiMA. It also appears to interact with perlecan 
(Anderson et al., 2008) by an unidentified site. The overlay technique used by Bigbee 
and Sharma (2004) has suggested a number of additional binding partners of MW 200, 
110, 35 and 33 kDa, respectively (the 200 kDa protein is probably laminin γ1). These are 
all documented interactions. The investigations into possible functional redundancy open 
up the field still further. With the caveat that neural cells from different tissue sources 
(peripheral or central nervous system) were used in these studies, and these tissues have 
different compositions and physiological requirements, a degree of promiscuity is 
evident, suggesting  that AChE could possibly be functioning in stabilising the matrix and 
basement membrane through these multiple interactions.  
 
 
4.1 Defining the interaction between AChE and laminin 
 
The first aim of this study was to demonstrate the interaction between AChE and laminin, 
and to identify and describe the interaction sites of AChE and laminin involved in this 
binding. Unlike AChE, where preliminary results showed the site involved to be PAS-
associated, no specifications concerning the associated laminin site had been made. The 
only clue came from the assays which showed that laminin-111 interacts with AChE 
(Johnson & Moore, 2003; Figure 17). An additional problem is that laminin is a very big 
molecule (400-900kDa), and is known to interact with a large number of ligands and 
receptors such as integrins, heparin, dystroglycan, collagen IV, etc. (e.g. Tzu & 
Marinkovich, 2008; Chen et al., 1999; Schneider et al., 2006; Mecham, 1991). This 
makes working with this molecule, to identify a particular binding site, quite difficult. 
The interference of NaCl, which alters the ionic conditions, on the binding of AChE with 
laminin, supported the notion that the binding involves electrostatics (Johnson & Moore, 
2003; Figure 19). Seeing as the MAbs interfered with both the AChE-laminin interaction 
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and cell adhesion, it appeared likely that the epitope on AChE that they recognised was 
the same as the laminin-binding site.  
 
Peptides and binders identified through phage display would represent ligands, or rather, 
parts of ligands, for AChE. The identified binders could then be BLASTed in order to 
determine where they came from, thus possibly identifying a protein ligand for AChE. 
Sequences obtained from phage display could also contribute towards identifying the 
particular sites involved in the interaction. Unfortunately no consensus sequences were 
produced with the peptide phage display. The site on AChE was previously shown to be a 
highly conformational structure (Johnson & Moore, 2003). A possible explanation for the 
negative results could be that the peptides may not adequately define the site, possibly 
binding to only a small section of it. The results obtained in the microarray suggest that 
the MAbs may show cross-recognition of different proline-containing sequences on 
AChE; it is possible that an analogous recognition of multiple proline-containing 
sequences by the phage-displayed peptides may have complicated the issue and affected 
the enrichment of a single binder. Proline is almost always found on the surfaces of 
proteins due to its ability to destabilise and prevent ordered folding (Levitt, 1980). 
Proline is also very strongly antigenic (partly due to its own ring structure and partly 
because of the characteristic kink it induces in the polypeptide chain), and Abs tend to 
prefer proline and proline-rich regions. 
 
Ab display, using three dimensional binders, could possibly make up for where the 
peptide phage display was lacking. The Ab phage display work was contracted out as the 
Ab libraries used were not commercially available at the time. The basic technique is the 
same as peptide phage display. The Ab phage display provides information on both the 
sequences that bind the AChE site, as well as the three dimensional structure of the site 
(from modelling). The panning process was completed with success and two specific 
binders were identified. In particular, among the 23 DNA-sequences clones, 15 shared 
two homologous sequences (clone no. 7 & clone no. 21). Sequence alignment of the two 
identified binders showed them to share 95% sequence identity (Figure 30). The CDRs of 
the scFv sequences both showed a relatively large number of basic residues (sequence 7: 
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6 basic & 1 acidic; sequence 21: 4 basic & 0 acidic). This would agree with the findings 
on the the laminin site that interacts with AChE, which also has a predominance of basic 
residues, and also supports the overall supposition that electrostatic interactions play a 
major role in the interaction of AChE with binding partners and with laminin in 
particular.  
 
The models of the sequences of the two clones produced from the Ab phage display were 
used to dock with AChE (Figure 34 & 35). The docking results indicate recognition of 
the 69-96 omega loop, including the 88 PNRELSED motif and the VVDATT (human) 
motif. These results agree closely with the laminin interaction, but with some differences. 
While the laminin interaction appears to be centred on the 90RELSED motif itself, with 
contributions from 40PPVG (mouse) and 59VLDATT (mouse), the sequences recognised 
by the scFv, as well as by the MAbs, as shown by the microarray epitope analysis (see 
below), is skewed slightly to include Pro 88 and Asn 89 just before. These results 
indicate that the epitope recognised by both the scFv and the MAbs is the same. Although 
this project was begun with the premise that the epitope recognised by these MAbs, 
which inhibit both cell adhesion and the AChE-laminin interaction, is the same as the 
adhesion-mediating and laminin-binding site, this appears not to be the case. The site is 
very close and has much in common, but is not precisely the same. The inclusion of part 
of the site in the MAbs’ epitope, together with steric hindrance, would account for both 
the interference with cell adhesion and the AChE-laminin interaction.  
  
Previous studies (Johnson & Moore, 2004) had suggested, based on epitope analysis of 
the adhesion-inhibiting MAbs using long synthetic peptides, that the adhesion-mediating 
site was located primarily on the 37-53 sequence along with contributions from residues 
on the omega loop and the 55-66 sequence. This is structurally feasible as these 
sequences lie very close to one another in the tertiary structure. In this study, a peptide 
microarray using 500 peptides varying in length from 9 to 15 residues as well as different 
degrees of constraint, were used to define the binding site on AChE. Results confirmed 
the previous findings and showed the primary epitope to be the proline-rich motif 
40PPMGPRRFL (human) of the 37-53 peptide. Proline is not the only antigenic amino 
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acid found in this motif, arginine and phenylalanine residues are also known to attract 
Abs. This motif was identified as one of the most antigenic regions of the AChE surface 
by the Antigenicity Plot program (JaMBW) which computes and plots antigenicity along 
a polypeptide chain as predicted by the algorithm of Hopp and Woods (1983). In Torpedo 
AChE, the analogous peptide has also been identified as an epitope (Wasserman et al., 
1993). In contrast with the long peptide results, the microarray was able to show that the 
MAbs’ reactivity increased on addition of proline to a peptide. Possible interpretations of 
these findings have been described above.  
 
The α-chain of the laminin-111 molecule contains most of the receptor-binding sites. 
Here, these sites are located predominantly in the G domains (Suzuki et al., 2005; Figure 
15). Due to the evident involvement of electrostatics in the binding between AChE and 
laminin, the search for potential sites on laminin was focussed on cationic sites. Analysis 
of the laminin α1 chain showed this chain to have 14 potential cationic sites that could, 
theoretically, be attracted to the anionic PAS-region of the AChE molecule. Among them 
was the laminin AG-73 site, a site that had previously been described as being involved 
in cell attachment and spreading (Nomizu et al., 1995). The initial observation that AChE 
is able to dock with the equivalent of this site in laminin-211 (the sequence identity 
between laminin α1 and α2 is 63%; Figures 38 & 39), suggests that it is possible that 
AChE interacts with laminin-211 (merosin) in vivo. Merosin is expressed in peripheral 
nerves, striated muscle and placenta. Deficiency of merosin is associated with congenital 
muscular dystrophy (Wewer & Engvall, 1996). These docking results also led to the in 
vitro examination of this sequence by using binding assays. The binding assays 
confirmed the docking results and indicated that the AG-73 site plays an important role in 
the AChE-laminin interaction (Figure 41). Docking of AChE with the laminin α1 chain 
(Figure 45), confirmed the importance of AG-73. The docking performed was rigid-body, 
and thus did not take into account conformational changes that might occur during the 
interaction.  
 
Docking of AChE with the laminin α1 G4-5 domain pair showed that AChE interacts 
with laminin primarily by the 90RELSED motif. Part of this motif is recognized by the 
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adhesion-inhibiting MAbs. This strongly suggests that the motif is involved in cell 
adhesion, which, in turn, involves the AChE-laminin interaction. The observation that the 
MAbs that recognized the 90RELSED motif were able to block cell adhesion, while those 
that do not recognize the 90RELSED have no effect, supports the significance of this 
motif for cell adhesion. The slight offset in the recognition sequence of the the MAbs and 
scFv (88PNRELS) and the laminin-binding motif (90RELSED) may be explained by steric 
hindrance: binding of the antibody molecule prevents binding by laminin, even though 
they do not compete for exactly the same site. The highly antigenic 40PPMGPRRFL motif 
also appears to be involved in the laminin interaction; because of the salt bridge link 
between Arg 46 and Glu 94 (Figure 36), it lies closely apposed to this section of the 
omega loop. Along with disulfide bonds, the salt bridge acts in stabilizing the tertiary 
structure of the AChE molecule. Residues involved in these bonds, as well as residues in 
their vicinity, also have a strong propensity towards conservation. This is evident when 
comparing the AChE and BChE sequences (Figure 37). As mentioned, this part of the 
sequence forms part of the carboxylesterase type 2 signature B, conserved around a 
cysteine residue involved in a disulfide bond, and is strongly conserved throughout the 
α/β hydrolase fold family. The 90RELSED motif also falls within the conserved area as it 
lies very close to Cys 96 (Cys 94 in Torpedo AChE and Cys 92 in BChE). The inability 
of Torpedo AChE and BChE to dock with laminin could possibly be due to sequence 
differences between Torpedo AChE and mouse AChE, and BChE and mouse AChE 
(Figure 37). Although the mouse structure (1J06.pdb) used in the docking is dimeric and 
both the Torpedo (2ACE.pdb) and BChE (1P0I.pdb) structures are monomeric, it is 
unlikely that conformational differences are responsible, as such differences are not 
observed in the crystallography. Another possible explanation could be the important role 
that the charge distribution over the entire PAS plays in cell adhesion, as BChE does not 
have the same concentration of charge in this area (Botti et al., 1998). BChE has not been 
observed to be able to bind laminin in vitro or to promote cell adhesion (Johnson & 
Moore, 2000).  
 
The sequence data obtained from the Ab phage display is empirical experimental data as 
the two sequences of the scFvs are definite and the positions of the CDRs are also fact. 
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The same cannot be said for results obtained from molecular modelling and protein 
docking. In silico simulation and modelled structures are not in the same category as data 
obtained in a laboratory and structures obtained through crystallography. Another 
important implication is that both the scFvs and MAbs were raised against human AChE 
and the conformational site mapping was also done against human AChE. The docking, 
however, was performed with mouse AChE (due to availability of the structure). 
Sequence identity between mouse and human AChE is 92% and that for the laminin α1 
chain, 86% Although the sequences for human and mouse AChE differ, they are still 
strongly conserved in critical regions, in particular, the catalytic apparatus, including the 
PAS and its surrounds, that have specific functions (see Figure 37). Comparison of these 
AChE sequences shows that conservative replacements of Val 42 and Met 48 in the 
mouse with Met 42 and Leu 48 in the human occur, respectively. These differences could 
have had an effect on the reported results. The results obtained for both the MAbs and 
conformational site mapping, as well as for the scFvs and docking with AChE, largely 
agree, but there are some subtle differences. These differences may be due to the 
limitations of the docking technology; they may simply be due to the differences in the 
experimental approach.  
 
Overall, both the MAbs and the scFvs were found to recognize aspects associated with 
the PAS of AChE. The conformational site mapping indicated the strongest recognition 
by the Abs was to the 40PPMGPRR motif. Other proline-containing motifs were also 
recognized, especially 78PGFEGTE and 88PNRELSED on the omega loop. The peptide 
arrays suggested that the Abs responded strongly to the presence of proline. Here the 
59VVDATT did not seem to play a significant role in the Ab recognition. The scFv 
docking results, however, show a reaction/recognition pattern very similar to the site that 
laminin interacts with. This suggests direct competition between laminin and the Abs, 
which correlates with the adhesion experiments on the N2α cells (Johnson & Moore, 
2000). The findings from the conformational epitope mapping, indicating the primary Ab 
recognition sequence as being the 40PPMGPRR motif, suggest that the competition is not 
1:1. One explanation of this is steric hindrance, in other words, that the Abs, which are 
fairly substantial molecules, while binding to the 40PPMGPRR motif, prevent laminin, an 
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even more substantial molecule, from binding to the 90RELSED motif. Another 
explanation is that the peptide array effectively “dissects” the epitope, quantitating the 
recognition of individual components. As already discussed, the highly antigenic amino 
acid proline forms a major recognition component of the epitope. It could be that the 
strength of recognition of the 40PPMGPRR motif is primarily a response to its proline 
content, and that the adjacent 90RELSED motif, although not showing as strong a 
recognition, is nevertheless a critical, even a primary, part of the epitope. The docking 
results with the scFv and mouse AChE indicate a recognition of the 90RELSED motif, the 
PPMG (PPVG in mouse) sequence, as well as a recognition of the 59VVDATT 
(VLDATT in mouse), which agrees with the laminin interaction.  
 
4.2 The question of redundancy 
 
The term "functional redundancy" suggests the possibility of a formal backup system, 
with AChE standing in the wings as an understudy in the event of the principal's failure. 
This may not necessarily be the case, and the less restrictive term "functional 
compensation" may, in many cases, be preferable. However, in this thesis, the term 
"functional redundancy" has been used to cover both the more formal and the less formal 
applications. 
 
The AG-73 site on laminin, that binds AChE, was initially identified as a heparin-binding 
site (Hoffman et al., 1998). Through site-directed mutagenesis, Harrison et al. (2007) 
showed that heparin was bound largely by two clusters of basic residues: 2719RKR (AG-
73) and 2791KRK. Andac et al. (1999), using the same method, found contributions by 
three basic regions: 2766–2770, 2791–2793 and 2819–2820. The same basic clusters with 
some additional basic residues were also found to contribute to the binding of α-
dystroglycan and sulfatides. AChE was observed to interact with 2718VRKR, 
2738YYYIKRK, 2789YIKRK as well as 2817VERK. These residues are all either charged, 
hydrophobic or, in the case of tyrosine, aromatic.  
 
Stellenbosch University http://scholar.sun.ac.za
 172 
From these findings it would thus appear that AChE is able to compete with other 
molecules for binding to laminin. The competition ELISA performed in this study, 
confirmed this by showing competition between AChE and heparan sulfate (Figure 44). 
Both heparin and the AChE surface (in the vicinity of the PAS) are anionic. This is not 
the first demonstration that both a protein and carbohydrate is able to bind to a single 
polypeptide site (Ma et al., 2002). The PAS thus appears to promote an array of functions 
involving molecular binding. These functions range from binding ACh and promoting 
catalysis to binding laminin. This agrees with Wyman’s principle of linked functions 
(Wyman, 1964). The principle considers the likelihood of an interdependence of several 
functions of a molecule.  
 
These findings, that AChE binds to a heparin-binding site and is able to compete with 
heparin for binding to laminin, indicate the possibility of functional redundancy between 
AChE and heparin, in vivo. Functional redundancy would explain the apparent 
inconsistency between the in vitro experimental findings detailing non-cholinergic 
functions (the importance of AChE for neural cell survival and differentiation), and the 
evidence from the knockout models (Xie et al., 2000). Survival of the AChE knockout 
led to the questioning of the non-cholinergic structural involvement of AChE in neural 
differentiation (Cousin et al., 2005). The well documented evidence of ACh’s inhibition 
of neurite outgrowth (Biagioni et al., 2000), indicate that as least part of AChE’s neurite-
promoting ability may be due to the hydrolysis, and thus removal, of ACh, allowing 
neurite outgrowth to proceed. However, there is clear evidence indicating non-cholinergic 
involvement: De Jaco et al. (2002) observed AChE-mediated neurite outgrowth in a cell 
line lacking acetylcholine, and there are also several studies using both inhibitory and 
non-inhibitory anti-AChE MAbs (Johnson & Moore, 2000; Sharma & Bigbee, 1998). The 
possibility that the adhesion-inhibiting Abs react with a particular site, whether on AChE 
or another molecule, should be considered.  
 
This raises some interesting speculative questions, perhaps the most challenging being 
whether the adhesion-mediating ability of AChE is purely fortuitous and perhaps even 
irrelevant. It could be argued that the AChE–laminin interaction is of no functional 
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significance at all, arising by chance and surviving because there is no selective pressure 
to remove it. Although, against this is the demonstrated importance of the interaction site 
on AChE, i.e. the importance of the PAS site. The AG-73 site on laminin has been 
previously shown to play a role in mediating cell adhesion, neurite outgrowth, as well as 
metastasis (Nomizu et al., 1995; Richard et al., 1996). Blocking the complementary site 
whether on AChE or some other molecule, also showed to abrogate cell adhesion and 
result in cell death (Johnson & Moore, 2000).  
 
Although the specific signaling mechanisms involved have yet to be determined, the 
possibility that AChE (or another molecule) may bind synergistically with, for example, 
an integrin or α-dystroglycan, should be considered. Integrins and α-dystroglycans are 
molecules capable of transducing a signal to the cell’s interior. Although PRiMA-linked 
AChE does have a small cytoplasmic domain, details of its ability to transduce 
information from the cell surface to the interior remain unknown. The presumption that it 
relies on complexation with other molecules for signal transduction, is thus feasible. 
 
Neural development is an extremely complex process. Development of peripheral 
neurons involves the migration of neural crest cells, their settling and differentiation at 
the required destinations, followed by the development of the synaptic pathways. Cellular 
signals in this process are mediated by cell surface receptors, ECM and BM molecules, 
growth factors and cytokines, governed by a complex array of transcriptional switches. 
Functional redundancy is known to occur. From a ‘design’ point of view, redundancy 
could be a fail-safe mechanism in view of the complexity of these processes and potential 
for error. Carbohydrates, due to their microheterogeneity, have the potential for subtle 
changes in signaling.  
 
Molecules on the cell surfaces that could possibly be functionally redundant with AChE 
are the syndecans and glypicans. It has been shown that AG-73 binds syndecan-1, 
through heparan sulfate chains (Hoffman et al., 1998). Syndecan-1, however, is not 
expressed to any significant extent in neural cells (Kim et al., 1994). An unusually high 
number of proteoglycans are expressed during nervous system development (Hartmann & 
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Maurer, 2001). The lack of comprehensive information on the developmental expression 
and interactions of HSPGs makes it difficult to narrow the field of possibilities. The 
neuroligins are also possible candidates. Functional redundancy of AChE with 
neuroligin-1 has been reported as both molecules seem to interact with the cell surface 
receptor β-neurexin (Grifman et al., 1998). Unfortunately there is no documented 
evidence that neuroligins are expressed prior to synaptogenesis. Findings from this study 
show, however, that it is unlikely that AChE and neuroligin could function with laminin 
as the neuroligin sequence of the omega loop is not conserved and is very different. 
Sequence conservation of the latter part of the omega loop does occur, but this is 
probably because it is in the region of the disulfide-forming Cys 96, and functions in 
stabilization of the molecule’s tertiary structure. The cell surface receptor tyrosine kinase 
Mer, is another cell surface candidate for redundancy. Together with the LDL receptor, 
Mer seem to have similar peptide motifs to AChE.  
 
In the ECM, perlecan could be a possible candidate due to the double virtue of its 
heparan sulfate chains and the speculation of it containing motifs similar to both AChE 
and the LDL receptor. Perlecan has also been shown to bind laminin through the AG-73 
site (Brown et al., 1997), as well as the asymmetric AChE forms through interactions 
with ColQ (Kimbell et al., 2004). It also appears that PRiMA-linked AChE may bind 
perlecan through an unknown mechanism (Anderson et al., 2008). ECM molecules 
characteristically demonstrate multiple interactions, by means of various sites. Many of 
these molecules are modular containing several types of domains. A number of ECM 
cells, including agrin, pentraxin, slit protein, serum amyloid P component, Gas6 and β-
neurexin, have domains resembling the laminin G domains, thus resembling the laminin 
site with which AChE interacts in vitro. Docking results from this study indicate that 
AChE may bind Gas6 (Figure 47). Interactions of AChE with a number of ECM 
molecules have been described: laminin (evidence from this study; Johnson & Moore, 
2003; Paraoanu & Layer, 2004), collagen IV (Johnson & Moore, 2003), fibronectin 
(Giordano et al., 2007), nAChR (Greenfield et al., 2004), prion protein (Pera et al., 
2006), as well as amyloid-β peptide (De Ferrari et al., 2001). AChE also appears to have 
a number of interaction sites itself. It would seem that AChE, in its potential for multiple 
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interactions, thus resembles ECM molecules. Interestingly a number of ECM cells with 
which AChE interacts, are found in amyloid deposits. These include: amyloid-β peptide, 
laminin, collagen, fibronectin, perlecan, various HSPGs, apoE, agrin, and serum amyloid 
P component.  
 
Results from the scFv BLAST also produced a number of ECM molecules (laminin, 
fibronectin, tenascin-c), along with TREM1, α-synuclein and tetanus and botulinium 
toxins. Although the resemblance between AChE and laminin appeared to be an 
artefactual consequence of using a similar antibody library, and thus can be discounted, 
there are distinct resemblances between fibronectin and tenascin-C and AChE. The 
observation that fibronectin, as well as the amyloid β-peptide, which have been shown to 
be AChE ligands, are included in the list raises some questions. A possible explanation 
for this is the apparent presence of complementary sites at or associated with the PAS 
(Johnson & Moore, 2009): structural resemblances between the 78PGFEGTE motif on the 
69-96 omega loop, the 257-272 short omega loop, and the C-terminal peptide, and their 
(demonstrated or presumed) interaction with the PAS itself. This suggests that AChE 
may have more than one site of interaction with ECM molecules, acting as both receptor 
and ligand. Apart from the PAS and its interaction sites, AChE interacts with the basal 
lamina through ColQ, attached to the C-terminal T-peptide. A multiplicity of interactions 
is characteristic of ECM molecules, and this would support the view that AChE’s 
function in cell adhesion is related to strengthening the ECM, providing support for the 
cell and the developing neurites, rather than a specific receptor-ligand interaction. 
 
TREM1 also appears to resemble AChE, TREM is involved in the haematopoietic 
system, and AChE has long been associated with the haematopoietic system. AChE is 
expressed in significant quantities in erythrocyte membranes and deletions of the ACHE 
locus at 7q22 are associated with the myelodysplastic syndrome and acute myeloid 
leukemia (Stephenson et al., 1996). AChE has also been implicated, enzymatically and 
non-enzymatically, in haematopoiesis (Soreq et al., 1994; Grisaru et al., 2006), and 
numerous epidemiological studies have linked exposure to anti-cholinesterase pesticides 
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to leukemia (reviewed in Merhi et al., 2007). The link to the haematopoietic system, 
suggested by the scFv, warrants further investigation. 
 
The structurally related Clostridium toxins, the tetanus and botulinum toxins, both 
interact with neurons and, indirectly, alter acetylcholine levels. This also warrants further 
investigation. 
  
BLAST-searches for potentially redundant molecules in neurodegeneration were limited 
to the (R)ELSED and DGSDE (which is very similar to the AChE 90RELSED sequence). 
The focus was on molecules specifically associated with brain function and AD. Searches 
for the RELSED motif did not deliver any molecules with potential for redundancy with 
AChE. The conserved LDL receptor pentapeptide DGSDE has previously been shown to 
be very important (Noonan et al., 1991) and the LDL ligand that binds to this motif is 
also known to bind heparin. LDL receptors are the main class of apoE receptors found in 
the CNS (reviewed in Strittmatter et al., 1993). Members of the LDLR family themselves 
have been implicated in Alzheimer’s disease; the LDL receptor-related protein (LRP), in 
particular, has been shown to be involved in APP endocytic trafficking and its processing 
to the Aβ-peptide (Bu et al., 2006). Human apoE receptors are known to bind soluble Aβ 
(Koudinov et al., 1998). The cholesterol transporter, apoE4 is a risk factor in late-onset 
AD (Chalmers et al., 2003; Fagan & Holtzman, 2000) and was found to bind Aβ more 
rapidly than other apolipoproteins (Sanan et al., 1994; Beffert et al., 2004). However, the 
exact influence of apoE-4 on AD is not known. ApoE is a major constituent of amyloid 
plaques (Namda et al., 1991). The role of LDL receptors in cholesterol homeostasis, 
along with their ability to clear apoE and apoE-Aβ from the extracellular space, as well as 
their role in APP processing, indicates a strong association of these receptors with the 
pathogenesis of AD. The LDL receptors and their variations are all candidates for 
functional redundancy with AChE in neurodegeneration. Although these findings are 
based on a number of presumptions and suppositions (that AChE is functionally 
redundant with LDL receptors and LDL receptor domain-containing molecules, 
specifically), they do offer intriguing suggestions for future hypotheses. 
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SORL1, a neuronal apoE receptor, has also been linked to APP processing and AD. 
SORL1 has been shown to, through its interaction with APP; reduce the production of Aβ 
(Anderson et al., 2005; Offe et al., 2006; Dodson et al., 2008). Studies show that 
variations in the SORL1 gene are associated with an increased rate of late-onset AD 
(Kimura et al., 2009). The strong apparent association of SORL1 with the pathology of 
AD suggests the possibility for redundancy with AChE in neurodegeneration.  
 
The BLAST-search once again indicated perlecan as a possible candidate. Perlecan 
contains LDL repeats, and although this molecule has been associated with amyloid 
plaques and tau aggregation, polymorphisms do not appear to confer risk for AD. 
Perlecan thus seems an unlikely candidate for redundancy with AChE in reemergence to 
neurodegeneration. 
 
From an evolutionary perspective, the ChEs, CLAMs and ACh appear to have been 
around for a very long time. AChE and ACh, for example, are found in bacteria, algae 
and protozoa as well as, as far as is known, throughout the plant and animal kingdoms. 
CLAMs have been described not only in mammals and insects, but also in the slime 
mould Dictyostelium. This suggests that the split between enzymes and non-enzymes 
may have occurred in the earliest of life-forms. It seems that the common ancestor 
probably had both enzymatic and adhesive characteristics, and the cholinesterase-domain 
protein branch of the family specialized in cell adhesion and signaling, losing their 
catalytic function. AChE, on the other hand, retained and perfected its enzymatic ability 
and along with it, apparently its adhesive capabilities. Interestingly, early organisms did 
not have nervous systems, it is thus possible that AChE, along with ACh, may have 
obtained morphogenetic functions and that these functions (both enzymatic and non-
enzymatic) may be more ancient than its synaptic capabilities. Such presumed antiquity 
suggests there may have been a distinct selective advantage in retaining these functions, 
that they fulfill a definite role and are neither trivial nor fortuitous.  
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4.3 Conclusions 
 
In conclusion, it was observed that AChE is able to interact with laminin α1 through its 
G4 domain. The sites of interaction on both AChE and laminin have also been defined. It 
is strongly suggested that the AChE-laminin interaction is involved in cell adhesion as is 
seen from the adhesion-inhibiting MAbs that recognize the associated AChE site. While 
it is possible that the AChE and laminin interaction sites may have evolved specifically 
for this interaction, this is probably unlikely due to a number of different factors. The 
structure of the interaction site on AChE appears to be a consequence of the conservation 
of structural features involved in stabilisation of the tertiary structure of the protein (the 
carboxylesterase signature 2 motif and the Arg46-Glu94 salt bridge) together with the 
evolution of structures enhancing catalysis (the PAS and the negative charge surrounding 
it). Nevertheless, the presence of these features in the non-enzymatic CLAMS as well 
suggests an adaptation to cell adhesion, and that present-day mammalian AChE is a dual-
purpose enzyme and adhesion molecule. The interaction site on laminin, however, is not 
specifically directed towards AChE; it is well-documented adhesion-mediating site and 
binds heparan sulfate proteoglycans. Furthermore, the apparently promiscuous 
interactions of AChE, not only with the laminin β1 and γ1 chains as well, but with other 
matrix molecules, suggests that AChE’s role in this respect may be in enhancing the 
structure and stability of the extracellular matrix or basement membrane. This is a 
structural, rather than a signalling role, and, although it is possible that PRiMA-linked 
AChE, through the small cytoplasmic domain, may be capable of signal transduction, the 
proposed structural role fits the expression data showing the secretion of the hydophilic 
tetramer into the matrix, and the later presence of the amphiphilic tetramer in the cell 
membrane. This relatively non-specific role also fits the evidence of the knockout mouse; 
although there are some instances (particularly in the development of the retina) where 
non-enzymatic roles of AChE cannot be compensated for.  
 
The search for proteins that could compensate for AChE loss in the non-enzymatic 
context, or for which AChE could compensate in the reverse situation, has shown some 
intriguing possibilties. Heparan sulfate proteoglycans are ubiquitous and important 
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components of the extracellular matrix, as well as the basal lamina. They are also closely 
associated with amyloid deposits in Alzheimer’s disease. Similarly, LDL receptor 
domains are found in a variety of proteins, and apoliprotein E is also associated with 
Alzheimer’s disease. These apparent structural similarities offer interesting possibilties 
for future research, particularly in view of the close association of AChE with 
Alzheimer’s pathology.  
 
In conclusion, therefore, the interaction sites between AChE and the G4 domain of the 
laminin α1 chain have been identified and investigated by in vitro and in silico 
techniques. Coimmunoprecipitation evidence suggests that this interaction occurs in the 
in vivo situation as well. Using the interaction sites as a template, various molecules that 
could compensate for the AChE-laminin interaction in the absence of AChE, as in the 
knockout, or for which AChE could possibly function as a backup device, have been 
identified or suggested. 
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